0000010795-20-000010.txt : 20200206 0000010795-20-000010.hdr.sgml : 20200206 20200206160019 ACCESSION NUMBER: 0000010795-20-000010 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200206 DATE AS OF CHANGE: 20200206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BECTON DICKINSON & CO CENTRAL INDEX KEY: 0000010795 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 220760120 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-04802 FILM NUMBER: 20582615 BUSINESS ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKES STATE: NJ ZIP: 07417-1880 BUSINESS PHONE: 2018476800 MAIL ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKE STATE: NJ ZIP: 07417 10-Q 1 bdx1231201910-q.htm 10-Q Document
false--09-30Q12020000001079514000000003750000001500000000 0000010795 2019-10-01 2019-12-31 0000010795 2018-10-01 2018-12-31 0000010795 2019-12-31 0000010795 exch:XNYS bdx:Notes1.000dueDecember152022Member 2019-10-01 2019-12-31 0000010795 exch:XNYS bdx:Notes1.401dueMay242023Member 2019-10-01 2019-12-31 0000010795 exch:XNYS bdx:DepositarysharesMember 2019-10-01 2019-12-31 0000010795 exch:XNYS bdx:Notes0.174dueJune42021Member 2019-10-01 2019-12-31 0000010795 exch:XNYS bdx:Notes1.208dueJune42026Member 2019-10-01 2019-12-31 0000010795 exch:XNYS bdx:Notes3.020dueMay242025Member 2019-10-01 2019-12-31 0000010795 exch:XNYS bdx:Notes0.632dueJune42023Member 2019-10-01 2019-12-31 0000010795 exch:XNYS us-gaap:CommonStockMember 2019-10-01 2019-12-31 0000010795 exch:XNYS bdx:Notes1.900dueDecember152026Member 2019-10-01 2019-12-31 0000010795 2019-09-30 0000010795 2018-12-31 0000010795 2018-09-30 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-10-01 2018-12-31 0000010795 us-gaap:CommonStockMember 2018-09-30 0000010795 us-gaap:RetainedEarningsMember 2018-12-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-09-30 0000010795 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0000010795 us-gaap:TreasuryStockMember 2018-10-01 2018-12-31 0000010795 us-gaap:TreasuryStockMember 2018-09-30 0000010795 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000010795 us-gaap:CommonStockMember 2018-12-31 0000010795 us-gaap:TreasuryStockMember 2018-12-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-12-31 0000010795 us-gaap:RetainedEarningsMember 2018-09-30 0000010795 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000010795 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000010795 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0000010795 us-gaap:TreasuryStockMember 2019-12-31 0000010795 us-gaap:RetainedEarningsMember 2019-09-30 0000010795 us-gaap:TreasuryStockMember 2019-10-01 2019-12-31 0000010795 us-gaap:RetainedEarningsMember 2019-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-09-30 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-12-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-10-01 2019-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000010795 us-gaap:TreasuryStockMember 2019-09-30 0000010795 us-gaap:CommonStockMember 2019-09-30 0000010795 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000010795 us-gaap:CommonStockMember 2019-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-10-01 2018-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-09-30 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-09-30 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-10-01 2018-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2018-10-01 2018-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2019-10-01 2019-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-09-30 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-10-01 2019-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-10-01 2019-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000010795 us-gaap:ConvertiblePreferredStockMember 2018-10-01 2018-12-31 0000010795 us-gaap:ConvertiblePreferredStockMember 2019-10-01 2019-12-31 0000010795 bdx:WomensHealthProductClaimsMember 2019-12-31 0000010795 us-gaap:OtherOperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000010795 us-gaap:OtherOperatingIncomeExpenseMember 2019-01-01 2019-03-31 0000010795 bdx:CompensatoryMember bdx:WomensHealthProductClaimsMember 2018-04-01 2018-04-30 0000010795 bdx:FilterProductClaimsMember 2019-12-31 0000010795 bdx:FilterProductClaimsMember 2019-10-01 2019-12-31 0000010795 bdx:WomensHealthProductClaimsMember 2018-04-01 2018-04-30 0000010795 bdx:PunitiveMember bdx:WomensHealthProductClaimsMember 2018-04-01 2018-04-30 0000010795 bdx:HerniaProductClaimsMember 2019-12-31 0000010795 2020-01-01 2019-12-31 0000010795 bdx:ProductsandorServicesMember 2020-01-01 2019-12-31 0000010795 bdx:ConsumablesMember 2020-01-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 us-gaap:CorporateNonSegmentMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember 2019-10-01 2019-12-31 0000010795 us-gaap:MaterialReconcilingItemsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 us-gaap:MaterialReconcilingItemsMember 2018-10-01 2018-12-31 0000010795 us-gaap:CorporateNonSegmentMember 2019-10-01 2019-12-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 country:US 2019-10-01 2019-12-31 0000010795 us-gaap:NonUsMember 2019-10-01 2019-12-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 country:US 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 us-gaap:NonUsMember 2018-10-01 2018-12-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:MedicationDeliverySolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:UrologyandCriticalCareMember us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:SurgeryMember us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:PeripheralInterventionMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 bdx:DiabetesCareMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 bdx:PharmaceuticalSystemsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 bdx:BiosciencesMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:DiagnosticSystemsMember us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:IntegratedDiagnosticSolutionsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 bdx:MedicationManagementSolutionsMember us-gaap:OperatingSegmentsMember bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 bdx:PreanalyticalSystemsMember us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:AdvancedBioprocessingMember 2018-10-01 2018-12-31 0000010795 bdx:IVFluidsMember country:US 2018-10-01 2018-12-31 0000010795 bdx:InterventionalSpecialtiesBrachytherapyandFeedingProductsMember us-gaap:NonUsMember 2018-10-01 2018-12-31 0000010795 bdx:InterventionalSpecialtiesBrachytherapyandFeedingProductsMember country:US 2018-10-01 2018-12-31 0000010795 us-gaap:PensionPlansDefinedBenefitMember 2019-10-01 2019-12-31 0000010795 us-gaap:PensionPlansDefinedBenefitMember 2018-10-01 2018-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:OtherInitiativesMember 2019-10-01 2019-12-31 0000010795 bdx:OtherInitiativesMember 2019-10-01 2019-12-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:CRBardIncMember 2019-09-30 0000010795 us-gaap:EmployeeSeveranceMember bdx:CRBardIncMember 2019-12-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:CRBardIncMember 2019-10-01 2019-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:CRBardIncMember 2019-10-01 2019-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:OtherInitiativesMember 2019-12-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:OtherInitiativesMember 2019-10-01 2019-12-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:OtherInitiativesMember 2019-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:CRBardIncMember 2019-09-30 0000010795 bdx:CRBardIncMember 2019-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:CRBardIncMember 2019-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:OtherInitiativesMember 2019-09-30 0000010795 bdx:OtherInitiativesMember 2019-12-31 0000010795 bdx:OtherInitiativesMember 2019-09-30 0000010795 bdx:CRBardIncMember 2019-10-01 2019-12-31 0000010795 bdx:CRBardIncMember 2019-09-30 0000010795 us-gaap:EmployeeSeveranceMember bdx:OtherInitiativesMember 2019-09-30 0000010795 bdx:LifeSciencesMember 2019-12-31 0000010795 bdx:MedicalMember 2019-09-30 0000010795 bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:LifeSciencesMember 2019-09-30 0000010795 bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:MedicalMember 2019-12-31 0000010795 bdx:InterventionalMember 2019-12-31 0000010795 bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 bdx:InterventionalMember 2019-09-30 0000010795 bdx:ProductRightsMember 2019-12-31 0000010795 us-gaap:TrademarksMember 2019-12-31 0000010795 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000010795 us-gaap:TrademarksMember 2019-12-31 0000010795 us-gaap:DevelopedTechnologyRightsMember 2019-09-30 0000010795 us-gaap:CustomerRelationshipsMember 2019-09-30 0000010795 bdx:ProductRightsMember 2019-09-30 0000010795 us-gaap:CustomerRelationshipsMember 2019-12-31 0000010795 us-gaap:IntellectualPropertyMember 2019-09-30 0000010795 us-gaap:TrademarksMember 2019-09-30 0000010795 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2019-12-31 0000010795 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2019-09-30 0000010795 us-gaap:IntellectualPropertyMember 2019-12-31 0000010795 us-gaap:TrademarksMember 2019-09-30 0000010795 us-gaap:CurrencySwapMember 2018-10-01 2018-12-31 0000010795 us-gaap:CurrencySwapMember 2019-10-01 2019-12-31 0000010795 bdx:ForeignCurrencyDenominatedDebtMember 2019-10-01 2019-12-31 0000010795 bdx:ForeignCurrencyDenominatedDebtMember 2018-10-01 2018-12-31 0000010795 bdx:FixedToFloatingMember us-gaap:FairValueHedgingMember 2019-12-31 0000010795 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-10-01 2019-12-31 0000010795 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0000010795 us-gaap:ForeignExchangeContractMember 2019-12-31 0000010795 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-12-31 0000010795 us-gaap:CurrencySwapMember 2019-12-31 0000010795 us-gaap:ForeignExchangeContractMember 2019-09-30 0000010795 us-gaap:CurrencySwapMember 2019-09-30 0000010795 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-09-30 0000010795 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember 2019-09-30 0000010795 bdx:FixedToFloatingMember us-gaap:FairValueHedgingMember 2019-09-30 0000010795 srt:MinimumMember 2019-10-01 2019-12-31 0000010795 srt:MaximumMember 2019-10-01 2019-12-31 0000010795 srt:MinimumMember 2019-12-31 0000010795 srt:MaximumMember 2019-12-31 bdx:segment iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2019
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission file number 001-4802
Becton, Dickinson and Company
(Exact name of registrant as specified in its charter)
New Jersey
 
22-0760120
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
 
 
 
 
 
1 Becton Drive,
Franklin Lakes,
New Jersey
07417-1880
 
(201)
847-6800
(Address of principal executive offices) (Zip Code)
 
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
 
Trading Symbol
 
Name of Each Exchange on Which Registered
Common stock, par value $1.00
 
BDX
 
New York Stock Exchange
Depositary Shares, each representing 1/20th of a share of 6.125% Cumulative Preferred Stock Series A
 
BDXA
 
New York Stock Exchange
1.000% Notes due December 15, 2022
 
BDX22A
 
New York Stock Exchange
1.900% Notes due December 15, 2026
 
BDX26
 
New York Stock Exchange
1.401% Notes due May 24, 2023
 
BDX23A
 
New York Stock Exchange
3.020% Notes due May 24, 2025
 
BDX25
 
New York Stock Exchange
0.174% Notes due June 4, 2021
 
BDX/21
 
New York Stock Exchange
0.632% Notes due June 4, 2023
 
BDX/23A
 
New York Stock Exchange
1.208% Notes due June 4, 2026
 
BDX/26A
 
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No   ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
☒
  
Accelerated filer
 
☐
Non-accelerated filer
 
☐
 
Smaller reporting company
 
☐
Emerging growth company
 
☐
 
 
 
 
 
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
There were 271,173,148 shares of Common Stock, $1.00 par value, outstanding at December 31, 2019.

 


BECTON, DICKINSON AND COMPANY
FORM 10-Q
For the quarterly period ended December 31, 2019
TABLE OF CONTENTS
 
 
Page
Number
Part I.
FINANCIAL INFORMATION
 
 
 
 
Item 1.
 
 
 
 
 
 
Item 2.
Item 3.
Item 4.
 
 
 
Part II.
 
 
 
 
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
 
 
 
 

2


ITEM 1. FINANCIAL STATEMENTS
BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED BALANCE SHEETS
Millions of dollars
 
December 31,
2019
 
September 30,
2019
Assets
(Unaudited)
 
 
Current Assets:
 
 
 
Cash and equivalents
$
560

 
$
536

Restricted cash
49

 
54

Short-term investments
8

 
30

Trade receivables, net
2,074

 
2,345

Inventories:
 
 
 
Materials
599

 
544

Work in process
350

 
318

Finished products
1,811

 
1,717

 
2,760

 
2,579

Prepaid expenses and other
987

 
1,119

Total Current Assets
6,438

 
6,664

Property, Plant and Equipment
11,425

 
11,128

Less allowances for depreciation and amortization
5,643

 
5,469

Property, Plant and Equipment, Net
5,782

 
5,659

Goodwill
23,435

 
23,376

Developed Technology, Net
10,848

 
11,054

Customer Relationships, Net
3,345

 
3,424

Other Intangibles, Net
532

 
500

Other Assets
1,573

 
1,088

Total Assets
$
51,952

 
$
51,765

Liabilities and Shareholders’ Equity
 
 
 
Current Liabilities:
 
 
 
Short-term debt
$
2,456

 
$
1,309

Payables, accrued expenses and other current liabilities
4,269

 
4,345

Total Current Liabilities
6,726

 
5,655

Long-Term Debt
16,949

 
18,081

Long-Term Employee Benefit Obligations
1,290

 
1,272

Deferred Income Taxes and Other Liabilities
5,785

 
5,676

Commitments and Contingencies (See Note 5)


 


Shareholders’ Equity
 
 
 
Preferred stock
2

 
2

Common stock
347

 
347

Capital in excess of par value
16,320

 
16,270

Retained earnings
12,938

 
12,913

Deferred compensation
24

 
23

Common stock in treasury - at cost
(6,228
)
 
(6,190
)
Accumulated other comprehensive loss
(2,202
)
 
(2,283
)
Total Shareholders’ Equity
21,202

 
21,081

Total Liabilities and Shareholders’ Equity
$
51,952

 
$
51,765

Amounts may not add due to rounding.
See notes to condensed consolidated financial statements

3


BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Millions of dollars, except per share data
(Unaudited)
 
Three Months Ended
December 31,
 
2019
 
2018
Revenues
$
4,225

 
$
4,160

Cost of products sold
2,247

 
2,187

Selling and administrative expense
1,121

 
1,073

Research and development expense
270

 
258

Acquisitions and other restructurings
86

 
91

Other operating income, net
—

 
(335
)
Total Operating Costs and Expenses
3,724

 
3,273

Operating Income
501

 
888

Interest expense
(136
)
 
(171
)
Interest income, net
1

 
(12
)
Other income, net
27

 
10

Income Before Income Taxes
394

 
714

Income tax provision
117

 
115

Net Income
278

 
599

Preferred stock dividends
(38
)
 
(38
)
Net income applicable to common shareholders
$
240

 
$
562

 
 
 
 
 
 
 
 
Basic Earnings per Share
$
0.88

 
$
2.09

Diluted Earnings per Share
$
0.87

 
$
2.05

Dividends per Common Share
$
0.79

 
$
0.77

Amounts may not add due to rounding.
See notes to condensed consolidated financial statements

4


BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Millions of dollars
(Unaudited)
 
Three Months Ended
December 31,
 
2019
 
2018
Net Income
$
278

 
$
599

Other Comprehensive Income (Loss), Net of Tax
 
 
 
Foreign currency translation adjustments
26

 
(35
)
Defined benefit pension and postretirement plans
17

 
15

Cash flow hedges
39

 
1

Other Comprehensive Income (Loss), Net of Tax
82

 
(18
)
Comprehensive Income
$
359

 
$
581

Amounts may not add due to rounding.
See notes to condensed consolidated financial statements

5


BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Millions of dollars
(Unaudited)
 
Three Months Ended
December 31,
 
2019
 
2018
Operating Activities
 
 
 
Net income
$
278

 
$
599

Adjustments to net income to derive net cash provided by operating activities:
 
 
 
Depreciation and amortization
530

 
563

Share-based compensation
82

 
93

Deferred income taxes
(71
)
 
(28
)
Change in operating assets and liabilities
102

 
(473
)
Pension obligation
24

 
(225
)
Gain on sale of business
—

 
(335
)
Other, net
(231
)
 
52

Net Cash Provided by Operating Activities
713

 
245

Investing Activities
 
 
 
Capital expenditures
(173
)
 
(167
)
Proceeds from divestitures, net
—

 
476

Other, net
(114
)
 
(9
)
Net Cash (Used for) Provided by Investing Activities
(287
)
 
299

Financing Activities
 
 
 
Change in credit facility borrowings
210

 
50

Payments of debt and term loans
(303
)
 
(453
)
Dividends paid
(252
)
 
(245
)
Other, net
(68
)
 
(86
)
Net Cash Used for Financing Activities
(413
)
 
(734
)
Effect of exchange rate changes on cash and equivalents and restricted cash
6

 
(5
)
Net increase (decrease) in cash and equivalents and restricted cash
18

 
(195
)
Opening Cash and Equivalents and Restricted Cash
590

 
1,236

Closing Cash and Equivalents and Restricted Cash
$
609

 
$
1,042

Amounts may not add due to rounding.
See notes to condensed consolidated financial statements

6


BECTON, DICKINSON AND COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2019
Note 1 – Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, in the opinion of the management of Becton, Dickinson and Company (the "Company" or "BD"), include all adjustments which are of a normal recurring nature, necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented. However, the financial statements do not include all information and accompanying notes required for a presentation in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s 2019 Annual Report on Form 10-K. Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.
Note 2 – Accounting Changes
New Accounting Principle Adopted
In February 2016, the Financial Accounting Standards Board ("FASB") issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet, as well as requires expanded disclosures regarding leasing arrangements. The Company adopted this standard on October 1, 2019 and elected certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company also elected not to perform any reassessments relative to its expired and existing leases upon its adoption of the new requirements. The Company's adoption of this standard did not materially impact its condensed consolidated financial statements. Additional disclosures regarding the Company’s lease arrangements are provided in Note 14.
New Accounting Principles Not Yet Adopted
In June 2016, the FASB issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption on October 1, 2020.
In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The standard is effective for the Company on October 1, 2020, but early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption.

7


Note 3 – Shareholders' Equity
Changes in certain components of shareholders' equity for the first quarters of fiscal years 2020 and 2019 were as follows:
 
Common
Stock  Issued
at Par Value
 
Capital in
Excess of
Par Value
 
Retained
Earnings
 
Deferred
Compensation
 
Treasury Stock
(Millions of dollars)
Shares (in
thousands)
 
Amount
Balance at September 30, 2019
$
347

 
$
16,270

 
$
12,913

 
$
23

 
(76,260
)
 
$
(6,190
)
Net income
—

 
—

 
278

 
—

 
—

 
—

Common dividends ($0.79 per share)
—

 
—

 
(215
)
 
—

 
—

 
—

Preferred dividends
—

 
—

 
(38
)
 
—

 
—

 
—

Common stock issued for share-based compensation and other plans, net
—

 
(32
)
 
—

 
1

 
758

 
(38
)
Share-based compensation
—

 
82

 
—

 
—

 
—

 
—

Common stock held in trusts, net (a)
—

 
—

 
—

 
—

 
(12
)
 
—

Balance at December 31, 2019
$
347

 
$
16,320

 
$
12,938

 
$
24

 
(75,514
)
 
$
(6,228
)
 
Common
Stock  Issued
at Par Value
 
Capital in
Excess of
Par Value
 
Retained
Earnings
 
Deferred
Compensation
 
Treasury Stock
(Millions of dollars)
Shares (in
thousands)
 
Amount
Balance at September 30, 2018
$
347

 
$
16,179

 
$
12,596

 
$
22

 
(78,463
)
 
$
(6,243
)
Net income
—

 
—

 
599

 
—

 
—

 
—

Common dividends ($0.77 per share)
—

 
—

 
(207
)
 
—

 
—

 
—

Preferred dividends
—

 
—

 
(38
)
 
—

 
—

 
—

Common stock issued for share-based compensation and other plans, net
—

 
(97
)
 
—

 
2

 
851

 
9

Share-based compensation
—

 
92

 
—

 
—

 
—

 
—

Common stock held in trusts, net (a)
—

 
—

 
—

 
—

 
(12
)
 
—

Effect of change in accounting principles
—

 
—

 
68

 
—

 
—

 
—

Balance at December 31, 2018
$
347

 
$
16,174

 
$
13,018

 
$
24

 
(77,624
)
 
$
(6,235
)
(a)
Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.

8


The components and changes of Accumulated other comprehensive income (loss) for the first quarters of fiscal years 2020 and 2019 were as follows:
(Millions of dollars)
Total
 
Foreign Currency
Translation
 
Benefit Plans
 

Cash Flow Hedges
Balance at September 30, 2019
$
(2,283
)
 
$
(1,256
)
 
$
(1,005
)
 
$
(23
)
Other comprehensive income before reclassifications, net of taxes
63

 
26

 
—

 
37

Amounts reclassified into income, net of taxes
19

 
—

 
17

 
2

Balance at December 31, 2019
$
(2,202
)
 
$
(1,230
)
 
$
(988
)
 
$
16

(Millions of dollars)
Total
 
Foreign Currency
Translation
 
Benefit Plans
 

Cash Flow Hedges
Balance at September 30, 2018
$
(1,909
)
 
$
(1,162
)
 
$
(729
)
 
$
(17
)
Other comprehensive (loss) income before reclassifications, net of taxes
(32
)
 
(35
)
 
3

 
(1
)
Amounts reclassified into income, net of taxes
14

 
—

 
13

 
1

Balance at December 31, 2018
$
(1,927
)
 
$
(1,197
)
 
$
(714
)
 
$
(16
)
The amounts of foreign currency translation recognized in other comprehensive income during the three months ended December 31, 2019 and 2018 included net (losses) gains relating to net investment hedges. The amount recognized in other comprehensive income relating to cash flow hedges during the three months ended December 31, 2019 related to forward starting interest rate swaps. Additional disclosures regarding the Company's derivatives are provided in Note 12.
 
 
 
 
 
 
 
 

Note 4 – Earnings per Share
The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:
 
Three Months Ended
December 31,
 
2019
 
2018
Average common shares outstanding
271,102

 
269,035

Dilutive share equivalents from share-based plans
3,850

 
5,221

Average common and common equivalent shares outstanding – assuming dilution
274,952

 
274,256

 
 
 
 
Share equivalents excluded from the diluted shares outstanding calculation because the result would have been antidilutive:
 
 
 
Mandatory convertible preferred stock
11,685

 
11,685


Note 5 – Contingencies
Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved.

9


In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows.
Product Liability Matters
The Company believes that certain settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the Company from other parties, which if disputed, the Company intends to vigorously contest. Amounts recovered under the Company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available.
Hernia Product Claims
As of December 31, 2019, the Company is defending approximately 14,330 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The majority of those claims are currently pending in a coordinated proceeding in Rhode Island State Court, but claims are also pending in other state and/or federal court jurisdictions. In addition, those claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. From time to time, the Company engages in resolution discussions with plaintiffs’ law firms regarding certain of the Hernia Product Claims, but the Company also intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Trials are scheduled throughout 2020 in various state and/or federal courts. The Company expects additional trials of Hernia Product Claims to take place over the next 12 months. In August 2018, a new hernia multi-district litigation (“MDL”) was ordered to be established in the Southern District of Ohio. The Company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity.
Women’s Health Product Claims
As of December 31, 2019, the Company is defending approximately 750 product liability claims involving the Company’s line of pelvic mesh devices. The majority of those claims are currently pending in various federal court jurisdictions, and a coordinated proceeding in New Jersey State Court, but claims are also pending in other state court jurisdictions. In addition, those claims include putative class actions filed in the United States. Not included in the figures above are approximately 1,010 filed and unfiled claims that have been asserted or threatened against the Company but lack sufficient information to determine whether a pelvic mesh device of the Company is actually at issue.
The claims identified above also include products manufactured by both the Company and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of the Company. Medtronic has an obligation to defend and indemnify the Company with respect to any product defect liability relating to products its subsidiaries had manufactured. In July 2015, the Company reached an agreement with Medtronic in which Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the Company under supply agreements with Medtronic. In June 2017, the Company amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic towards these potential settlements. As of December 31, 2019, the Company has paid Medtronic $141 million towards these potential settlements. The Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. The foregoing lawsuits, unfiled claims, putative class actions, and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims.” The Women’s Health Product Claims generally seek damages for personal injury allegedly resulting from use of the products.
As of December 31, 2019, the Company has reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately 15,165 of the Women’s Health Product Claims. The Company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which are not included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain

10


minimum number of plaintiffs. The Company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements.
Starting in 2014 in the MDL, the court entered certain pre-trial orders requiring trial work up and remand of a significant number of Women’s Health Product Claims, including an order entered in the MDL on January 30, 2018, that requires the work up and remand of all remaining unsettled cases (the “WHP Pre-Trial Orders”). The WHP Pre-Trial Orders may result in material additional costs or trial verdicts in future periods in defending Women’s Health Product Claims. Trials are anticipated throughout 2020 in state and federal courts. A trial in the New Jersey coordinated proceeding began in March 2018, and in April 2018 a jury entered a verdict against the Company in the total amount of $68 million ($33 million compensatory; $35 million punitive). The Company is in the process of appealing that verdict. The Company expects additional trials of Women’s Health Product Claims to take place over the next 12 months, which may potentially include consolidated trials.
During the course of engaging in settlement discussions with plaintiffs’ law firms, the Company has learned, and may in future periods learn, additional information regarding these and other unfiled claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company.
Filter Product Claims
As of December 31, 2019, the Company is defending approximately 2,650 product liability claims involving the Company’s line of inferior vena cava filters (collectively, the “Filter Product Claims”). The majority of those claims are currently pending in an MDL in the United States District Court for the District of Arizona, but those MDL claims either have been, or are in the process of being, remanded to various federal jurisdictions. Filter Product Claims are also pending in various state court jurisdictions, including a coordinated proceeding in Arizona State Court. In addition, those claims include putative class actions filed in the United States and Canada. The Filter Product Claims generally seek damages for personal injury allegedly resulting from use of the products. The Company has limited information regarding the nature and quantity of certain of the Filter Product Claims. The Company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. On May 31, 2019, the MDL Court ceased accepting direct filings or transfers into the Filter Product Claims MDL and, as noted above, remands for non-settled cases have begun and are expected to continue over the next three months. Federal and state court trials are scheduled throughout 2020. As of December 31, 2019, the Company entered into settlement agreements and/or settlement agreements in principle for approximately 6,400 cases. On March 30, 2018, a jury in the first MDL trial found the Company liable for negligent failure to warn and entered a verdict in favor of plaintiffs. The jury found the Company was not liable for (a) strict liability design defect; (b) strict liability failure to warn; and (c) negligent design. The Company has appealed that verdict. On June 1, 2018, a jury in the second MDL trial unanimously found in favor of the Company on all claims. On August 17, 2018, the Court entered summary judgment in favor of the Company on all claims in the third MDL trial. On October 5, 2018, a jury in the fourth MDL trial unanimously found in favor of the Company on all claims. The Company expects additional trials of Filter Product Claims may take place over the next 12 months.
In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.
In connection with the settlement of a prior litigation with certain of the Company's insurance carriers, an agreement with the Company's insurance carriers was reached to reimburse the Company for certain future costs incurred in connection with Filter Product Claims up to an agreed amount. For certain product liability claims or lawsuits, the Company does not maintain or has limited remaining insurance coverage.
Other Legal Matters
Since early 2013, the Company has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the Company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The Company is cooperating with these requests. Although the Company has had, and continues to have, discussions with the State Attorneys General with respect to overall potential resolution of this matter, there can be no assurance that a resolution will be reached or what the terms of any such resolution may be.
In July 2017, a civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec® and

11


QuantaFloTM devices. The Company is cooperating with these requests. Since it is not feasible to predict the outcome of these matters, the Company cannot give any assurances that the resolution of these matters will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity.
The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the Company’s business and/or results of operations.
The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses to these suits pending against the Company and is engaged in a vigorous defense of each of these matters.
Litigation Reserves
The Company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.
In the second and fourth quarters of fiscal year 2019, the Company recorded pre-tax charges to Other operating expense, net, of approximately $331 million and $582 million, respectively, related to certain of the product liability matters discussed above under the heading “Product Liability Matters,” including the related legal defense costs. The Company recorded these charges based on additional information obtained during the second and fourth quarters of fiscal year 2019, including but not limited to: the nature and quantity of unfiled and filed claims and the continued rate of claims being filed in certain product liability matters; the status of certain settlement discussions with plaintiffs’ counsel; the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the Company; and the stage of litigation.
Accruals for the Company's product liability claims which are discussed above, as well as the related legal defense costs, amounted to approximately $2.4 billion at December 31, 2019 and $2.5 billion at September 30, 2019. These accruals, which are generally long-term in nature, are largely recorded within Deferred Income Taxes and Other Liabilities on the Company's condensed consolidated balance sheets. As of December 31, 2019 and September 30, 2019, the Company had $48 million and $53 million, respectively, in qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters. Payments to QSFs are recorded as a component of Restricted cash. The Company's expected recoveries related to product liability claims and related legal defense costs were approximately $152 million and $150 million at December 31, 2019 and September 30, 2019, respectively. A substantial amount of these expected recoveries at December 31, 2019 and September 30, 2019 related to the Company’s agreements with Medtronic related to certain Women’s Health Product Claims. The expected recoveries at December 31, 2019 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements.
Note 6 – Revenues
The Company’s policies for recognizing sales have not changed from those described in the Company’s 2019 Annual Report on Form 10-K. The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

12


Measurement of Revenues
The Company’s estimate of probable credit losses relating to trade receivables is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. Such amounts are not material to the Company's consolidated financial results.
The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. The impact of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues.
Effects of Revenue Arrangements on Consolidated Balance Sheets
Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's condensed consolidated balance sheets. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's condensed consolidated balance sheets.
Contract liabilities for unearned revenue that is allocable to performance obligations, such as extended warranty and software maintenance contracts, which are performed over time are immaterial to the Company's consolidated financial results. The Company's liability for product warranties provided under its agreements with customers is not material to its condensed consolidated balance sheets.
Remaining Performance Obligations
The Company's obligations relative to service contracts and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided are estimated to be approximately $1.8 billion at December 31, 2019. The Company expects to recognize the majority of this revenue over the next three years.
Within the Company's Medication Management Solutions, Medication Delivery Solutions, Integrated Diagnostic Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately $2.7 billion at December 31, 2019.  This revenue will be recognized over the customer relationship period.
Disaggregation of Revenues
A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note 7.
Note 7 – Segment Data
The Company's organizational structure is based upon three principal business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.

13


Effective October 1, 2019, Life Sciences joined its former Preanalytical Systems and Diagnostic Systems organizational units to create a new Integrated Diagnostic Solutions organizational unit which focuses on driving growth and innovation around integrated specimen management to diagnostic solutions. The Integrated Diagnostic Solutions organizational unit consists of the following principal product lines:
Organizational Unit
 
Principal Product Lines
Integrated Diagnostic Solutions
 
Integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays for testing of respiratory infections; microbiology laboratory automation and plated media for clinical and industrial applications.
Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues.
 
Three Months Ended December 31,
(Millions of dollars)
2019
 
2018
 
United States
 
International
 
Total
 
United States
 
International
 
Total
Medical
 
 
 
 
 
 
 
 
 
 
 
Medication Delivery Solutions (a)
$
520

 
$
428

 
$
948

 
$
519

 
$
438

 
$
956

Medication Management Solutions (a)
462

 
113

 
575

 
508

 
118

 
625

Diabetes Care
139

 
129

 
268

 
145

 
129

 
274

Pharmaceutical Systems
84

 
215

 
299

 
68

 
212

 
280

Total segment revenues
$
1,204

 
$
886

 
$
2,090

 
$
1,239

 
$
896

 
$
2,135

 
 
 
 
 
 
 
 
 
 
 
 
Life Sciences
 
 
 
 
 
 
 
 
 
 
 
Integrated Diagnostic Solutions
 
 
 
 
 
 
 
 
 
 
 
Preanalytical Systems
$
202

 
$
196

 
$
398

 
$
201

 
$
192

 
$
393

Diagnostic Systems
184

 
218

 
402

 
175

 
207

 
382

Total Integrated Diagnostic Solutions
386

 
414

 
800

 
376

 
399

 
774

Biosciences
152

 
171

 
323

 
108

 
173

 
281

Total segment revenues
$
538

 
$
585

 
$
1,123

 
$
484

 
$
572

 
$
1,056

 
 
 
 
 
 
 
 
 
 
 
 
Interventional
 
 
 
 
 
 
 
 
 
 
 
Surgery (b)
$
256

 
$
70

 
$
326

 
$
246

 
$
64

 
$
310

Peripheral Intervention (b)
225

 
170

 
395

 
223

 
160

 
382

Urology and Critical Care (b)
206

 
85

 
291

 
195

 
83

 
277

Total segment revenues
$
688

 
$
325

 
$
1,012

 
$
664

 
$
306

 
$
970

 
 
 
 
 
 
 
 
 
 
 
 
Total Company revenues
$
2,430

 
$
1,795

 
$
4,225

 
$
2,387

 
$
1,773

 
$
4,160

(a)
Prior-period amounts reflect the reclassification of U.S. revenues of $2 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.
(b)Prior-period amounts reflect the total reclassifications of $31 million of U.S. revenues and $14 million of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.
 
 
 
 
 
 
 
 
 
 
 
 

14


Segment income for the three-month periods was as follows:
 
Three Months Ended
December 31,
(Millions of dollars)
2019
 
2018
Income Before Income Taxes
 
 
 
Medical (a)
$
564

 
$
665

Life Sciences
361

 
305

Interventional
243

 
209

Total Segment Operating Income
1,167

 
1,180

Acquisitions and other restructurings
(86
)
 
(91
)
Net interest expense
(134
)
 
(183
)
Other unallocated items (b)
(553
)
 
(192
)
Total Income Before Income Taxes
$
394

 
$
714

(a)
The amount for the three months ended December 31, 2019 included the estimated cost of a product recall of $59 million which was recorded to Cost of products sold and is further discussed in Note 15.
(b)
Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount for the three months ended December 31, 2018 included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $335 million, which is further discussed in Note 9.
Note 8 – Benefit Plans
The Company has defined benefit pension plans covering certain employees in the United States and certain international locations. The measurement date used for these plans is September 30.
Net pension cost included the following components for the three months ended December 31:
 
Three Months Ended
December 31,
(Millions of dollars)
2019
 
2018
Service cost
$
40

 
$
35

Interest cost
22

 
28

Expected return on plan assets
(49
)
 
(47
)
Amortization of prior service credit
(3
)
 
(3
)
Amortization of loss
25

 
20

Net pension cost
$
35

 
$
32

The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in Accumulated other comprehensive income (loss) in prior periods. All components of the Company’s net periodic pension cost, aside from service cost, are recorded to Other income (expense), net on its condensed consolidated statements of income.
Note 9 – Divestiture
The Company completed the sale of its Life Sciences segment's Advanced Bioprocessing business in October 2018 pursuant to a definitive agreement that was signed in September 2018. The Company recognized a pre-tax gain on the sale of approximately $335 million which was recorded as a component of Other operating income, net in the first quarter of fiscal year 2019.

15


Note 10 – Business Restructuring Charges
The Company incurred restructuring costs during the three months ended December 31, 2019, in connection with the Company's acquisition of C.R. Bard, Inc. ("Bard") and portfolio rationalization initiatives, which were largely recorded within Acquisitions and other restructurings. Restructuring liability activity for the three months ended December 31, 2019 was as follows:
(Millions of dollars)
Employee
Termination
 
Other
 
Total
 
Bard
 
Other Initiatives
 
Bard (a)
 
Other Initiatives
 
Bard
 
Other Initiatives
Balance at September 30, 2019
$
22

 
$
31

 
$
1

 
$
3

 
$
23

 
$
34

Charged to expense
4

 
2

 
13

 
4

 
17

 
6

Cash payments
(7
)
 
(12
)
 
(6
)
 
(4
)
 
(13
)
 
(16
)
Non-cash settlements
—

 
—

 
(7
)
 
—

 
(7
)
 
—

Balance at December 31, 2019
$
19

 
$
21

 
1

 
$
3

 
$
20

 
$
24


(a)
Largely represents the cost associated with certain pre-acquisition equity awards of Bard which, to encourage post-acquisition employee retention, were converted to BD equity awards with substantially the same terms and conditions as were applicable under such Bard awards immediately prior to the acquisition date. 
Note 11 – Intangible Assets
Intangible assets consisted of:
 
December 31, 2019
 
September 30, 2019
(Millions of dollars)
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Gross
Carrying
Amount
 
Accumulated
Amortization
Amortized intangible assets
 
 
 
 
 
 
 
Developed technology
$
14,010

 
$
3,161

 
$
13,960

 
$
2,906

Customer relationships
4,610

 
1,265

 
4,608

 
1,183

Product rights
115

 
65

 
110

 
60

Trademarks
407

 
106

 
407

 
102

Patents and other
488

 
311

 
445

 
305

Amortized intangible assets
$
19,630

 
$
4,908

 
$
19,530

 
$
4,555

Unamortized intangible assets
 
 
 
 
 
 
 
Acquired in-process research and development
$
1

 
 
 
$
1

 
 
Trademarks
2

 
 
 
2

 
 
Unamortized intangible assets
$
3

 
 
 
$
3

 
 

Intangible amortization expense for the three months ended December 31, 2019 and 2018 was $345 million and $378 million, respectively.
The following is a reconciliation of goodwill by business segment:
(Millions of dollars)
Medical
 
Life Sciences
 
Interventional
 
Total
Goodwill as of September 30, 2019
$
9,989

  
$
772

 
$
12,615

  
$
23,376

Acquisitions (a)
10

 
—

 
—

 
10

Currency translation
17

 
2

 
30

 
49

Goodwill as of December 31, 2019
$
10,016

  
$
774

 
$
12,645

  
$
23,435

(a)
Represents goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate.

16


Note 12 – Derivative Instruments and Hedging Activities
The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items have on financial position, financial performance, and cash flows are provided below.
Foreign Currency Risks and Related Strategies
The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts. In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has hedged the currency risk associated with those investments with instruments, such as foreign currency-denominated debt, cross-currency swaps and currency exchange contracts, which are designated as net investment hedges.
Hedges of the transactional foreign exchange exposures resulting primarily from intercompany payables and receivables are undesignated hedges. As such, the gains or losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. The net amounts recognized in Other income, net, during the three months ended December 31, 2019 and 2018 were immaterial to the Company's consolidated financial results. The total notional amounts of the Company’s outstanding foreign exchange contracts as of December 31, 2019 and September 30, 2019 were $1.2 billion and $2.3 billion, respectively.
Certain of the Company's foreign currency-denominated long-term notes outstanding, which had a total carrying value of $1.4 billion as of December 31, 2019 and September 30, 2019, were designated as, and were effective as, economic hedges of net investments in certain of the Company's foreign subsidiaries. The Company has entered into cross-currency swaps, all of which are designated and effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. The notional amounts of the cross-currency swaps were $3.0 billion and $2.3 billion as of December 31, 2019 and September 30, 2019, respectively.
Net gains or losses relating to the net investment hedges, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as accumulated foreign currency translation in Other comprehensive income (loss). Upon the termination of a net investment hedge, any net gain or loss included in Accumulated other comprehensive income (loss) relative to the investment hedge remains until the foreign subsidiary investment is disposed of or is substantially liquidated.
Net (losses) gains recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges for the three-month periods were as follows:
 
Three Months Ended
December 31,
(Millions of dollars)
2019
 
2018
Foreign currency-denominated debt
$
(34
)
 
$
59

Cross-currency swaps
$
(52
)
 
$
—


Interest Rate Risks and Related Strategies
The Company’s policy is to manage interest rate exposure using a mix of fixed and variable rate debt. The Company periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either fair value or cash flow hedges.
For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates.
The total notional amount of the Company’s outstanding interest rate swaps designated as fair value hedges was $375 million at December 31, 2019 and September 30, 2019. The outstanding swaps represent fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. Changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt. The amounts recorded during the three months ended December 31, 2019 and 2018 for changes in the fair value of these hedges were immaterial to the Company's consolidated financial results.

17


Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss). If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings over the remaining life of the hedged debt. The net realized loss related to terminated interest rate swaps expected to be reclassified and recorded in Interest expense within the next 12 months is $6 million, net of tax.
The total notional amount of the Company's outstanding forward starting interest rate swaps was $1.5 billion at December 31, 2019 and September 30, 2019. The Company entered into these contracts in the fourth quarter of fiscal year 2019 to mitigate its exposure to interest rate risk. The Company recognized an after-tax gain of $37 million in other comprehensive income relating to these interest rate hedges during the three months ended December 31, 2019.
 
 
 
 
 
 
 
 

Other Risk Exposures
The Company purchases resins, which are oil-based components used in the manufacture of certain products. Significant increases in world oil prices that lead to increases in resin purchase costs could impact future operating results. From time to time, the Company has managed price risks associated with these commodity purchases through commodity derivative forward contracts. The Company's outstanding commodity derivative forward contracts at December 31, 2019 and September 30, 2019 were immaterial to the Company's consolidated financial results.
Financial Statement Effects
The fair values of derivative instruments outstanding at December 31, 2019 and September 30, 2019 were not material to the Company's consolidated balance sheets.
 

The amounts reclassified from accumulated other comprehensive income relating to cash flow hedges during the three months ended December 31, 2019 and 2018 were not material to the Company's consolidated financial results.
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 

Note 13 – Financial Instruments and Fair Value Measurements
The following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at December 31, 2019 and September 30, 2019 to the total of these amounts shown on the Company's consolidated statements of cash flows:
(Millions of dollars)
December 31, 2019
 
September 30, 2019
Cash and equivalents
$
560

 
$
536

Restricted cash
49

 
54

Cash and equivalents and restricted cash
$
609

 
$
590


Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted cash consists of cash restricted from withdrawal and usage except for certain product liability matters.
The Company’s cash and equivalents include institutional money market accounts which permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy. The fair value of these accounts was immaterial at December 31, 2019 and the fair value of these accounts at September 30, 2019 was $39 million. The Company’s remaining cash and equivalents, excluding restricted cash, were $560 million and $497 million at December 31, 2019 and September 30, 2019, respectively.
Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments consist of instruments with maturities greater than three months and less than one year.
Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments, which are considered Level 2 inputs in the fair value hierarchy. The fair value of long-term debt was $18.1 billion and $19.2 billion at December 31, 2019 and September 30, 2019, respectively. The fair value of the current portion of long-term debt was $2.5 billion and $1.3 billion at December 31, 2019 and September 30, 2019, respectively.
All other instruments measured by the Company at fair value, including derivatives and contingent consideration liabilities, are immaterial to the Company's consolidated balance sheets.

18


Transfers of trade receivables
Over the normal course of its business activities, the Company transfers certain trade receivable assets to third parties under factoring agreements. Per the terms of these agreements, the Company surrenders control over its trade receivables upon transfer.  Accordingly, the Company accounts for the transfers as sales of trade receivables by recognizing an increase to Cash and equivalents and a decrease to Trade receivables, net when proceeds from the transactions are received.  The Company’s balance of Trade receivables, net at December 31, 2019 excludes trade receivables of $328 million that have been transferred to third parties under factoring arrangements.  The costs incurred by the Company in connection with factoring activities were not material to its consolidated financial results.  The Company’s transfers of trade receivables during the three months ended December 31, 2018 were not material to its consolidated financial results.

Note 14 – Leases
The Company leases real estate, vehicles and other equipment which are used in the Company’s manufacturing, administrative and research and development activities. The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. The Company’s lease arrangements are generally classified as operating leases. These arrangements have remaining terms ranging from less than one year to approximately 25 years and the weighted-average remaining lease term of the Company’s leases is approximately 7.5 years. An option to renew or terminate the current term of a lease arrangement is included in the lease term if the Company is reasonably certain to exercise that option.
The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet. For the longer-term lease arrangements that are recognized on the Company’s consolidated balance sheet, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. The costs associated with the Company’s short-term leases, as well as variable costs relating to the Company’s lease arrangements, are not material to its consolidated financial results.
The implicit interest rates of the Company’s lease arrangements are generally not readily determinable and as such, the Company applies an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. The weighted-average incremental borrowing rate that has been applied to measure the Company’s lease liabilities is 2.3%.
The Company’s lease costs recorded in its consolidated statement of income for the three months ended December 31, 2019 were $34 million. Cash payments arising from the Company’s lease arrangements are reflected on its condensed consolidated statement of cash flows as outflows used for operating activities. The right-of-use assets and lease liabilities recognized on the Company’s condensed consolidated balance sheet as of December 31, 2019 were as follows:
(Millions of dollars)
December 31, 2019
Right-use-assets recorded in Other Assets
$
426

Current lease liabilities recorded in Payables, accrued expenses and other current liabilities
$
105

Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities
$
340


The Company’s payments due under its operating leases are as follows:
(Millions of dollars)
 
Remaining for 2020
$
86

2021
95

2022
74

2023
49

2024
33

Thereafter
158

Total payments due
494

Less: imputed interest
49

Total
$
445



19


The Company’s future minimum rental commitments on non-cancelable leases at September 30, 2019, as disclosed in the Company’s 2019 Annual Report on Form 10-K, were as follows:
(Millions of dollars)
 
2020
$
122

2021
103

2022
83

2023
57

2024
56

Thereafter
123

Total
$
546


Note 15 – Subsequent Event
On February 4, 2020, the Company initiated a voluntary recall of certain AlarisTM pump systems in order to address software errors and other alarm prioritization matters. The estimated cost of this recall of $59 million was recorded to Cost of products sold during the three months ended December 31, 2019. The Company may record incremental charges in future periods associated with this recall.

20



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following commentary should be read in conjunction with the condensed consolidated financial statements and accompanying notes presented in this report. Within the tables presented throughout this discussion, certain columns may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts.
Company Overview
Becton, Dickinson and Company (“BD”) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's organizational structure is based upon three principal business segments, BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”).

BD’s products are manufactured and sold worldwide. Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. We organize our operations outside the United States as follows: Europe; EMA (which includes the Commonwealth of Independent States, the Middle East and Africa); Greater Asia (which includes countries in East Asia, South Asia, Southeast Asia and the Oceania region); Latin America (which includes Mexico, Central America, the Caribbean, and South America); and Canada. We continue to pursue growth opportunities in emerging markets, which include the following geographic regions: Eastern Europe, the Middle East, Africa, Latin America and certain countries within Greater Asia. We are primarily focused on certain countries whose healthcare systems are expanding.
Overview of Financial Results and Financial Condition
For the three months ended December 31, 2019, worldwide revenues of $4.225 billion increased 1.6% from the prior-year period which reflected volume growth of approximately 3.5%, an unfavorable impact from foreign currency translation of approximately 0.9% and pricing pressures of approximately 0.8%. Revenue growth in the first quarter also reflected an unfavorable impact of 0.2% attributable to the Biosciences unit's divestiture of its Advanced Bioprocessing business at the end of October 2018, as is further discussed in Note 9 in the Notes to Condensed Consolidated Financial Statements. Volume growth in the first quarter of fiscal year 2020 reflected the following:
•
Medical segment revenues in the first quarter reflected strong growth in the Pharmaceutical Systems unit.
•
Life Sciences segment revenues in the first quarter reflected growth in both of the segment's units, particularly in the Biosciences unit.
•
Interventional segment revenues in the first quarter reflected sales growth in all units.
First quarter Medical segment revenues were unfavorably impacted by the Medication Management Solutions unit's delay of shipments of AlarisTM infusion pumps pending compliance with certain regulatory filing requirements of the U.S. Food and Drug Administration ("FDA").  Currently, BD will only sell pumps to existing customers who demonstrate a medical necessity for the pumps.  As a result, we expect revenues from our Medication Management Solutions unit for the current fiscal year to decline significantly compared to the prior year. We expect the filing with the FDA to be made in BD’s fourth fiscal quarter.
We continue to invest in research and development, geographic expansion, and new product development programs to drive further revenue and profit growth. Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business (including geographical expansion), develop innovative new products, and continue to improve operating efficiency and organizational effectiveness. While the economic environment for the healthcare industry and healthcare utilization in the United States is generally stable, destabilization in the future could adversely impact our businesses. Additionally, macroeconomic challenges in Europe continue to constrain healthcare utilization, although we currently view the environment as stable. In emerging markets, the Company’s growth is dependent primarily on government funding for healthcare systems. In addition, pricing pressure exists globally which could adversely impact our businesses. 
Cash flows from operating activities were $713 million in the first three months of fiscal year 2020. At December 31, 2019, we had $617 million in cash and equivalents and short-term investments, including restricted cash. We continued to return value to our shareholders in the form of dividends. During the first three months of fiscal year 2020, we paid cash dividends of $252 million, including $215 million paid to common shareholders and $38 million paid to preferred shareholders.
Each reporting period, we face currency exposure that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. A stronger U.S. dollar, compared to the prior-year period, resulted in an unfavorable foreign currency translation impact to our revenues and earnings during the first quarter

21


of fiscal year 2020.  We evaluate our results of operations on both a reported and a foreign currency-neutral basis, which excludes the impact of fluctuations in foreign currency exchange rates. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Foreign currency-neutral ("FXN") information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a foreign currency-neutral basis as one measure to evaluate our performance. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior-period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. generally accepted accounting principles ("GAAP"). Results on a foreign currency-neutral basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.
Results of Operations
Medical Segment
The following summarizes first quarter Medical revenues by organizational unit:
 
Three months ended December 31,
(Millions of dollars)
2019
 
2018
 
Total
Change
 
Estimated
FX
Impact
 
FXN Change
Medication Delivery Solutions (a)
$
948

 
$
956

 
(0.9
)%
 
(1.1
)%
 
0.2
 %
Medication Management Solutions (a)
575

 
625

 
(8.0
)%
 
(0.5
)%
 
(7.5
)%
Diabetes Care
268

 
274

 
(1.9
)%
 
(0.9
)%
 
(1.0
)%
Pharmaceutical Systems
299

 
280

 
6.8
 %
 
(2.4
)%
 
9.2
 %
Total Medical Revenues
$
2,090

 
$
2,135

 
(2.1
)%
 
(1.0
)%
 
(1.1
)%
(a)
The presentation of prior-period amounts reflects the reclassification of $2 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.
First quarter Medical segment revenues were unfavorably impacted by the Medication Management Solutions unit's delay of shipments of AlarisTM infusion pumps, as previously discussed above. The Pharmaceutical Systems unit's revenues in the first quarter reflected strong sales of prefillable products. The Medication Delivery Solutions unit's revenues in the first quarter reflected strong global growth in sales of vascular access devices; however, this growth was largely offset by pricing pressures in China that were driven by a new volume-based procurement process which has been adopted by several of China's provinces. First quarter revenues in the Diabetes Care unit were unfavorably impacted by pricing pressures in the United States and also by the recent timing of orders, which favorably impacted revenues in the fourth quarter of fiscal year 2019.
 
 
 
 
 
 
 
 
 
 
Medical segment operating income for the three-month period is provided below.
 
Three months ended December 31,
(Millions of dollars)
2019
 
2018
Medical segment operating income
$
564

 
$
665

 
 
 
 
Segment operating income as % of Medical revenues
27.0
%
 
31.2
%

22


The Medical segment's operating income in the first quarter was driven by its performance with respect to gross profit margin and operating expenses as discussed in greater detail below:
•
Gross profit margin was lower in the first quarter of 2020 as compared with the first quarter of 2019 primarily due to the recognition of the estimated cost of a product recall, as noted below, and pricing pressures. These unfavorable impacts were partially offset by lower manufacturing costs resulting from continuous improvement projects which enhanced the efficiency of our operations.
•
Selling and administrative expense as a percentage of revenues was relatively flat in the first quarter of 2020 compared with the first quarter of 2019.
•
Research and development expense as a percentage of revenues was relatively flat in the first quarter of 2020 compared with the first quarter of 2019.
Life Sciences Segment
The following summarizes first quarter Life Sciences revenues by organizational unit:
 
Three months ended December 31,
(Millions of dollars)
2019
 
2018
 
Total
Change
 
Estimated
FX
Impact
 
FXN Change
Integrated Diagnostic Solutions (a)
 
 
 
 
 
 
 
 
 
Preanalytical Systems
$
398

 
$
393

 
1.4
%
 
(1.1
)%
 
2.5
%
Diagnostic Systems
402

 
382

 
5.3
%
 
(0.9
)%
 
6.2
%
Total Integrated Diagnostic Solutions
800

 
774

 
3.3
%
 
(1.0
)%
 
4.3
%
Biosciences
323

 
281

 
14.8
%
 
(1.2
)%
 
16.0
%
Total Life Sciences Revenues
$
1,123

 
$
1,056

 
6.4
%
 
(1.0
)%
 
7.4
%
(a)
Effective October 1, 2019, the Preanalytical Systems and Diagnostic Systems units were joined to create the new Integrated Diagnostic Solutions unit. Additional disclosures regarding this change are provided in Note 7 in the Notes to Condensed Consolidated Financial Statements.
The Life Sciences segment's revenues in the first quarter reflected strong sales of our molecular diagnostic platforms and microbiology solutions in the Integrated Diagnostic Solutions unit, as well as an earlier start to the current year's influenza season as compared with the prior year's season. This unit's growth was impacted by an unfavorable comparison of current-period sales in the former Preanalytical Systems unit to sales in the prior-year period, which benefited from both the introduction of new capacity during the first quarter of 2019 and the timing of distributor orders. First quarter revenue growth in the Biosciences unit was driven by licensing revenues, as well as by sales of instruments and reagents, but was unfavorably impacted by the divestiture of the Advanced Bioprocessing business, which was previously discussed above.
 
 
 
 
 
 
 
 
 
 
Life Sciences segment operating income for the three-month period was as follows:
 
Three months ended December 31,
(Millions of dollars)
2019
 
2018
Life Sciences segment operating income
$
361

 
$
305

 
 
 
 
Segment operating income as % of Life Sciences revenues
32.1
%
 
28.9
%
The Life Sciences segment's operating income in the first quarter was driven by its performance with respect to gross profit margin and operating expenses as discussed in greater detail below:
•
Gross margin in the first quarter of 2020 was higher as compared with the first quarter of 2019 which primarily reflected the impact of licensing revenues recognized by the Biosciences unit in the quarter, as noted above.
•
Selling and administrative expense as a percentage of revenues in the first quarter of 2020 was lower compared with the prior-year period primarily due to expense synergies realized from the combination of the Preanalytical Systems and Diagnostic Systems units, as noted above.
•
Research and development expense as a percentage of revenues was lower in the first quarter of 2020 compared with the first quarter of 2019 primarily due to the timing of project spending.

23


Interventional Segment
The following summarizes first quarter Interventional revenues by organizational unit:
 
Three months ended December 31,
(Millions of dollars)
2019
 
2018
 
Total
Change
 
Estimated
FX
Impact
 
FXN Change
Surgery (a)
$
326

 
$
310

 
5.2
%
 
(0.4
)%
 
5.6
%
Peripheral Intervention (a)
395

 
382

 
3.4
%
 
(1.0
)%
 
4.4
%
Urology and Critical Care (a)
291

 
277

 
4.9
%
 
(0.1
)%
 
5.0
%
Total Interventional Revenues
$
1,012

 
$
970

 
4.4
%
 
(0.6
)%
 
5.0
%
(a)
The presentation of prior-period amounts reflects the total reclassifications of $45 million associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.
The Interventional segment's revenues in the first quarter were driven by growth in the Surgery unit's sales of hernia and biosurgery products, as well as strong sales in Europe and China. First quarter revenue growth in the Urology and Critical Care unit reflected strength in sales of acute urology products and sales by the unit's home care and targeted temperature management businesses. The Peripheral Intervention unit's first quarter revenues reflected broad-based growth in sales of the unit's products, which was partially offset by lower sales of our drug-coated balloon products following the FDA's March 2019 letter to healthcare professionals regarding the use of paclitaxel-coated devices. The period-over-period decline in sales was not as unfavorable as compared with the trend we had been seeing since the FDA letter. The extent and duration of the impact from the FDA letter on the Peripheral Intervention unit’s future revenues is difficult to predict.
 
 
 
 
 
 
 
 
 
 
Interventional segment operating income for the three-month period is provided below.
 
Three months ended December 31,
(Millions of dollars)
2019
 
2018
Interventional segment operating income
$
243

 
$
209

 
 
 
 
Segment operating income as % of Interventional revenues
24.0
%
 
21.6
%
The Interventional segment's operating income in the first quarter was driven by its performance with respect to gross profit margin and operating expenses as discussed in greater detail below:
•
Gross profit margin was higher in the first quarter of 2020 as compared with the first quarter of 2019 primarily due to favorable product mix, which was partially offset by pricing pressures.
•
Selling and administrative expense as a percentage of revenues in the first quarter of 2020 was lower compared with the prior-year period.
•
Research and development expense as a percentage of revenues was lower in the first quarter of 2020 compared with the first quarter of 2019 primarily due to the timing of project spending.
Geographic Revenues
BD’s worldwide first quarter revenues by geography were as follows:
 
Three months ended December 31,
(Millions of dollars)
2019
 
2018
 
Total
Change
 
Estimated
FX
Impact
 
FXN Change
United States
$
2,430

 
$
2,387

 
1.8
%
 
—
 %
 
1.8
%
International
1,795

 
1,773

 
1.2
%
 
(2.2
)%
 
3.4
%
Total Revenues
$
4,225

 
$
4,160

 
1.6
%
 
(0.9
)%
 
2.5
%
U.S. revenue growth in the first quarter of 2020 was largely attributable to sales in the Medical segment's Pharmaceutical Systems unit and sales in the Life Sciences segment's Biosciences unit. U.S. revenue growth in the current-year period also reflected growth in the Interventional segment's Surgery unit and Urology and Critical Care unit. First quarter U.S. revenue

24


growth was unfavorably impacted by results in the Medical segment's Medication Management Solutions unit, as further discussed above.
International revenues in the first quarter of 2020 reflected growth in all three segments. First quarter international revenue growth was particularly driven by sales in the Life Sciences segment's Integrated Diagnostic Solutions unit. International revenue growth in the first quarter of 2020 was also driven by sales in the Medical segment's Pharmaceutical Systems unit and sales in the Interventional segment's Peripheral Intervention unit.
Emerging market revenues for the first quarter were $654 million, compared with $633 million in the prior year’s quarter. Emerging market revenues in the current-year period also included an estimated $11 million unfavorable impact due to foreign currency translation. First quarter revenue growth in emerging markets was primarily driven by sales growth in China. As previously discussed above, revenues in our Medication Delivery Solutions unit were unfavorably impacted by a new volume-based procurement process which has been adopted by several of China's provinces. To date, the impact of these procurement initiatives to our revenues in China has been limited to our Medication Delivery Solutions unit.
Specified Items
Reflected in the financial results for the three-month periods of fiscal years 2020 and 2019 were the following specified items:
 
Three months ended December 31,
(Millions of dollars)
2019
 
2018
Integration costs (a)
$
62

  
$
73

Restructuring costs (a)
23

  
41

Transaction costs
—

  
1

Purchase accounting adjustments (b)
348

 
379

Transaction gain/loss and product-related matters (c)
59

 
(335
)
European regulatory initiative-related costs (d)
17

 
5

Total specified items
511

  
163

Less: tax impact of specified items and tax reform (e)
22

  
(17
)
After-tax impact of specified items
$
489

  
$
180

(a)
Represents integration and restructuring costs which are primarily recorded in Acquisitions and other restructurings and are further discussed below.
(b)
Includes amortization and other adjustments related to the purchase accounting for acquisitions impacting identified intangible assets and valuation of fixed assets and debt. BD’s amortization expense is primarily recorded in Cost of products sold.
(c)
The current-year period amount represents the estimated cost of a product recall which was recorded by the Medical segment in Cost of products sold. The amount in the prior-year period represents the pre-tax gain recognized in Other operating income, net on BD's sale of its Advanced Bioprocessing business.
(d)
Represents initial costs required to develop processes and systems to comply with emerging regulations such as the European Union Medical Device Regulation ("EUMDR") and General Data Protection Regulation ("GDPR"). These costs were recorded in Cost of products sold and Research and development expense.
(e)
The amount in the three-month period of fiscal year 2019 included additional tax expense, net, of $51 million relating to new U.S. tax legislation, as further discussed below.
Gross Profit Margin
Gross profit margin for the three-month period of fiscal year 2020 compared with the prior-year period in fiscal year 2019 reflected the following impacts:
 
Three-month period
December 31, 2018 gross profit margin %
47.4
 %
Impact of purchase accounting adjustments and other specified items
(0.8
)%
Operating performance
0.3
 %
Foreign currency translation
(0.1
)%
December 31, 2019 gross profit margin %
46.8
 %

25


Operating performance for the three-month period primarily reflected lower manufacturing costs resulting from continuous operations improvement projects and synergy initiatives, partially offset by pricing pressures.
Operating Expenses
A summary of operating expenses for the three-month periods of fiscal years 2020 and 2019 is as follows:
 
Three months ended December 31,
 
Increase (decrease) in basis points
 
2019
 
2018
 
(Millions of dollars)
 
 
 
 
 
Selling and administrative expense
$
1,121

 
$
1,073

 
 
% of revenues
26.5
%
 
25.8
%
 
70

 
 
 
 
 
 
Research and development expense
$
270

 
$
258

 
 
% of revenues
6.4
%
 
6.2
%
 
20

 
 
 
 
 
 
Acquisitions and other restructurings
$
86

 
$
91

 
 
 
 
 
 
 
 
Other operating income, net
$
—

 
$
(335
)
 
 
Selling and administrative expense
The increase in selling and administrative expense as a percentage of revenues in the current three-month period compared with the prior-year period primarily reflected an increase in the deferred compensation plan liability due to market performance. The gains on investment assets, which offset the expense recorded in Selling and administrative expense, are recorded within Other income, net on our condensed consolidated statements of income. Selling and administrative expense as a percentage of revenues in the current-year period also reflected our ongoing focus on disciplined spending and the achievement of cost synergies resulting from our acquisition of C.R. Bard, Inc. ("Bard").
Research and development expense
Research and development expense as a percentage of revenues in the three-month period was higher compared with the prior-year period primarily due to costs incurred to achieve compliance with emerging regulations, as further discussed above. Spending in both the current and prior-year periods reflected our continued commitment to drive innovation with new products and platforms.
Acquisitions and other restructurings
Costs relating to acquisitions and other restructurings in the three-month periods of 2020 and 2019 largely represented integration and restructuring costs incurred due to our acquisition of Bard in the first quarter of fiscal year 2018. For further disclosures regarding restructuring costs, refer to Note 10 in the Notes to Condensed Consolidated Financial Statements.
Other operating income, net
Other operating income in the prior-year three-month period represented the pre-tax gain of $335 million recognized on BD's sale of its Advanced Bioprocessing business in the first quarter of fiscal year 2019.
Nonoperating Income
Net interest expense
The components for the three-month periods of fiscal years 2020 and 2019 were as follows:
 
Three months ended December 31,
(Millions of dollars)
2019
 
2018
Interest expense
$
(136
)
 
$
(171
)
Interest income, net
1

 
(12
)
Net interest expense
$
(134
)
 
$
(183
)

26


Lower interest expense in the current year's three-month period compared with the prior-year period primarily reflected debt repayments during fiscal year 2019, as well as lower overall interest rates on debt outstanding during the current-year period as a result of fiscal year 2019 refinancing activities.
Interest income was not material to our consolidated financial results in the current and prior-year three-month periods.
Other income, net
The components of Other income, net for the three-month periods of fiscal years 2020 and 2019 were not material to our consolidated financial results.
Income Taxes
The income tax rates for the three-month periods of fiscal years 2020 and 2019 are provided below.
 
Three months ended December 31,
 
2019
 
2018
Effective income tax rate
29.6
%
 
16.1
%
 
 
 
 
Impact, in basis points, from specified items and tax reform
1,430

 
490

The effective income tax rate for the three-month period of fiscal year 2020 reflected a tax impact from specified items that was less favorable compared with the benefit associated with specified items recognized in the prior-year period. The effective income tax rate for the three-month period of fiscal year 2019 reflected the recognition of additional tax expense of $51 million as a result of U.S. tax legislation that was enacted in December 2017. The effective income tax rate for the three-month period of fiscal year 2019 was favorably impacted by the timing of certain discrete items.
Net Income and Diluted Earnings per Share
Net Income and Diluted Earnings per Share for the three-month periods of fiscal years 2020 and 2019 were as follows:
 
Three months ended December 31,
 
2019
 
2018
Net Income (Millions of dollars)
$
278

 
$
599

Diluted Earnings per Share
$
0.87

 
$
2.05

 
 
 
 
Unfavorable impact-specified items
$
(1.78
)
 
$
(0.66
)
Unfavorable impact-foreign currency translation
$
(0.03
)
 
 

Liquidity and Capital Resources
The following table summarizes our condensed consolidated statements of cash flows:
 
Three months ended December 31,
(Millions of dollars)
2019
 
2018
Net cash provided by (used for)
 
 
 
Operating activities
$
713

 
$
245

Investing activities
$
(287
)
 
$
299

Financing activities
$
(413
)
 
$
(734
)
Cash generated from operations, along with available cash and cash equivalents, is expected to be sufficient to fund our normal operating needs for the remainder of fiscal year 2020. Normal operating needs in fiscal year 2020 include working capital, capital expenditures, and cash dividends.

27


Net Cash Flows from Operating Activities
Cash flows from operating activities in the first three months of fiscal year 2020 reflected net income, adjusted by a change in operating assets and liabilities that was a net source of cash. This net source of cash primarily reflected lower levels of trade receivables and prepaid expenses, partially offset by higher levels of inventory and lower levels of accounts payable and accrued expenses.

Cash flows from operating activities in the first three months of fiscal year 2019 reflected net income, adjusted by a change in operating assets and liabilities that was a net use of cash. Cash flows from operating activities in the prior-year period additionally reflected an adjustment for a gain of $335 million on our sale of a business, which is further discussed in Note 9 in the Notes to Condensed Consolidated Financial Statements, as well as $200 million of discretionary cash contributions to fund our pension obligation.
Net Cash Flows from Investing Activities
Our investments in capital expenditures are focused on projects that enhance our cost structure and manufacturing capabilities, and support our strategy of geographic expansion with select investments in growing markets.  Net outflows from investing activities in the first three months of fiscal year 2020 included capital expenditure-related outflows of $173 million, compared with $167 million in the prior-year period. Net cash flows from investing activities in the first three months of fiscal year 2019 also included proceeds $476 million from our sale of a business during the period, as further discussed above.
Net Cash Flows from Financing Activities
Net cash from financing activities in the first three months of fiscal years 2020 and 2019 included the following significant cash flows:
 
Three months ended December 31,
(Millions of dollars)
2019
 
2018
Cash inflow (outflow)
 
 
 
Change in credit facility borrowings
$
210

 
$
50

Payments of debt and term loans
$
(303
)
 
$
(453
)
Dividends paid
$
(252
)
 
$
(245
)
Certain measures relating to our total debt were as follows:
(Millions of dollars)
December 31, 2019
 
September 30, 2019
Total debt
$
19,405

 
$
19,390

 
 
 
 
Short-term debt as a percentage of total debt
12.7
%
 
6.8
%
Weighted average cost of total debt
2.8
%
 
2.9
%
Total debt as a percentage of total capital*
45.5
%
 
45.6
%
*    Represents shareholders’ equity, net non-current deferred income tax liabilities, and debt.
The increase in the ratio of short-term debt as a percentage of total debt at December 31, 2019 was primarily driven by the reclassification of certain notes from long-term to short-term.
Cash and Short-term Investments
At December 31, 2019, total worldwide cash and short-term investments, including restricted cash, were approximately $617 million, which were primarily held in jurisdictions outside of the United States.
Financing Facilities
We have a five-year senior unsecured revolving credit facility in place which provides borrowing of up to $2.25 billion. This facility will expire in December 2022. We are able to issue up to $100 million in letters of credit under this revolving credit facility and it also includes a provision that enables BD, subject to additional commitments made by the lenders, to access up to an additional $500 million in financing through the facility for a maximum aggregate commitment of $2.75 billion. We use proceeds from this facility to fund general corporate needs. Borrowings outstanding under the revolving credit facility at December 31, 2019 were $695 million.

28


The agreement for our revolving credit facility contained the following financial covenants. We were in compliance with these covenants as of December 31, 2019.
•
We are required to maintain an interest expense coverage ratio of not less than 4-to-1 as of the last day of each fiscal quarter.
•
We are required to have a leverage coverage ratio of no more than:
◦
6-to-1 from the closing date of the Bard acquisition until and including the first fiscal quarter-end thereafter;
◦
5.75-to-1 for the subsequent four fiscal quarters thereafter;
◦
5.25-to-1 for the subsequent four fiscal quarters thereafter;
◦
4.5-to-1 for the subsequent four fiscal quarters thereafter;
◦
4-to-1 for the subsequent four fiscal quarters thereafter;
◦
3.75-to-1 thereafter.
We also have informal lines of credit outside the United States. The Company had no commercial paper borrowings outstanding as of December 31, 2019. We may, from time to time, sell certain trade receivable assets to third parties as we manage working capital over the normal course of our business activities. Additional disclosures regarding these transactions are provided in Note 13 in the Notes to Condensed Consolidated Financial Statements.
Access to Capital and Credit Ratings
Our corporate credit ratings with the rating agencies Standard & Poor's Ratings Services, Moody's Investor Service and Fitch Ratings at December 31, 2019 were unchanged compared with our ratings at September 30, 2019.
Lower corporate debt ratings and downgrades of our corporate credit ratings or other credit ratings may increase our cost of borrowing. We believe that given our debt ratings, our financial management policies, our ability to generate cash flow and the non-cyclical, geographically diversified nature of our businesses, we would have access to additional short-term and long-term capital should the need arise. A rating reflects only the view of a rating agency and is not a recommendation to buy, sell or hold securities. Ratings can be revised upward or downward at any time by a rating agency if such rating agency decides that circumstances warrant such a change.
Concentrations of Credit Risk
We continually evaluate our accounts receivables for potential collection risks, particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries, as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. We continually evaluate all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. We believe the current reserves related to all governmental receivables are adequate and that these receivables will not have a material adverse impact on our financial position or liquidity.
Regulatory Matters

In January 2018, BD received a Warning Letter from the U.S. FDA, citing certain alleged violations of quality system regulations and of law with respect to our Preanalytical Systems facility in Franklin Lakes, New Jersey. The Warning Letter states that, until BD resolves the outstanding issues covered by the Warning Letter, the FDA will not clear or approve any premarket submissions for Class III devices to which the non-conformances are reasonably related or grant requests for certificates to foreign governments. BD is working closely with the FDA and intends to fully implement corrective actions to address the concerns identified in the Warning Letter. However, BD cannot give any assurances that the FDA will be satisfied with its responses to the Warning Letter or as to the expected date of resolution of matters included in the Warning Letter. While BD does not believe that the issues identified in the Warning Letter will have a material impact on BD’s operation, no assurances can be given that the resolution of this matter will not have a material adverse effect on BD’s business, results of operations, financial conditions and/or liquidity.

In October 2019, BD entered into a consent order with the Environmental Protection Division of the Georgia Department of Natural Resources (“EPD”), following the filing of a complaint and motion for temporary restraining order by the EPD seeking to enjoin BD from continuing sterilization operations at its Covington, Georgia facility. Under the terms of the consent order, BD voluntarily agreed to a number of operational changes at its Covington and Madison, Georgia facilities designed to further reduce ethylene oxide emissions, including but not limited to operating at a reduced capacity. BD does not believe that the consent order will have a material impact on its operations. Violation of the consent order could subject us to additional restrictions on the sterilization operations at our Covington and Madison facilities. BD has business continuity plans in place to mitigate the impact of any additional restrictions on our operations at these facilities, although it is possible that these plans will not be able to fully offset such impact.


29


Cautionary Statement Regarding Forward-Looking Statements
BD and its representatives may from time to time make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases, and our reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,”, “may”, “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures. All statements that address our future operating performance or events or developments that we expect or anticipate will occur in the future are forward-looking statements.
Forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events, developments and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, we undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events and developments or otherwise, except as required by applicable law or regulations.
The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of certain of these factors, see Item 1A. Risk Factors in our 2019 Annual Report on Form 10-K.
•
Weakness in the global economy and financial markets, which could increase the cost of operating our business, weaken demand for our products and services, negatively impact the prices we can charge for our products and services, or impair our ability to produce our products.
•
Competitive factors that could adversely affect our operations, including new product introductions and technologies (for example, new forms of drug delivery) by our current or future competitors, consolidation or strategic alliances among healthcare companies, distributors and/or payers of healthcare to improve their competitive position or develop new models for the delivery of healthcare, increased pricing pressure due to the impact of low-cost manufacturers, patents attained by competitors (particularly as patents on our products expire), new entrants into our markets and changes in the practice of medicine.
•
Risks relating to our acquisition of Bard, including our ability to successfully combine and integrate the Bard operations in order to obtain the anticipated benefits and costs savings from the transaction, and the significant additional indebtedness we incurred in connection with the financing of the acquisition and the impact it may have on our ability to operate the combined company.
•
The adverse financial impact resulting from unfavorable changes in foreign currency exchange rates.
•
Regional, national and foreign economic factors, including inflation, deflation, and fluctuations in interest rates, and their potential effect on our operating performance.
•
Our ability to achieve our projected level or mix of product sales, as our earnings forecasts are based on projected sales volumes and pricing of many product types, some of which are more profitable than others.
•
Changes in reimbursement practices of governments or third-party payers, or adverse decisions relating to our products by such payers, which could reduce demand for our products or the price we can charge for such products.
•
Cost containment efforts in the U.S. or in other countries in which we do business, including alternative payment reform and increased use of competitive bidding and tenders.
•
Changes in the domestic and foreign healthcare industry or in medical practices that result in a reduction in procedures using our products or increased pricing pressures, including the continued consolidation among healthcare providers.
•
The impact of changes in U.S. federal laws and policy that could affect fiscal and tax policies, healthcare, and international trade, including import and export regulation and international trade agreements. In particular, tariffs or other trade barriers imposed by the U.S. could adversely impact our supply chain costs or otherwise adversely impact our results of operations.
•
Increases in operating costs, including fluctuations in the cost and availability of oil-based resins and other raw materials, as well as certain components, used in our products, the ability to maintain favorable supplier arrangements and relationships (particularly with respect to sole-source suppliers), and the potential adverse effects of any disruption in the availability of such items.

30


•
Security breaches of our information technology systems or our products, which could impair our ability to conduct business, result in the loss of BD trade secrets or otherwise compromise sensitive information of BD or its customers, suppliers and other business partners, or of customers' patients, or result in product efficacy or safety concerns for certain of our products, and result in actions by regulatory bodies or civil litigation.
•
Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, successfully complete clinical trials, obtain regulatory approvals in the United States and abroad, obtain intellectual property protection for our products, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of infringement claims by competitors with respect to patents or other intellectual property rights, all of which can preclude or delay commercialization of a product. Delays in obtaining necessary approvals or clearances from United States Food and Drug Administration (“FDA”) or other regulatory agencies or changes in the regulatory process may also delay product launches and increase development costs.
•
The impact of business combinations or divestitures, including any volatility in earnings relating to acquisition-related costs, and our ability to successfully integrate any business we may acquire.
•
Our ability to penetrate or expand our operations in emerging markets, which depends on local economic and political conditions, and how well we are able to make necessary infrastructure enhancements to production facilities and distribution networks.
•
Conditions in international markets, including social and political conditions, civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders, tariffs and other protectionist measures, difficulties in protecting and enforcing our intellectual property rights and governmental expropriation of assets. This includes the possible impact of the United Kingdom's exit from the European Union ("EU"), which has created uncertainties affecting our business operations in the United Kingdom and the EU, and possibly other countries. Our international operations also increase our compliance risks, including risks under the Foreign Corrupt Practices Act and other anti-corruption laws, as well as regulatory and privacy laws.
•
Deficit reduction efforts or other actions that reduce the availability of government funding for healthcare and research, which could weaken demand for our products and result in additional pricing pressures, as well as create potential collection risks associated with such sales.
•
Fluctuations in university or U.S. and international governmental funding and policies for life sciences research.
•
Fluctuations in the demand for products we sell to pharmaceutical companies that are used to manufacture, or are sold with, the products of such companies, as a result of funding constraints, consolidation or otherwise.
•
The effects of weather, regulatory or other events that adversely impact our supply chain, including our ability to manufacture our products (particularly where production of a product line or sterilization operations are concentrated in one or more plants), source materials or components or services from suppliers (including sole-source suppliers) that are needed for such manufacturing (including sterilization), or provide products to our customers, including events that impact key distributors. 
•
Natural disasters (including pandemics), war, terrorism, labor disruptions and international conflicts that could cause significant economic disruption and political and social instability, resulting in decreased demand for our products, adversely affect our manufacturing and distribution capabilities, or cause interruptions in our supply chain. Recently, a strain of coronavirus was reported in China and the virus has begun to spread to other countries.  While we believe this situation will have some negative impact on our near-term financial results as a result of deferred medical procedures, the longer-term impact is difficult to assess or predict at this time.
•
Pending and potential future litigation or other proceedings asserting, and/or subpoenas seeking information with respect to, alleged violations of law (including in connection with federal and/or state healthcare programs (such as Medicare or Medicaid) and/or sales and marketing practices (such as investigative subpoenas and the civil investigative demands received by BD and Bard)), antitrust claims, product liability (which may involve lawsuits seeking class action status or seeking to establish multi-district litigation proceedings, including claims relating to our hernia repair implant products, surgical continence products for women and vena cava filter products), claims with respect to environmental matters, and patent infringement, and the availability or collectability of insurance relating to any such claims.
•
New or changing laws and regulations affecting our domestic and foreign operations, or changes in enforcement practices, including laws relating to trade, monetary and fiscal policies, taxation (including tax reforms that could adversely impact multinational corporations), sales practices, environmental protection, price controls, and licensing and regulatory requirements for new products and products in the postmarketing phase. In particular, the U.S. and other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to

31


re-register products already on the market or otherwise impact our ability to market our products. Environmental laws, particularly with respect to the emission of greenhouse gases, are also becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes or those of our suppliers, or result in liability to BD.
•
Product efficacy or safety concerns regarding our products resulting in product holds or recalls, regulatory action on the part of the FDA or foreign counterparts (including restrictions on future product clearances and civil penalties), declining sales and product liability claims, and damage to our reputation. As a result of the CareFusion acquisition, we are operating under a consent decree with the FDA relating to our U.S. infusion pump business. The consent decree authorizes the FDA, in the event of any violations in the future, to order us to cease manufacturing and distributing products, recall products or take other actions, and we may be required to pay significant monetary damages if we fail to comply with any provision of the consent decree. Also, in 2019, the FDA letter to healthcare professionals regarding the use of paclitaxel-coated devices in the treatment of peripheral artery disease resulted in decreased sales of BD’s drug-coated balloons. While we have changed the labeling on our products as required by the FDA and continue to work with the FDA on patient data, the extent and duration of the impact from the FDA letter, and the likelihood of FDA approval of new drug-coated devices, is difficult to predict.
•
The effect of adverse media exposure or other publicity regarding BD’s business or operations, including the effect on BD’s reputation or demand for its products.
•
The effect of market fluctuations on the value of assets in BD’s pension plans and on actuarial interest rate and asset return assumptions, which could require BD to make additional contributions to the plans or increase our pension plan expense.
•
Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
•
Issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission.
The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.

32


Item 3.    Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in information reported since the end of the fiscal year ended September 30, 2019.
Item 4.    Controls and Procedures
An evaluation was carried out by BD’s management, with the participation of BD’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BD’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of December 31, 2019. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were, as of the end of the period covered by this report, effective and designed to ensure that material information relating to BD and its consolidated subsidiaries would be made known to them by others within these entities.
There were no changes in our internal control over financial reporting during the fiscal quarter ended December 31, 2019 identified in connection with the above-referenced evaluation that have materially affected, or are reasonably likely to materially affect, BD’s internal control over financial reporting.



33


PART II - OTHER INFORMATION
Item 1.    Legal Proceedings
We are involved, both as a plaintiff and a defendant, in various legal proceedings which arise in the ordinary course of business, including product liability and environmental matters as set forth in our 2019 Annual Report on Form 10-K, and in Note 5 of the Notes to Condensed Consolidated Financial Statements in this report, which is incorporated herein by reference. Since September 30, 2019, there have been no material developments with respect to the legal proceedings in which we are involved.


34


Item 1A.    Risk Factors
There were no material changes during the period covered by this report in the risk factors previously disclosed in Part I, Item 1A, of our 2019 Annual Report on Form 10-K.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
The table below sets forth certain information regarding our purchases of common stock of BD during the quarter ended December 31, 2019.
Issuer Purchases of Equity Securities
For the three months ended December 31, 2019
 
Total Number of
Shares Purchased (1)
 
Average Price
Paid per
Share
 
Total Number of
Shares Purchased
as Part of
Publicly
Announced Plans
or Programs
 
Maximum Number
of Shares that May
Yet Be Purchased
Under the Plans or
Programs (2)
October 1 – 31, 2019
 
1,299

 
$
247.52

 
—

 
7,857,742

November 1 – 30, 2019
 
208

 
244.02

 
—

 
7,857,742

December 1 – 31, 2019
 
—

 
—

 
—

 
7,857,742

Total
 
1,507

 
$
247.04

 
—

 
7,857,742

(1)
Consists of 1,507 shares purchased during the quarter in open market transactions by the trust relating to BD’s Deferred Compensation and Retirement Benefit Restoration Plan and 1996 Directors’ Deferral Plan.
(2)
Represents shares available under a repurchase program authorized by the Board of Directors on September 24, 2013 for 10 million shares, for which there is no expiration date.

35


Item 3.    Defaults Upon Senior Securities
Not applicable.
Item 4.    Mine Safety Disclosures
Not applicable.
Item 5.    Other Information
Not applicable.
Item 6.    Exhibits

10(a)
 
2004 Employee and Director Equity-Based Compensation Plan, as amended and restated as of January 28, 2020 (incorporated by reference to Exhibit 10.1 of the registrant's Current Report on Form 8-K filed on January 31, 2020).
 
 
 
10(b)
 
French Addendum to the 2004 Employee and Director Equity-Based Compensation Plan dated January 21, 2019 (incorporated by reference to Exhibit 10.2 of the registrant's Current Report on Form 8-K filed on January 31, 2020).
 
 
 
 
Terms of Awards under 2004 Employee and Director Equity-Based Compensation Plan.
 
 
 
  
Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to SEC Rule 13a - 14(a).
 
 
 
  
Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to Rule 13a - 14(b) and Section 1350 of Chapter 63 of Title 18 of the U.S. Code.
 
 
 
101
  
The following materials from this report, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.
 
 
 
104
 
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)


36


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Becton, Dickinson and Company
 
(Registrant)
Dated: February 6, 2020
 
/s/ Christopher Reidy
 
Christopher Reidy
 
Executive Vice President, Chief Financial Officer and Chief Administrative Officer
 
(Principal Financial Officer)
 
 
 
/s/ Thomas J. Spoerel
 
Thomas J. Spoerel
 
Vice President, Controller and Chief Accounting Officer
 
(Principal Accounting Officer)

37
 EX-10.C 2 ex10c12312019.htm EXHIBIT 10.C Exhibit

EXHIBIT 10(c)

Terms of Awards Under
2004 Employee and Director Equity-Based Compensation Plan (the “Plan”)

Capitalized terms used herein that are not defined shall have the same meaning as set forth in the Plan.

 
1.    Stock Appreciation Rights (SARs)
    
(a)
Vesting Period: Ratably over four (4) years, with twenty-five percent (25%) becoming exercisable on each of the first, second, third and fourth anniversary of the grant date, except as provided in the Plan.
    
(b)
Term: Ten (10) years from grant date.
    
(c)
Exercise Price: Fair market value of BD common stock on grant date.
    
(d)
Settlement: Upon exercise, the holder receives shares of BD common stock equal in value to the difference between the BD common stock price at the time of exercise and the exercise price.

(e)
Termination of Employment. Upon death, Disability or Retirement, all unvested SARs become fully exercisable for their remaining term. Upon termination due to involuntary termination without Cause, SARs may be exercised for three months following termination, but only to the extent vested at the time of termination. Upon voluntary termination or termination with Cause, unexercised SARs are forfeited.

2.    Performance Units
    
(a)
Vesting Period: Third anniversary of grant date.
    
(b)
Settlement: Performance Units are settled in shares of BD common stock. Performance Unit awards are given a share target. A formula determines the actual number of shares that will be issued upon vesting, based on BD’s performance against pre-established performance targets over the performance period.
    
(c)
Performance Period: Three consecutive fiscal years, beginning with the fiscal year in which the award is granted.
    
(d)
Performance Measures: Consist of BD’s (1) average annual return on invested capital and (2) average annual revenue growth, each weighted 50%. Payouts are adjusted, subject to certain limits, based on BD’s relative total shareholder return compared to select peer companies during the performance period. Payouts may range from zero to 200% of award target.
    
(e)
Dividend Equivalent Rights: Dividends do not accrue on Performance Units.    


(f)
Termination of Employment: Upon death or 409A Disability, grantee vests in a pro rata amount of the award’s share target. Upon Disability (other than a 409A Disability), Retirement or involuntary termination without Cause, grantee vests in a pro rata amount of the shares that would have been distributable under the award based on the payout formula had the grantee remained employed with BD through the vesting period, with shares being distributed after the end of the applicable vesting period. Upon voluntary termination or termination with Cause, unvested awards are forfeited.


3.    Time-Vested Units (“TVU”)
    
(a)
Vesting Period: Awards vest ratably over three (3) years, with one-third becoming vested on each of the first, second, and third anniversary of the grant date.
    
(b)
Settlement: Each TVU entitles the grantee to one share of BD common stock upon vesting.
    
(c)
Dividend Equivalent Rights: Dividends do not accrue on TVUs.
    
(d)
Termination of Employment: Upon Retirement, death or Disability, TVUs vest in full. Upon voluntary or involuntary termination, unvested TVUs are forfeited.

4.     Performance Time-Vested Units (“P-TVU”).

(a)
Vesting Period: Third anniversary of grant date.

(b)
Settlement: Each P-TVU entitles the grantee to one share of BD common stock upon vesting, subject to satisfaction of performance target over the performance period.
    
(c)
Performance Period: Three consecutive fiscal years, beginning with the fiscal year in which the award is granted.
    
(d)
Performance Measure: Average annual growth in adjusted earnings per share (diluted earnings per share less acquisition-related purchase accounting adjustments and finance, integration, restructuring and transaction costs).

(e)
Dividend Equivalent Rights: Dividends do not accrue on P-TVUs.
    
(d)
Termination of Employment: Upon Retirement, death or Disability, P-TVUs vest in full. Upon voluntary or involuntary termination, unvested P-TVUs are forfeited.

5.    Change in Control Provisions

Awards automatically vest upon a Change in Control unless the awards are either continued or replaced with similar awards. In those instances where awards are continued or replaced, the awards will then automatically vest if the holder is terminated without Cause or the holder terminates employment for Good Reason within two years of the Change in Control.


EX-31 3 ex3112312019.htm EXHIBIT 31 Exhibit


Exhibit 31
CERTIFICATIONS
I, Thomas E. Polen, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Becton, Dickinson and Company;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 6, 2020
 
 
 
/s/ Thomas E. Polen
 
Thomas E. Polen
 
Chief Executive Officer and President





I, Christopher Reidy, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Becton, Dickinson and Company;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 6, 2020
 
 
 
/s/ Christopher Reidy
 
Christopher Reidy
 
Executive Vice President, Chief Financial Officer and Chief Administrative Officer


 EX-32 4 ex3212312019.htm EXHIBIT 32 Exhibit


Exhibit 32
The certification set forth below is being submitted in connection with the Quarterly Report on Form 10-Q of Becton, Dickinson and Company for the quarter ended December 31, 2019 (the “Report”) for the purpose of complying with Rule 13a – 14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
I, Thomas E. Polen, the Chief Executive Officer of Becton, Dickinson and Company, certify that:
1.
such Report fully complies with the requirements of Section 13(a) of the Exchange Act; and
2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Becton, Dickinson and Company.
February 6, 2020
 
 
 
/s/ Thomas E. Polen
 
Name: Thomas E. Polen
 
Chief Executive Officer




The certification set forth below is being submitted in connection with the Quarterly Report on Form 10-Q of Becton, Dickinson and Company for the quarter ended December 31, 2019 (the “Report”) for the purpose of complying with Rule 13a – 14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
I, Christopher Reidy, the Chief Financial Officer of Becton, Dickinson and Company, certify that:
1.
such Report fully complies with the requirements of Section 13(a) of the Exchange Act; and
2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Becton, Dickinson and Company.
February 6, 2020
 
 
 
/s/ Christopher Reidy
 
Name: Christopher Reidy
 
Chief Financial Officer


 EX-101.SCH 5 bdx-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2102100 - Disclosure - Accounting Changes link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Accounting Changes (Policies) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Benefit Plans - Net Pension and Postretirement Cost (Detail) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Business Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Business Restructuring Charges - Summary of Restructuring Accrual Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Business Restructuring Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Derivative Instruments and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - Derivative Instruments and Hedging Activities Disclosure - Gains (Losses) on Net Investment Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Divestiture link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - Divestiture - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Earnings Per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Financial Instruments and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Intangible Assets - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Intangible Assets - Components of Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2417404 - Disclosure - Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2422402 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2422404 - Disclosure - Leases - Lessee, Operating Lease, Liability, Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2422405 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2422403 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2322301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Revenues - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Segment Data link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Segment Data - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Segment Data - Financial Information for Company's Segments (Detail) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Segment Data - Revenues by Geographic Areas (Detail) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Segment Data (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2423401 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Subsequent Event (Notes) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 bdx-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 bdx-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 bdx-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Retirement Benefits [Abstract] Net Pension and Postretirement Cost Schedule of Net Benefit Costs [Table Text Block] Stockholders' Equity Note [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Issued at Par Value Common Stock [Member] Capital in Excess of Par Value Additional Paid-in Capital [Member] Retained Earnings Retained Earnings [Member] Deferred Compensation Deferred Compensation, Share-based Payments [Member] Treasury Stock Treasury Stock [Member] Statement [Line Items] Statement [Line Items] Dividends per Common Share (USD per share) Common Stock, Dividends, Per Share, Declared Beginning balance Stockholders' Equity Attributable to Parent Beginning balance (shares) Treasury Stock, Shares Net income Net Income (Loss) Attributable to Parent Common dividends Dividends, Common Stock, Cash Preferred dividends Dividends, Preferred Stock Common stock issued for share-based compensation and other plans, net Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Common stock issued for share-based compensation and other plans, net (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Common stock held in trusts, net Common Stock Held In Trusts Net Shares Number of common stock shares held in trust. Effect of changes in accounting principle New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets Ending balance Ending balance (shares) Segment Reporting [Abstract] Revenue from External Customers by Geographic Area Revenue from External Customers by Geographic Areas [Table Text Block] Financial Information for Company's Segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Cover page. Entities [Table] Entities [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock Depositary shares Depositary shares [Member] Depositary shares [Member] Notes 1.000% due December 15, 2022 Notes 1.000% due December 15, 2022 [Member] Notes 1.000% due December 15, 2022 [Member] Notes 1.900% due December 15, 2026 Notes 1.900% due December 15, 2026 [Member] Notes 1.900% due December 15, 2026 [Member] Notes 1.401% due May 24, 2023 Notes 1.401% due May 24, 2023 [Member] Notes 1.401% due May 24, 2023 [Member] Notes 3.020% due May 24, 2025 [Member] Notes 3.020% due May 24, 2025 [Member] Notes 3.020% due May 24, 2025 [Member] Notes 0.174% due June 4, 2021 [Member] Notes 0.174% due June 4, 2021 [Member] Notes 0.174% due June 4, 2021 [Member] Notes 0.632% due June 4, 2023 Notes 0.632% due June 4, 2023 [Member] Notes 0.632% due June 4, 2023 [Member] Notes 1.208% due June 4, 2026 Notes 1.208% due June 4, 2026 [Member] Notes 1.208% due June 4, 2026 [Member] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Exchange [Domain] Exchange [Domain] NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Entity Information [Line Items] Entity Information [Line Items] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Statement of Cash Flows [Abstract] Operating Activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustments to net income to derive net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Share-based compensation Share-based Payment Arrangement, Noncash Expense Deferred income taxes Increase (Decrease) in Deferred Income Taxes Change in operating assets and liabilities Increase (Decrease) in Operating Capital Pension obligation Increase (Decrease) in Obligation, Pension Benefits Gain on sale of business Gain (Loss) on Disposition of Business Other, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Investing Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Capital expenditures Payments to Acquire Property, Plant, and Equipment Proceeds from divestitures, net Proceeds from Divestiture of Businesses Other, net Payments for (Proceeds from) Other Investing Activities Net Cash (Used for) Provided by Investing Activities Net Cash Provided by (Used in) Investing Activities Financing Activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Change in credit facility borrowings Proceeds from (Repayments of) Short-term Debt Payments of debt and term loans Repayments of Long-term Debt Dividends paid Payments of Dividends Other, net Proceeds from (Payments for) Other Financing Activities Net Cash Used for Financing Activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net increase (decrease) in cash and equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Opening Cash and Equivalents and Restricted Cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Closing Cash and Equivalents and Restricted Cash Non-Cash Investing Activities Noncash Investing and Financing Items [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments Operating Segments [Member] Segment Reconciling Items Segment Reconciling Items [Member] Corporate, Non-Segment Corporate, Non-Segment [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Medical Medical [Member] Medical. Life Sciences Life Sciences [Member] Life Sciences [Member] Interventional Interventional [Member] Interventional [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Advanced Bioprocessing Advanced Bioprocessing [Member] Advanced Bioprocessing [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Income (Loss) Before Income Taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Acquisitions and other restructurings Acquisition Related Costs And Restructuring Charges Acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; business integration costs, systems integration and conversion costs, and severance and other employee-related costs; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Additionally includes the amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Net interest expense Interest Income (Expense), Net Inventory Recall Expense Inventory Recall Expense Schedule of Goodwill [Table] Schedule of Goodwill [Table] Goodwill [Line Items] Goodwill [Line Items] Goodwill [Roll Forward] Goodwill [Roll Forward] Goodwill as of September 30, 2019 Goodwill Goodwill, Acquired During Period Goodwill, Acquired During Period Currency translation Goodwill, Foreign Currency Translation Gain (Loss) Goodwill as of December 31, 2019 Revenue from Contract with Customer [Abstract] Revenue Revenue from Contract with Customer [Text Block] Leases [Abstract] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Lessee, Operating Lease, Term of Contract Lessee, Operating Lease, Term of Contract Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Lease, Cost Lease, Cost Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Operating Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating Lease, Liability Operating Lease, Liability Earnings Per Share [Abstract] Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share Schedule of Weighted Average Number of Shares [Table Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign Currency-Denominated Debt Foreign Currency-Denominated Debt [Member] Foreign-Currency Denominated Debt [Member] Currency Swap Currency Swap [Member] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Schedule of Shareholders Equity Schedule of Stockholders Equity [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Contingencies Commitments and Contingencies Disclosure [Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Hernia Product Claims HerniaProductClaims [Member] HerniaProductClaims [Member] Womens Health Product Claims WomensHealthProductClaims [Member] WomensHealthProductClaims [Member] Punitive Punitive [Member] Punitive [Member] Filter Product Claims FilterProductClaims [Member] FilterProductClaims [Member] Type of Damages [Axis] Type of Damages [Axis] Type of Damages [Axis] Type of Damages [Domain] Type of Damages [Domain] [Domain] for Type of Damages [Axis] Compensatory Compensatory [Member] Compensatory [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Other Operating Income (Expense) Other Operating Income (Expense) [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Pending claims Loss Contingency, Pending Claims, Number Claims lacking sufficient information ClaimsLackingSufficientInformation The number of complaints for which the company cannot, based on the allegations in such complaints, determine whether the company's products are involved. PaymentstoSupplier PaymentstoSupplier Payments to a supplier with an obligation to defend and indemnify the company with respect to any product defect liability for products its subsidiaries had manufactured. Number of claims in settlement agreement NumberOfClaimsInSettlementAgreement Number of settlements or settlements in principle reached. Damages awarded Loss Contingency, Damages Awarded, Value Loss Contingency, Claims Settled, Number Loss Contingency, Claims Settled, Number Product liability accrual, period expense Product Liability Accrual, Period Expense Loss contingency accrual Loss Contingency Accrual Qualified settlement funds QualifiedSettlementFunds An amount of cash the entity has designated as qualified settlement funds relative to pending legal matters. Loss contingency, receivable Loss Contingency, Receivable Right-use-assets recorded in Other Assets Operating Lease, Right-of-Use Asset Current lease liabilities recorded in Payables, accrued expenses and other current liabilities Operating Lease, Liability, Current Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities Operating Lease, Liability, Noncurrent Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Restructuring and Related Activities [Abstract] Business Restructuring Charges Restructuring and Related Activities Disclosure [Text Block] Segment Data Segment Reporting Disclosure [Text Block] Organizational Unit [Axis] Organizational Unit [Axis] Organizational Unit [Axis] Organizational Unit [Domain] Organizational Unit [Domain] [Domain] for Organizational Unit [Axis] Medication Delivery Solutions Medication Delivery Solutions [Member] Medication Delivery Solutions [Member] Medication Management Solutions Medication Management Solutions [Member] Medication Management Solutions [Member] Diabetes Care Diabetes Care [Member] Diabetes Care [Member] Pharmaceutical Systems Pharmaceutical Systems [Member] Pharmaceutical Systems [Member] Preanalytical Systems Preanalytical Systems [Member] Preanalytical Systems [Member] Diagnostic Systems Diagnostic Systems [Member] Diagnostic Systems [Member] Integrated Diagnostic Solutions Integrated Diagnostic Solutions [Member] Integrated Diagnostic Solutions [Member] Biosciences Biosciences [Member] Biosciences [Member] Surgery Surgery [Member] Surgery [Member] Peripheral Intervention Peripheral Intervention [Member] Peripheral Intervention [Member] Urology and Critical Care Urology and Critical Care [Member] Urology and Critical Care [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES International Non-US [Member] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] IVFluids IVFluids [Member] IVFluids [Member] InterventionalSpecialties,BrachytherapyandFeedingProducts [Member] InterventionalSpecialties,BrachytherapyandFeedingProducts [Member] InterventionalSpecialties,BrachytherapyandFeedingProducts [Member] Revenues Revenues Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Cash Flow Hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Accumulated other comprehensive income (loss), net of tax, beginning balance Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income before reclassifications, net of taxes Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Amounts reclassified into income, net of taxes Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Accumulated other comprehensive income (loss), net of tax, ending balance Components of Intangible Assets Schedule of Intangible Assets and Goodwill [Table Text Block] Reconciliation of Goodwill by Business Segment Schedule of Goodwill [Table Text Block] Finite And Indefinite Lived Intangible Assets [Table] Finite And Indefinite Lived Intangible Assets [Table] Finite And Indefinite Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Developed technology Developed Technology Rights [Member] Customer relationships Customer Relationships [Member] Product rights Product Rights [Member] Acquired technological intellectual property and know how, as well as product marketing rights. Trademarks Trademarks [Member] Patents and other Intellectual Property [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Acquired in-process research and development Unclassified Indefinite-lived Intangible Assets [Member] Finite And Indefinite Lived Intangible Assets [Line Items] Finite And Indefinite Lived Intangible Assets [Line Items] Finite And Indefinite Lived Intangible Assets [Line Items] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Unamortized intangible assets Indefinite-lived Intangible Assets (Excluding Goodwill) Fair Value Disclosures [Abstract] Financial Instruments and Fair Value Measurements Fair Value Disclosures [Text Block] Subsequent Events [Abstract] Earnings per Share Earnings Per Share [Text Block] Supplemental Balance Sheet Information Related to Leases [Table Text Block] Supplemental Balance Sheet Information Related to Leases [Table Text Block] Supplemental Balance Sheet Information Related to Leases [Table Text Block] Lessee, Operating Lease, Liability, Maturity [Table Text Block] Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Foreign Exchange Contract Foreign Exchange Contract [Member] Fixed to Floating Fixed To Floating [Member] Fixed To Floating [Member] Interest Rate Swap [Member] Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Debt [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Net Investment Hedging Net Investment Hedging [Member] Fair Value Hedging Fair Value Hedging [Member] Cash Flow Hedging [Member] Cash Flow Hedging [Member] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative, Notional Amount Derivative, Notional Amount Reclassification of terminated interest rate swaps to interest expense within the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Unrealized Gain (Loss) on Cash Flow Hedging Instruments Unrealized Gain (Loss) on Cash Flow Hedging Instruments Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Accounting Changes and Error Corrections [Abstract] New Accounting Principles Adopted New Accounting Pronouncements, Policy [Policy Text Block] Commitments and Contingencies Commitments and Contingencies, Policy [Policy Text Block] Revenue Revenue from Contract with Customer [Policy Text Block] Derivatives Derivatives, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Lessee, Leases Lessee, Leases [Policy Text Block] Short-term Leases Short-term Leases [Policy Text Block] Income Statement [Abstract] Cost of products sold Cost of Goods and Services Sold Selling and administrative expense Selling, General and Administrative Expense Research and development expense Research and Development Expense Acquisitions and other restructurings Other operating income, net Other Operating Income (Expense), Net Total Operating Costs and Expenses Costs and Expenses Operating Income Operating Income (Loss) Interest expense Interest Expense Interest income, net Investment Income, Interest Other income, net Other Nonoperating Income (Expense) Income Before Income Taxes Income tax provision Income Tax Expense (Benefit) Net Income Preferred stock dividends Preferred Stock Dividends, Income Statement Impact Net income applicable to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Basic Earnings per Share (USD per share) Earnings Per Share, Basic Diluted Earnings per Share (USD per share) Earnings Per Share, Diluted Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] CR Bard Inc CR Bard Inc [Member] C.R. Bard Inc. [Member] Other Initiatives Other Initiatives [Member] Other Initiatives [Member] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Termination Employee Severance [Member] Other Restructuring Other Restructuring [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Balance at September 30, 2019 Restructuring Reserve Charged to expense Restructuring Charges Cash payments Payments for Restructuring Non-cash settlements Restructuring Reserve, Settled without Cash Balance at December 31, 2019 Revenue Disclosure [Abstract] Revenue Disclosure [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Products and/or Services Products and/or Services [Member] Products and/or Services [Member] Consumables [Member] Consumables [Member] Consumables [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Revenue, remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Revenue, remaining performance obligation, expected timing of satisfaction Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Number of principal business segments (segment) Number of Operating Segments Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Discontinued Operations and Disposal Groups [Abstract] Divestiture Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Accounting Changes Accounting Changes and Error Corrections [Text Block] Statement of Comprehensive Income [Abstract] Net Income Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Defined benefit pension and postretirement plans Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Subsequent Events Subsequent Events [Text Block] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Pension Plans Pension Plan [Member] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Service cost Defined Benefit Plan, Service Cost Interest cost Defined Benefit Plan, Interest Cost Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Amortization of prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Amortization of loss Defined Benefit Plan, Amortization of Gain (Loss) Net pension and postretirement cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Operating Leases, Future Minimum Payments Due Operating Leases, Future Minimum Payments Due Intangible amortization expense Amortization of Intangible Assets Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Convertible Preferred Stock Convertible Preferred Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Average common shares outstanding (shares) Weighted Average Number of Shares Outstanding, Basic Dilutive share equivalents from share-based plans (shares) Weighted Average Number Diluted Shares Outstanding Adjustment Average common and common equivalent shares outstanding - assuming dilution (shares) Weighted Average Number of Shares Outstanding, Diluted Antidilutive securities excluded (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Summary of Restructuring Accrual Activity Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash and cash equivalents, fair value Cash and Cash Equivalents, Fair Value Disclosure Remaining cash equivalents Remaining Cash Equivalents Amounts of cash equivalents that are carried at cost and are not measured at fair value under the fair value measurement requirements for financial assets and liabilities. Maturity period of short-term investments at the time of purchase Maturity Period Of Short Term Investment The maturity period of time deposits classified as short-term investments in the consolidated balance sheet. Fair value of long-term debt Loans Payable, Fair Value Disclosure Fair value of debt reclassified from long term to short term Fair Value Of Debt Classified From Long Term To Short Term Fair Value Of Debt Classified From Long Term To Short Term Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Leases of Lessee Disclosure [Text Block] Leases of Lessee Disclosure [Text Block] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Gain (loss) on disposition of business Statement of Financial Position [Abstract] Assets Assets [Abstract] Current Assets: Assets, Current [Abstract] Cash and equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash Restricted Cash and Investments, Current Short-term investments Other Short-term Investments Trade receivables, net Accounts Receivable, after Allowance for Credit Loss, Current Inventories: Inventory, Net [Abstract] Materials Inventory, Raw Materials, Net of Reserves Work in process Inventory, Work in Process, Net of Reserves Finished products Inventory, Finished Goods, Net of Reserves Inventories Inventory, Net Prepaid expenses and other Other Assets, Current Total Current Assets Assets, Current Property, Plant and Equipment Property, Plant and Equipment, Gross Less allowances for depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Net Property, Plant and Equipment, Net Goodwill Developed Technology, Net Core And Developed Technology Net Intangible assets arising from acquisitions. These assets represent acquired intellectual property that is already technologically feasible upon the acquisition date. Customer Relationships, Net Finite Lived Customer Relationships Net Net carrying amount as of the balance sheet date of an asset acquired in a business combination representing a favorable existing relationship with customers having a finite beneficial life. Other Intangibles, Net Other Intangible Assets, Net Other Assets Other Assets, Noncurrent Total Assets Assets Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Current Liabilities: Liabilities, Current [Abstract] Short-term debt Debt, Current Payables, accrued expenses and other current liabilities Accounts Payable and Accrued Liabilities, Current Total Current Liabilities Liabilities, Current Long-Term Debt Long-term Debt, Excluding Current Maturities Long-Term Employee Benefit Obligations Liability, Defined Benefit Plan, Noncurrent Deferred Income Taxes and Other Liabilities Other Liabilities, Noncurrent Commitments and Contingencies Commitments and Contingencies Shareholders’ Equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock Preferred Stock, Value, Issued Common stock Common Stock, Value, Issued Capital in excess of par value Additional Paid in Capital, Common Stock Retained earnings Retained Earnings (Accumulated Deficit) Deferred compensation Common Stock, Shares Held in Employee Trust1 Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees. Common stock in treasury - at cost Treasury Stock, Value Accumulated other comprehensive loss Total Shareholders’ Equity Total Liabilities and Shareholders’ Equity Liabilities and Equity Cash and equivalents and restricted cash Benefit Plans Pension and Other Postretirement Benefits Disclosure [Text Block] EX-101.PRE 9 bdx-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets (Tables)
 3 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Components of Intangible Assets
Intangible assets consisted of:
 
December 31, 2019
 
September 30, 2019
(Millions of dollars)
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Gross
Carrying
Amount
 
Accumulated
Amortization
Amortized intangible assets
 
 
 
 
 
 
 
Developed technology
$
14,010

 
$
3,161

 
$
13,960

 
$
2,906

Customer relationships
4,610

 
1,265

 
4,608

 
1,183

Product rights
115

 
65

 
110

 
60

Trademarks
407

 
106

 
407

 
102

Patents and other
488

 
311

 
445

 
305

Amortized intangible assets
$
19,630

 
$
4,908

 
$
19,530

 
$
4,555

Unamortized intangible assets
 
 
 
 
 
 
 
Acquired in-process research and development
$
1

 
 
 
$
1

 
 
Trademarks
2

 
 
 
2

 
 
Unamortized intangible assets
$
3

 
 
 
$
3

 
 
Reconciliation of Goodwill by Business Segment
The following is a reconciliation of goodwill by business segment:
(Millions of dollars)
Medical
 
Life Sciences
 
Interventional
 
Total
Goodwill as of September 30, 2019
$
9,989

  
$
772

 
$
12,615

  
$
23,376

Acquisitions (a)
10

 
—

 
—

 
10

Currency translation
17

 
2

 
30

 
49

Goodwill as of December 31, 2019
$
10,016

  
$
774

 
$
12,645

  
$
23,435

(a)
Represents goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate.
XML 11 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share (Tables)
 3 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share
The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:
 
Three Months Ended
December 31,
 
2019
 
2018
Average common shares outstanding
271,102

 
269,035

Dilutive share equivalents from share-based plans
3,850

 
5,221

Average common and common equivalent shares outstanding – assuming dilution
274,952

 
274,256

 
 
 
 
Share equivalents excluded from the diluted shares outstanding calculation because the result would have been antidilutive:
 
 
 
Mandatory convertible preferred stock
11,685

 
11,685
XML 12 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Basis of Presentation
 3 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, in the opinion of the management of Becton, Dickinson and Company (the "Company" or "BD"), include all adjustments which are of a normal recurring nature, necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented. However, the financial statements do not include all information and accompanying notes required for a presentation in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s 2019 Annual Report on Form 10-K. Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2019
Sep. 30, 2019
Current Assets:    
Cash and equivalents $ 560 $ 536
Restricted cash 49 54
Short-term investments 8 30
Trade receivables, net 2,074 2,345
Inventories:    
Materials 599 544
Work in process 350 318
Finished products 1,811 1,717
Inventories 2,760 2,579
Prepaid expenses and other 987 1,119
Total Current Assets 6,438 6,664
Property, Plant and Equipment 11,425 11,128
Less allowances for depreciation and amortization 5,643 5,469
Property, Plant and Equipment, Net 5,782 5,659
Goodwill 23,435 23,376
Developed Technology, Net 10,848 11,054
Customer Relationships, Net 3,345 3,424
Other Intangibles, Net 532 500
Other Assets 1,573 1,088
Total Assets 51,952 51,765
Current Liabilities:    
Short-term debt 2,456 1,309
Payables, accrued expenses and other current liabilities 4,269 4,345
Total Current Liabilities 6,726 5,655
Long-Term Debt 16,949 18,081
Long-Term Employee Benefit Obligations 1,290 1,272
Deferred Income Taxes and Other Liabilities 5,785 5,676
Commitments and Contingencies
Shareholders’ Equity    
Preferred stock 2 2
Common stock 347 347
Capital in excess of par value 16,320 16,270
Retained earnings 12,938 12,913
Deferred compensation 24 23
Common stock in treasury - at cost (6,228) (6,190)
Accumulated other comprehensive loss (2,202) (2,283)
Total Shareholders’ Equity 21,202 21,081
Total Liabilities and Shareholders’ Equity $ 51,952 $ 51,765
XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets - Components of Intangible Assets (Detail) - USD ($)
$ in Millions
Dec. 31, 2019
Sep. 30, 2019
Finite And Indefinite Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 19,630 $ 19,530
Accumulated Amortization 4,908 4,555
Unamortized intangible assets 3 3
Trademarks    
Finite And Indefinite Lived Intangible Assets [Line Items]    
Unamortized intangible assets 2 2
Acquired in-process research and development    
Finite And Indefinite Lived Intangible Assets [Line Items]    
Unamortized intangible assets 1 1
Developed technology    
Finite And Indefinite Lived Intangible Assets [Line Items]    
Gross Carrying Amount 14,010 13,960
Accumulated Amortization 3,161 2,906
Customer relationships    
Finite And Indefinite Lived Intangible Assets [Line Items]    
Gross Carrying Amount 4,610 4,608
Accumulated Amortization 1,265 1,183
Product rights    
Finite And Indefinite Lived Intangible Assets [Line Items]    
Gross Carrying Amount 115 110
Accumulated Amortization 65 60
Trademarks    
Finite And Indefinite Lived Intangible Assets [Line Items]    
Gross Carrying Amount 407 407
Accumulated Amortization 106 102
Patents and other    
Finite And Indefinite Lived Intangible Assets [Line Items]    
Gross Carrying Amount 488 445
Accumulated Amortization $ 311 $ 305
XML 16 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Derivative Instruments and Hedging Activities Disclosure - Gains (Losses) on Net Investment Hedges (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Foreign Currency-Denominated Debt    
Derivative Instruments, Gain (Loss) [Line Items]    
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax $ (34) $ 59
Currency Swap    
Derivative Instruments, Gain (Loss) [Line Items]    
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax $ (52) $ 0
XML 17 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Event (Details)
$ in Millions
 3 Months Ended
Dec. 31, 2019
USD ($)
Subsequent Events [Abstract]  
Inventory Recall Expense $ 59
XML 18 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Accumulated other comprehensive income (loss), net of tax, beginning balance $ (2,283) $ (1,909)
Other comprehensive income before reclassifications, net of taxes 63 (32)
Amounts reclassified into income, net of taxes 19 14
Accumulated other comprehensive income (loss), net of tax, ending balance (2,202) (1,927)
Foreign Currency Translation    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Accumulated other comprehensive income (loss), net of tax, beginning balance (1,256) (1,162)
Other comprehensive income before reclassifications, net of taxes 26 (35)
Amounts reclassified into income, net of taxes 0 0
Accumulated other comprehensive income (loss), net of tax, ending balance (1,230) (1,197)
Benefit Plans    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Accumulated other comprehensive income (loss), net of tax, beginning balance (1,005) (729)
Other comprehensive income before reclassifications, net of taxes 0 3
Amounts reclassified into income, net of taxes 17 13
Accumulated other comprehensive income (loss), net of tax, ending balance (988) (714)
Cash Flow Hedges    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Accumulated other comprehensive income (loss), net of tax, beginning balance (23) (17)
Other comprehensive income before reclassifications, net of taxes 37 (1)
Amounts reclassified into income, net of taxes 2 1
Accumulated other comprehensive income (loss), net of tax, ending balance $ 16 $ (16)
XML 19 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Data - Additional Information (Detail)
 3 Months Ended
Dec. 31, 2019
segment
Segment Reporting [Abstract]  
Number of principal business segments (segment) 3
XML 20 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases
 3 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Leases of Lessee Disclosure [Text Block] Leases
The Company leases real estate, vehicles and other equipment which are used in the Company’s manufacturing, administrative and research and development activities. The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. The Company’s lease arrangements are generally classified as operating leases. These arrangements have remaining terms ranging from less than one year to approximately 25 years and the weighted-average remaining lease term of the Company’s leases is approximately 7.5 years. An option to renew or terminate the current term of a lease arrangement is included in the lease term if the Company is reasonably certain to exercise that option.
The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet. For the longer-term lease arrangements that are recognized on the Company’s consolidated balance sheet, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. The costs associated with the Company’s short-term leases, as well as variable costs relating to the Company’s lease arrangements, are not material to its consolidated financial results.
The implicit interest rates of the Company’s lease arrangements are generally not readily determinable and as such, the Company applies an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. The weighted-average incremental borrowing rate that has been applied to measure the Company’s lease liabilities is 2.3%.
The Company’s lease costs recorded in its consolidated statement of income for the three months ended December 31, 2019 were $34 million. Cash payments arising from the Company’s lease arrangements are reflected on its condensed consolidated statement of cash flows as outflows used for operating activities. The right-of-use assets and lease liabilities recognized on the Company’s condensed consolidated balance sheet as of December 31, 2019 were as follows:
(Millions of dollars)
December 31, 2019
Right-use-assets recorded in Other Assets
$
426

Current lease liabilities recorded in Payables, accrued expenses and other current liabilities
$
105

Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities
$
340


The Company’s payments due under its operating leases are as follows:
(Millions of dollars)
 
Remaining for 2020
$
86

2021
95

2022
74

2023
49

2024
33

Thereafter
158

Total payments due
494

Less: imputed interest
49

Total
$
445


The Company’s future minimum rental commitments on non-cancelable leases at September 30, 2019, as disclosed in the Company’s 2019 Annual Report on Form 10-K, were as follows:
(Millions of dollars)
 
2020
$
122

2021
103

2022
83

2023
57

2024
56

Thereafter
123

Total
$
546
XML 21 bdx1231201910-q_htm.xml IDEA: XBRL DOCUMENT 0000010795 2019-10-01 2019-12-31 0000010795 2018-10-01 2018-12-31 0000010795 2019-12-31 0000010795 bdx:Notes1.000dueDecember152022Member exch:XNYS 2019-10-01 2019-12-31 0000010795 bdx:Notes1.401dueMay242023Member exch:XNYS 2019-10-01 2019-12-31 0000010795 bdx:DepositarysharesMember exch:XNYS 2019-10-01 2019-12-31 0000010795 bdx:Notes0.174dueJune42021Member exch:XNYS 2019-10-01 2019-12-31 0000010795 bdx:Notes1.208dueJune42026Member exch:XNYS 2019-10-01 2019-12-31 0000010795 bdx:Notes3.020dueMay242025Member exch:XNYS 2019-10-01 2019-12-31 0000010795 bdx:Notes0.632dueJune42023Member exch:XNYS 2019-10-01 2019-12-31 0000010795 us-gaap:CommonStockMember exch:XNYS 2019-10-01 2019-12-31 0000010795 bdx:Notes1.900dueDecember152026Member exch:XNYS 2019-10-01 2019-12-31 0000010795 2019-09-30 0000010795 2018-12-31 0000010795 2018-09-30 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-10-01 2018-12-31 0000010795 us-gaap:CommonStockMember 2018-09-30 0000010795 us-gaap:RetainedEarningsMember 2018-12-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-09-30 0000010795 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0000010795 us-gaap:TreasuryStockMember 2018-10-01 2018-12-31 0000010795 us-gaap:TreasuryStockMember 2018-09-30 0000010795 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000010795 us-gaap:CommonStockMember 2018-12-31 0000010795 us-gaap:TreasuryStockMember 2018-12-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-12-31 0000010795 us-gaap:RetainedEarningsMember 2018-09-30 0000010795 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000010795 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000010795 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0000010795 us-gaap:TreasuryStockMember 2019-12-31 0000010795 us-gaap:RetainedEarningsMember 2019-09-30 0000010795 us-gaap:TreasuryStockMember 2019-10-01 2019-12-31 0000010795 us-gaap:RetainedEarningsMember 2019-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-09-30 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-12-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-10-01 2019-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000010795 us-gaap:TreasuryStockMember 2019-09-30 0000010795 us-gaap:CommonStockMember 2019-09-30 0000010795 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000010795 us-gaap:CommonStockMember 2019-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-10-01 2018-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-09-30 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-09-30 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-10-01 2018-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2018-10-01 2018-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2019-10-01 2019-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-09-30 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-10-01 2019-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-10-01 2019-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000010795 us-gaap:ConvertiblePreferredStockMember 2018-10-01 2018-12-31 0000010795 us-gaap:ConvertiblePreferredStockMember 2019-10-01 2019-12-31 0000010795 bdx:WomensHealthProductClaimsMember 2019-12-31 0000010795 us-gaap:OtherOperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000010795 us-gaap:OtherOperatingIncomeExpenseMember 2019-01-01 2019-03-31 0000010795 bdx:WomensHealthProductClaimsMember bdx:CompensatoryMember 2018-04-01 2018-04-30 0000010795 bdx:FilterProductClaimsMember 2019-12-31 0000010795 bdx:FilterProductClaimsMember 2019-10-01 2019-12-31 0000010795 bdx:WomensHealthProductClaimsMember 2018-04-01 2018-04-30 0000010795 bdx:WomensHealthProductClaimsMember bdx:PunitiveMember 2018-04-01 2018-04-30 0000010795 bdx:HerniaProductClaimsMember 2019-12-31 0000010795 2020-01-01 2019-12-31 0000010795 bdx:ProductsandorServicesMember 2020-01-01 2019-12-31 0000010795 bdx:ConsumablesMember 2020-01-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 us-gaap:CorporateNonSegmentMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember 2019-10-01 2019-12-31 0000010795 us-gaap:MaterialReconcilingItemsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 us-gaap:MaterialReconcilingItemsMember 2018-10-01 2018-12-31 0000010795 us-gaap:CorporateNonSegmentMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember bdx:UrologyandCriticalCareMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember bdx:SurgeryMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:BiosciencesMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:MedicationDeliverySolutionsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:PharmaceuticalSystemsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:DiagnosticSystemsMember 2019-10-01 2019-12-31 0000010795 country:US 2019-10-01 2019-12-31 0000010795 us-gaap:NonUsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:MedicationManagementSolutionsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember bdx:SurgeryMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember bdx:SurgeryMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:DiagnosticSystemsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember bdx:SurgeryMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember bdx:SurgeryMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:DiagnosticSystemsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:BiosciencesMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:MedicationDeliverySolutionsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:IntegratedDiagnosticSolutionsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:MedicationDeliverySolutionsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:DiagnosticSystemsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:PharmaceuticalSystemsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:PharmaceuticalSystemsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember bdx:UrologyandCriticalCareMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:DiabetesCareMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember bdx:UrologyandCriticalCareMember 2018-10-01 2018-12-31 0000010795 country:US 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember bdx:PeripheralInterventionMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember bdx:UrologyandCriticalCareMember 2018-10-01 2018-12-31 0000010795 us-gaap:NonUsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:PreanalyticalSystemsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:MedicationManagementSolutionsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember bdx:PeripheralInterventionMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember bdx:UrologyandCriticalCareMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember bdx:PeripheralInterventionMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:DiabetesCareMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:PharmaceuticalSystemsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember bdx:PeripheralInterventionMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:DiabetesCareMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:IntegratedDiagnosticSolutionsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:MedicationDeliverySolutionsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:BiosciencesMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:PreanalyticalSystemsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:IntegratedDiagnosticSolutionsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:DiabetesCareMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:PreanalyticalSystemsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember bdx:PeripheralInterventionMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:BiosciencesMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:MedicationDeliverySolutionsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:IntegratedDiagnosticSolutionsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:DiabetesCareMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:PharmaceuticalSystemsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:DiagnosticSystemsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:MedicationDeliverySolutionsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:IntegratedDiagnosticSolutionsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember bdx:UrologyandCriticalCareMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:BiosciencesMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember bdx:SurgeryMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:MedicationManagementSolutionsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:PreanalyticalSystemsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember bdx:PeripheralInterventionMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:DiabetesCareMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:MedicationManagementSolutionsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:PharmaceuticalSystemsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:BiosciencesMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:PreanalyticalSystemsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:DiagnosticSystemsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:MedicationManagementSolutionsMember 2019-10-01 2019-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:IntegratedDiagnosticSolutionsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:MedicationManagementSolutionsMember 2018-10-01 2018-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:PreanalyticalSystemsMember 2019-10-01 2019-12-31 0000010795 bdx:AdvancedBioprocessingMember 2018-10-01 2018-12-31 0000010795 bdx:IVFluidsMember country:US 2018-10-01 2018-12-31 0000010795 bdx:InterventionalSpecialtiesBrachytherapyandFeedingProductsMember us-gaap:NonUsMember 2018-10-01 2018-12-31 0000010795 bdx:InterventionalSpecialtiesBrachytherapyandFeedingProductsMember country:US 2018-10-01 2018-12-31 0000010795 us-gaap:PensionPlansDefinedBenefitMember 2019-10-01 2019-12-31 0000010795 us-gaap:PensionPlansDefinedBenefitMember 2018-10-01 2018-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:OtherInitiativesMember 2019-10-01 2019-12-31 0000010795 bdx:OtherInitiativesMember 2019-10-01 2019-12-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:CRBardIncMember 2019-09-30 0000010795 us-gaap:EmployeeSeveranceMember bdx:CRBardIncMember 2019-12-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:CRBardIncMember 2019-10-01 2019-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:CRBardIncMember 2019-10-01 2019-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:OtherInitiativesMember 2019-12-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:OtherInitiativesMember 2019-10-01 2019-12-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:OtherInitiativesMember 2019-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:CRBardIncMember 2019-09-30 0000010795 bdx:CRBardIncMember 2019-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:CRBardIncMember 2019-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:OtherInitiativesMember 2019-09-30 0000010795 bdx:OtherInitiativesMember 2019-12-31 0000010795 bdx:OtherInitiativesMember 2019-09-30 0000010795 bdx:CRBardIncMember 2019-10-01 2019-12-31 0000010795 bdx:CRBardIncMember 2019-09-30 0000010795 us-gaap:EmployeeSeveranceMember bdx:OtherInitiativesMember 2019-09-30 0000010795 bdx:LifeSciencesMember 2019-12-31 0000010795 bdx:MedicalMember 2019-09-30 0000010795 bdx:MedicalMember 2019-10-01 2019-12-31 0000010795 bdx:LifeSciencesMember 2019-09-30 0000010795 bdx:LifeSciencesMember 2019-10-01 2019-12-31 0000010795 bdx:MedicalMember 2019-12-31 0000010795 bdx:InterventionalMember 2019-12-31 0000010795 bdx:InterventionalMember 2019-10-01 2019-12-31 0000010795 bdx:InterventionalMember 2019-09-30 0000010795 bdx:ProductRightsMember 2019-12-31 0000010795 us-gaap:TrademarksMember 2019-12-31 0000010795 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000010795 us-gaap:TrademarksMember 2019-12-31 0000010795 us-gaap:DevelopedTechnologyRightsMember 2019-09-30 0000010795 us-gaap:CustomerRelationshipsMember 2019-09-30 0000010795 bdx:ProductRightsMember 2019-09-30 0000010795 us-gaap:CustomerRelationshipsMember 2019-12-31 0000010795 us-gaap:IntellectualPropertyMember 2019-09-30 0000010795 us-gaap:TrademarksMember 2019-09-30 0000010795 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2019-12-31 0000010795 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2019-09-30 0000010795 us-gaap:IntellectualPropertyMember 2019-12-31 0000010795 us-gaap:TrademarksMember 2019-09-30 0000010795 us-gaap:CurrencySwapMember 2018-10-01 2018-12-31 0000010795 us-gaap:CurrencySwapMember 2019-10-01 2019-12-31 0000010795 bdx:ForeignCurrencyDenominatedDebtMember 2019-10-01 2019-12-31 0000010795 bdx:ForeignCurrencyDenominatedDebtMember 2018-10-01 2018-12-31 0000010795 bdx:FixedToFloatingMember us-gaap:FairValueHedgingMember 2019-12-31 0000010795 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-10-01 2019-12-31 0000010795 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0000010795 us-gaap:ForeignExchangeContractMember 2019-12-31 0000010795 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-12-31 0000010795 us-gaap:CurrencySwapMember 2019-12-31 0000010795 us-gaap:ForeignExchangeContractMember 2019-09-30 0000010795 us-gaap:CurrencySwapMember 2019-09-30 0000010795 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-09-30 0000010795 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember 2019-09-30 0000010795 bdx:FixedToFloatingMember us-gaap:FairValueHedgingMember 2019-09-30 0000010795 srt:MinimumMember 2019-10-01 2019-12-31 0000010795 srt:MaximumMember 2019-10-01 2019-12-31 0000010795 srt:MinimumMember 2019-12-31 0000010795 srt:MaximumMember 2019-12-31 bdx:segment iso4217:USD shares pure iso4217:USD shares false --09-30 Q1 2020 0000010795 1400000000 375000000 1500000000 10-Q true 2019-12-31 false 001-4802 Becton, Dickinson and Company NJ 22-0760120 1 Becton Drive, Franklin Lakes, NJ 07417-1880 (201) 847-6800 Common stock, par value $1.00 BDX NYSE Depositary Shares, each representing 1/20th of a share of 6.125% Cumulative Preferred Stock Series A BDXA NYSE 1.000% Notes due December 15, 2022 BDX22A NYSE 1.900% Notes due December 15, 2026 BDX26 NYSE 1.401% Notes due May 24, 2023 BDX23A NYSE 3.020% Notes due May 24, 2025 BDX25 NYSE 0.174% Notes due June 4, 2021 BDX/21 NYSE 0.632% Notes due June 4, 2023 BDX/23A NYSE 1.208% Notes due June 4, 2026 BDX/26A NYSE Yes Yes Large Accelerated Filer false false false 271173148 560000000 536000000 49000000 54000000 8000000 30000000 2074000000 2345000000 599000000 544000000 350000000 318000000 1811000000 1717000000 2760000000 2579000000 987000000 1119000000 6438000000 6664000000 11425000000 11128000000 5643000000 5469000000 5782000000 5659000000 23435000000 23376000000 10848000000 11054000000 3345000000 3424000000 532000000 500000000 1573000000 1088000000 51952000000 51765000000 2456000000 1309000000 4269000000 4345000000 6726000000 5655000000 16949000000 18081000000 1290000000 1272000000 5785000000 5676000000 2000000 2000000 347000000 347000000 16320000000 16270000000 12938000000 12913000000 24000000 23000000 6228000000 6190000000 -2202000000 -2283000000 21202000000 21081000000 51952000000 51765000000 4225000000 4160000000 2247000000 2187000000 1121000000 1073000000 270000000 258000000 86000000 91000000 0 335000000 3724000000 3273000000 501000000 888000000 136000000 171000000 1000000 -12000000 27000000 10000000 394000000 714000000 117000000 115000000 278000000 599000000 38000000 38000000 240000000 562000000 0.88 2.09 0.87 2.05 0.79 0.77 278000000 599000000 26000000 -35000000 -17000000 -15000000 39000000 1000000 82000000 -18000000 359000000 581000000 278000000 599000000 530000000 563000000 82000000 93000000 71000000 28000000 -102000000 473000000 24000000 -225000000 0 335000000 231000000 -52000000 713000000 245000000 173000000 167000000 0 476000000 114000000 9000000 -287000000 299000000 210000000 50000000 303000000 453000000 252000000 245000000 -68000000 -86000000 -413000000 -734000000 6000000 -5000000 18000000 -195000000 590000000 1236000000 609000000 1042000000 Basis of Presentation<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, in the opinion of the management of Becton, Dickinson and Company (the "Company" or "BD"), include all adjustments which are of a normal recurring nature, necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented. However, the financial statements do not include all information and accompanying notes required for a presentation in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K. Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.</span></div> Accounting Changes<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Principle Adopted</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet, as well as requires expanded disclosures regarding leasing arrangements. The Company adopted this standard on October 1, 2019 and elected certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company also elected not to perform any reassessments relative to its expired and existing leases upon its adoption of the new requirements. The Company's adoption of this standard did not materially impact its condensed consolidated financial statements. Additional disclosures regarding the Company’s lease arrangements are provided in Note </span><span style="font-weight:normal;">14</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Principles Not Yet Adopted</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption on October 1, 2020.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The standard is effective for the Company on October 1, 2020, but early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption.</span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Principle Adopted</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet, as well as requires expanded disclosures regarding leasing arrangements. The Company adopted this standard on October 1, 2019 and elected certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company also elected not to perform any reassessments relative to its expired and existing leases upon its adoption of the new requirements. The Company's adoption of this standard did not materially impact its condensed consolidated financial statements. Additional disclosures regarding the Company’s lease arrangements are provided in Note </span><span style="font-weight:normal;">14</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Principles Not Yet Adopted</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption on October 1, 2020.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The standard is effective for the Company on October 1, 2020, but early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption.</span></div> Shareholders' Equity<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in certain components of shareholders' equity for the first quarters of fiscal years </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.05847953216374%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Common</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Stock  Issued</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">at Par Value</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Capital in</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Excess of</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Par Value</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Earnings</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Deferred</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Compensation</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Treasury Stock</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares (in</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(76,260</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common dividends ($0.79 per share)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(215</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred dividends</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock issued for share-based compensation and other plans, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>758</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock held in trusts, net (a)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,938</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75,514</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.05847953216374%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Common</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Stock  Issued</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">at Par Value</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Capital in</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Excess of</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Par Value</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Earnings</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Deferred</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Compensation</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Treasury Stock</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares (in</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,179</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,596</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78,463</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,243</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>599</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common dividends ($0.77 per share)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(207</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred dividends</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock issued for share-based compensation and other plans, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>851</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock held in trusts, net (a)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of change in accounting principles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,174</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,018</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77,624</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components and changes of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss) </span><span style="font-family:inherit;font-size:10pt;">for the first quarters of fiscal years </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.71929824561403%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash Flow Hedges</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,005</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income before reclassifications, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified into income, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,202</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,230</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(988</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.5243664717349%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash Flow Hedges</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,909</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(729</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income before reclassifications, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified into income, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,927</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(714</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><span style="font-family:inherit;font-size:10pt;">The amounts of foreign currency translation recognized in other comprehensive income during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> included net (losses) gains relating to net investment hedges. The amount recognized in other comprehensive income relating to cash flow hedges during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> related to forward starting interest rate swaps. Additional disclosures regarding the Company's derivatives are provided in Note </span><span style="font-weight:normal;">12</span><span style="font-family:inherit;font-size:10pt;">.</span> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in certain components of shareholders' equity for the first quarters of fiscal years </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.05847953216374%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Common</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Stock  Issued</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">at Par Value</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Capital in</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Excess of</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Par Value</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Earnings</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Deferred</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Compensation</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Treasury Stock</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares (in</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(76,260</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common dividends ($0.79 per share)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(215</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred dividends</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock issued for share-based compensation and other plans, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>758</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock held in trusts, net (a)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,938</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75,514</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.05847953216374%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Common</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Stock  Issued</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">at Par Value</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Capital in</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Excess of</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Par Value</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Retained</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Earnings</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Deferred</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Compensation</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Treasury Stock</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares (in</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,179</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,596</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(78,463</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,243</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>599</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common dividends ($0.77 per share)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(207</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred dividends</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock issued for share-based compensation and other plans, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>851</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock held in trusts, net (a)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of change in accounting principles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,174</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,018</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77,624</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.</span></div> 347000000 16270000000 12913000000 23000000 76260000 -6190000000 278000000 215000000 38000000 -32000000 1000000 758000 -38000000 82000000 -12000 347000000 16320000000 12938000000 24000000 75514000 -6228000000 347000000 16179000000 12596000000 22000000 78463000 -6243000000 599000000 207000000 38000000 -97000000 2000000 851000 9000000 92000000 -12000 68000000 347000000 16174000000 13018000000 24000000 77624000 -6235000000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components and changes of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss) </span><span style="font-family:inherit;font-size:10pt;">for the first quarters of fiscal years </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.71929824561403%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash Flow Hedges</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,005</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income before reclassifications, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified into income, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,202</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,230</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(988</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.5243664717349%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash Flow Hedges</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,909</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(729</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income before reclassifications, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified into income, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,927</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(714</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div> -2283000000 -1256000000 -1005000000 -23000000 63000000 26000000 0 37000000 -19000000 0 -17000000 -2000000 -2202000000 -1230000000 -988000000 16000000 -1909000000 -1162000000 -729000000 -17000000 -32000000 -35000000 3000000 -1000000 -14000000 0 -13000000 -1000000 -1927000000 -1197000000 -714000000 -16000000 Earnings per Share<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.48927875243665%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:67%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average common shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271,102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,035</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dilutive share equivalents from share-based plans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,850</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average common and common equivalent shares outstanding – assuming dilution</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share equivalents excluded from the diluted shares outstanding calculation because the result would have been antidilutive:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mandatory convertible preferred stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,685</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,685</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.48927875243665%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:67%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average common shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271,102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,035</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dilutive share equivalents from share-based plans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,850</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average common and common equivalent shares outstanding – assuming dilution</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share equivalents excluded from the diluted shares outstanding calculation because the result would have been antidilutive:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mandatory convertible preferred stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,685</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,685</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 271102000 269035000 3850000 5221000 274952000 274256000 11685000 11685000 Contingencies<div style="line-height:120%;padding-bottom:6px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Liability Matters</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company believes that certain settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the Company from other parties, which if disputed, the Company intends to vigorously contest. Amounts recovered under the Company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Hernia Product Claims</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company is defending approximately </span><span style="font-family:inherit;font-size:10pt;"><span>14,330</span></span><span style="font-family:inherit;font-size:10pt;"> product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The majority of those claims are currently pending in a coordinated proceeding in Rhode Island State Court, but claims are also pending in other state and/or federal court jurisdictions. In addition, those claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. From time to time, the Company engages in resolution discussions with plaintiffs’ law firms regarding certain of the Hernia Product Claims, but the Company also intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Trials are scheduled throughout 2020 in various state and/or federal courts. The Company expects additional trials of Hernia Product Claims to take place over the next 12 months. In August 2018, a new hernia multi-district litigation (“MDL”) was ordered to be established in the Southern District of Ohio. The Company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Women’s Health Product Claims</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company is defending approximately </span><span style="font-family:inherit;font-size:10pt;"><span>750</span></span><span style="font-family:inherit;font-size:10pt;"> product liability claims involving the Company’s line of pelvic mesh devices. The majority of those claims are currently pending in various federal court jurisdictions, and a coordinated proceeding in New Jersey State Court, but claims are also pending in other state court jurisdictions. In addition, those claims include putative class actions filed in the United States. Not included in the figures above are approximately </span><span style="font-family:inherit;font-size:10pt;"><span>1,010</span></span><span style="font-family:inherit;font-size:10pt;"> filed and unfiled claims that have been asserted or threatened against the Company but lack sufficient information to determine whether a pelvic mesh device of the Company is actually at issue. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The claims identified above also include products manufactured by both the Company and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of the Company. Medtronic has an obligation to defend and indemnify the Company with respect to any product defect liability relating to products its subsidiaries had manufactured. In July 2015, the Company reached an agreement with Medtronic in which Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the Company under supply agreements with Medtronic. In June 2017, the Company amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic towards these potential settlements. As of December 31, 2019, the Company has paid Medtronic </span><span style="font-family:inherit;font-size:10pt;"><span>$141 million</span></span><span style="font-family:inherit;font-size:10pt;"> towards these potential settlements. The Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. The foregoing lawsuits, unfiled claims, putative class actions, and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims.” The Women’s Health Product Claims generally seek damages for personal injury allegedly resulting from use of the products.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15,165</span></span><span style="font-family:inherit;font-size:10pt;"> of the Women’s Health Product Claims. The Company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which are not included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">minimum number of plaintiffs. The Company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Starting in 2014 in the MDL, the court entered certain pre-trial orders requiring trial work up and remand of a significant number of Women’s Health Product Claims, including an order entered in the MDL on January 30, 2018, that requires the work up and remand of all remaining unsettled cases (the “WHP Pre-Trial Orders”). The WHP Pre-Trial Orders may result in material additional costs or trial verdicts in future periods in defending Women’s Health Product Claims. Trials are anticipated throughout 2020 in state and federal courts. A trial in the New Jersey coordinated proceeding began in March 2018, and in April 2018 a jury entered a verdict against the Company in the total amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$68 million</span></span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;"><span>$33 million</span></span><span style="font-family:inherit;font-size:10pt;"> compensatory; </span><span style="font-family:inherit;font-size:10pt;"><span>$35 million</span></span><span style="font-family:inherit;font-size:10pt;"> punitive). The Company is in the process of appealing that verdict. The Company expects additional trials of Women’s Health Product Claims to take place over the next 12 months, which may potentially include consolidated trials.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the course of engaging in settlement discussions with plaintiffs’ law firms, the Company has learned, and may in future periods learn, additional information regarding these and other unfiled claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Filter Product Claims</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company is defending approximately </span><span style="font-family:inherit;font-size:10pt;"><span>2,650</span></span><span style="font-family:inherit;font-size:10pt;"> product liability claims involving the Company’s line of inferior vena cava filters (collectively, the “Filter Product Claims”). The majority of those claims are currently pending in an MDL in the United States District Court for the District of Arizona, but those MDL claims either have been, or are in the process of being, remanded to various federal jurisdictions. Filter Product Claims are also pending in various state court jurisdictions, including a coordinated proceeding in Arizona State Court. In addition, those claims include putative class actions filed in the United States and Canada. The Filter Product Claims generally seek damages for personal injury allegedly resulting from use of the products. The Company has limited information regarding the nature and quantity of certain of the Filter Product Claims. The Company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. On May 31, 2019, the MDL Court ceased accepting direct filings or transfers into the Filter Product Claims MDL and, as noted above, remands for non-settled cases have begun and are expected to continue over the next three months. Federal and state court trials are scheduled throughout 2020. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company entered into settlement agreements and/or settlement agreements in principle for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>6,400</span></span><span style="font-family:inherit;font-size:10pt;"> cases. On March 30, 2018, a jury in the first MDL trial found the Company liable for negligent failure to warn and entered a verdict in favor of plaintiffs. The jury found the Company was not liable for (a) strict liability design defect; (b) strict liability failure to warn; and (c) negligent design. The Company has appealed that verdict. On June 1, 2018, a jury in the second MDL trial unanimously found in favor of the Company on all claims. On August 17, 2018, the Court entered summary judgment in favor of the Company on all claims in the third MDL trial. On October 5, 2018, a jury in the fourth MDL trial unanimously found in favor of the Company on all claims. The Company expects additional trials of Filter Product Claims may take place over the next 12 months.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the settlement of a prior litigation with certain of the Company's insurance carriers, an agreement with the Company's insurance carriers was reached to reimburse the Company for certain future costs incurred in connection with Filter Product Claims up to an agreed amount. For certain product liability claims or lawsuits, the Company does not maintain or has limited remaining insurance coverage.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Legal Matters</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since early 2013, the Company has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the Company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The Company is cooperating with these requests. Although the Company has had, and continues to have, discussions with the State Attorneys General with respect to overall potential resolution of this matter, there can be no assurance that a resolution will be reached or what the terms of any such resolution may be.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2017, a civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> and </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">QuantaFlo</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></span><span style="font-family:inherit;font-size:10pt;"> devices. The Company is cooperating with these requests. Since it is not feasible to predict the outcome of these matters, the Company cannot give any assurances that the resolution of these matters will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the Company’s business and/or results of operations.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses to these suits pending against the Company and is engaged in a vigorous defense of each of these matters.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Litigation Reserves</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second and fourth quarters of fiscal year 2019, the Company recorded pre-tax charges to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other operating expense, net</span><span style="font-family:inherit;font-size:10pt;">, of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$331 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$582 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to certain of the product liability matters discussed above under the heading “Product Liability Matters,” including the related legal defense costs. The Company recorded these charges based on additional information obtained during the second and fourth quarters of fiscal year 2019, including but not limited to: the nature and quantity of unfiled and filed claims and the continued rate of claims being filed in certain product liability matters; the status of certain settlement discussions with plaintiffs’ counsel; the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the Company; and the stage of litigation.</span></div><span style="font-family:inherit;font-size:10pt;">Accruals for the Company's product liability claims which are discussed above, as well as the related legal defense costs, amounted to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. These accruals, which are generally long-term in nature, are largely recorded within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Income Taxes and Other Liabilities</span><span style="font-family:inherit;font-size:10pt;"> on the Company's condensed consolidated balance sheets. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$48 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$53 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters. Payments to QSFs are recorded as a component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted cash</span><span style="font-family:inherit;font-size:10pt;">. The Company's expected recoveries related to product liability claims and related legal defense costs were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$152 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. A substantial amount of these expected recoveries at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> related to the Company’s agreements with Medtronic related to certain Women’s Health Product Claims. The expected recoveries at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span> related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements. <div style="line-height:120%;padding-bottom:6px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows.</span></div> 14330 750 1010 141000000 15165 68000000 33000000 35000000 2650 6400 331000000 582000000 2400000000 2500000000 48000000 53000000 152000000 150000000 Revenues<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s policies for recognizing sales have not changed from those described in the Company’s </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K. The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Measurement of Revenues</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s estimate of probable credit losses relating to trade receivables is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. Such amounts are not material to the Company's consolidated financial results.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. The impact of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Effects of Revenue Arrangements on Consolidated Balance Sheets</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's condensed consolidated balance sheets. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liabilities for unearned revenue that is allocable to performance obligations, such as extended warranty and software maintenance contracts, which are performed over time are immaterial to the Company's consolidated financial results. The Company's liability for product warranties provided under its agreements with customers is not material to its condensed consolidated balance sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Remaining Performance Obligations</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's obligations relative to service contracts and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided are estimated to be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company expects to recognize the majority of this revenue over the next </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Within the Company's Medication Management Solutions, Medication Delivery Solutions, Integrated Diagnostic Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 billion</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.  This revenue will be recognized over the customer relationship period.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Disaggregation of Revenues</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note </span><span style="font-weight:normal;">7</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Measurement of Revenues</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s estimate of probable credit losses relating to trade receivables is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. Such amounts are not material to the Company's consolidated financial results.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. The impact of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues.</span></div> 1800000000 P3Y 2700000000 Segment Data<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's organizational structure is based upon </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> principal business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective October 1, 2019, Life Sciences joined its former Preanalytical Systems and Diagnostic Systems organizational units to create a new Integrated Diagnostic Solutions organizational unit which focuses on driving growth and innovation around integrated specimen management to diagnostic solutions. The Integrated Diagnostic Solutions organizational unit consists of the following principal product lines:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.13450292397661%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:16%;"/><td style="width:2%;"/><td style="width:82%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Organizational Unit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal Product Lines</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Integrated Diagnostic Solutions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;padding-top:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays for testing of respiratory infections; microbiology laboratory automation and plated media for clinical and industrial applications.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues by segment, organizational unit and geographical areas for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-month periods are detailed below. The Company has no material intersegment revenues. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.270955165692%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Medical</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medication Delivery Solutions (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>428</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>948</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>519</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>438</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>956</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medication Management Solutions (a)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diabetes Care</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical Systems</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>299</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,204</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>886</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,090</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>896</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Life Sciences</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Integrated Diagnostic Solutions</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preanalytical Systems</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>393</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostic Systems</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>184</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>402</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Integrated Diagnostic Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>414</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>800</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>376</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biosciences</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>323</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>585</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,123</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>484</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>572</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,056</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Interventional</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Surgery (b)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>310</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Peripheral Intervention (b)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Urology and Critical Care (b)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>688</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,012</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>664</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Company revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,773</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,160</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior-period amounts reflect the reclassification of U.S. revenues of </span><span style="font-family:inherit;font-size:10pt;"><span>$2 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.</span></div></td></tr></table><div style="padding-top:4px;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(b)</span><span style="font-family:inherit;font-size:10pt;">Prior-period amounts reflect the total reclassifications of </span><span style="font-family:inherit;font-size:10pt;"><span>$31 million</span></span><span style="font-family:inherit;font-size:10pt;"> of U.S. revenues and </span><span style="font-family:inherit;font-size:10pt;"><span>$14 million</span></span><span style="font-family:inherit;font-size:10pt;"> of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:29%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment income for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-month periods was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.09941520467837%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Income Before Income Taxes</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Life Sciences</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>361</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interventional </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Segment Operating Income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,167</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions and other restructurings</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(86</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(91</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other unallocated items (b)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(553</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Income Before Income Taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>394</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>714</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amount for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> included the estimated cost of a product recall of </span><span style="font-family:inherit;font-size:10pt;"><span>$59 million</span></span><span style="font-family:inherit;font-size:10pt;"> which was recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of products sold</span><span style="font-family:inherit;font-size:10pt;"> and is further discussed in Note 15. </span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(b)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$335 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is further discussed in Note </span><span style="font-weight:normal;">9</span><span style="font-family:inherit;font-size:10pt;">.</span></div> 3 <div style="line-height:120%;padding-top:12px;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues by segment, organizational unit and geographical areas for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-month periods are detailed below. The Company has no material intersegment revenues. </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.270955165692%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Medical</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medication Delivery Solutions (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>428</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>948</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>519</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>438</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>956</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medication Management Solutions (a)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diabetes Care</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical Systems</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>299</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,204</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>886</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,090</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>896</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Life Sciences</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Integrated Diagnostic Solutions</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preanalytical Systems</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>393</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostic Systems</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>184</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>402</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Integrated Diagnostic Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>414</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>800</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>376</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biosciences</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>323</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>585</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,123</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>484</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>572</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,056</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Interventional</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Surgery (b)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>310</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Peripheral Intervention (b)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Urology and Critical Care (b)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>688</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,012</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>664</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Company revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,773</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,160</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior-period amounts reflect the reclassification of U.S. revenues of </span><span style="font-family:inherit;font-size:10pt;"><span>$2 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.</span></div></td></tr></table><div style="padding-top:4px;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(b)</span><span style="font-family:inherit;font-size:10pt;">Prior-period amounts reflect the total reclassifications of </span><span style="font-family:inherit;font-size:10pt;"><span>$31 million</span></span><span style="font-family:inherit;font-size:10pt;"> of U.S. revenues and </span><span style="font-family:inherit;font-size:10pt;"><span>$14 million</span></span><span style="font-family:inherit;font-size:10pt;"> of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.51656920077973%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:29%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div> 520000000 428000000 948000000 519000000 438000000 956000000 462000000 113000000 575000000 508000000 118000000 625000000 139000000 129000000 268000000 145000000 129000000 274000000 84000000 215000000 299000000 68000000 212000000 280000000 1204000000 886000000 2090000000 1239000000 896000000 2135000000 202000000 196000000 398000000 201000000 192000000 393000000 184000000 218000000 402000000 175000000 207000000 382000000 386000000 414000000 800000000 376000000 399000000 774000000 152000000 171000000 323000000 108000000 173000000 281000000 538000000 585000000 1123000000 484000000 572000000 1056000000 256000000 70000000 326000000 246000000 64000000 310000000 225000000 170000000 395000000 223000000 160000000 382000000 206000000 85000000 291000000 195000000 83000000 277000000 688000000 325000000 1012000000 664000000 306000000 970000000 2430000000 1795000000 4225000000 2387000000 1773000000 4160000000 2000000 31000000 14000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment income for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-month periods was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.09941520467837%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Income Before Income Taxes</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Life Sciences</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>361</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interventional </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Segment Operating Income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,167</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions and other restructurings</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(86</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(91</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other unallocated items (b)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(553</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Income Before Income Taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>394</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>714</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amount for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> included the estimated cost of a product recall of </span><span style="font-family:inherit;font-size:10pt;"><span>$59 million</span></span><span style="font-family:inherit;font-size:10pt;"> which was recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of products sold</span><span style="font-family:inherit;font-size:10pt;"> and is further discussed in Note 15. </span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(b)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$335 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is further discussed in Note </span><span style="font-weight:normal;">9</span><span style="font-family:inherit;font-size:10pt;">.</span></div> 564000000 665000000 361000000 305000000 243000000 209000000 1167000000 1180000000 86000000 91000000 -134000000 -183000000 -553000000 -192000000 394000000 714000000 59000000 335000000 Benefit Plans<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has defined benefit pension plans covering certain employees in the United States and certain international locations. The measurement date used for these plans is September 30.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net pension cost included the following components for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.15009746588694%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of prior service credit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net pension cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss) </span><span style="font-family:inherit;font-size:10pt;">in prior periods. All components of the Company’s net periodic pension cost, aside from service cost, are recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other income (expense), net</span><span style="font-family:inherit;font-size:10pt;"> on its condensed consolidated statements of income.</span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net pension cost included the following components for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.15009746588694%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of prior service credit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net pension cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 40000000 35000000 22000000 28000000 49000000 47000000 -3000000 -3000000 -25000000 -20000000 35000000 32000000 Divestiture<span style="font-family:inherit;font-size:10pt;">The Company completed the sale of its Life Sciences segment's Advanced Bioprocessing business in October 2018 pursuant to a definitive agreement that was signed in September 2018. The Company recognized a pre-tax gain on the sale of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$335 million</span></span><span style="font-family:inherit;font-size:10pt;"> which was recorded as a component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other operating income, net </span>in the first quarter of fiscal year 2019. 335000000 Business Restructuring Charges<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company incurred restructuring costs during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, in connection with the Company's acquisition of C.R. Bard, Inc. ("Bard") and portfolio rationalization initiatives, which were largely recorded within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions and other restructurings</span><span style="font-family:inherit;font-size:10pt;">. Restructuring liability activity for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.62573099415205%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Employee</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Termination</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Bard</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Initiatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Bard (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Initiatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Bard</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Initiatives</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charged to expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash settlements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div>Largely represents the cost associated with certain pre-acquisition equity awards of Bard which, to encourage post-acquisition employee retention, were converted to BD equity awards with substantially the same terms and conditions as were applicable under such Bard awards immediately prior to the acquisition date. Restructuring liability activity for the <span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.62573099415205%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Employee</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Termination</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Bard</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Initiatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Bard (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Initiatives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Bard</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Initiatives</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charged to expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash settlements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div>Largely represents the cost associated with certain pre-acquisition equity awards of Bard which, to encourage post-acquisition employee retention, were converted to BD equity awards with substantially the same terms and conditions as were applicable under such Bard awards immediately prior to the acquisition date. 22000000 31000000 1000000 3000000 23000000 34000000 4000000 2000000 13000000 4000000 17000000 6000000 7000000 12000000 6000000 4000000 13000000 16000000 0 0 7000000 0 7000000 0 19000000 21000000 1000000 3000000 20000000 24000000 Intangible Assets<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets consisted of:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.85575048732943%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortized intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,010</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,610</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,265</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,608</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product rights</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trademarks</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>445</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortized intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,908</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired in-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trademarks</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible amortization expense for the three months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$345 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$378 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a reconciliation of goodwill by business segment:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.3625730994152%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life Sciences</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interventional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,989</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>772</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,615</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,376</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions (a)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,016</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>774</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,645</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,435</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Represents goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate.</span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets consisted of:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.85575048732943%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortized intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,010</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,610</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,265</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,608</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product rights</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trademarks</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>445</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>305</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortized intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,908</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired in-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trademarks</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 14010000000 3161000000 13960000000 2906000000 4610000000 1265000000 4608000000 1183000000 115000000 65000000 110000000 60000000 407000000 106000000 407000000 102000000 488000000 311000000 445000000 305000000 19630000000 4908000000 19530000000 4555000000 1000000 1000000 2000000 2000000 3000000 3000000 345000000 378000000 <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a reconciliation of goodwill by business segment:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.3625730994152%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Medical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life Sciences</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Interventional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,989</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>772</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,615</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,376</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions (a)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currency translation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,016</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>774</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,645</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,435</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Represents goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate.</span></div> 9989000000 772000000 12615000000 23376000000 10000000 0 0 10000000 17000000 2000000 30000000 49000000 10016000000 774000000 12645000000 23435000000 Derivative Instruments and Hedging Activities<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items have on financial position, financial performance, and cash flows are provided below.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Risks and Related Strategies</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts. In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has hedged the currency risk associated with those investments with instruments, such as foreign currency-denominated debt, cross-currency swaps and currency exchange contracts, which are designated as net investment hedges. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hedges of the transactional foreign exchange exposures resulting primarily from intercompany payables and receivables are undesignated hedges. As such, the gains or losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. The net amounts recognized in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other income, net</span><span style="font-family:inherit;font-size:10pt;">, during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were immaterial to the Company's consolidated financial results. The total notional amounts of the Company’s outstanding foreign exchange contracts as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 billion</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of the Company's foreign currency-denominated long-term notes outstanding, which had a total carrying value of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, were designated as, and were effective as, economic hedges of net investments in certain of the Company's foreign subsidiaries. The Company has entered into cross-currency swaps, all of which are designated and effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. The notional amounts of the cross-currency swaps were </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gains or losses relating to the net investment hedges, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as accumulated foreign currency translation in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;">. Upon the termination of a net investment hedge, any net gain or loss included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;"> relative to the investment hedge remains until the foreign subsidiary investment is disposed of or is substantially liquidated. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net (losses) gains recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;"> relating to the Company's net investment hedges for the </span><span style="font-family:inherit;font-size:10pt;">three-month</span><span style="font-family:inherit;font-size:10pt;"> periods were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.15009746588694%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency-denominated debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Rate Risks and Related Strategies</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s policy is to manage interest rate exposure using a mix of fixed and variable rate debt. The Company periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either fair value or cash flow hedges.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total notional amount of the Company’s outstanding interest rate swaps designated as fair value hedges was </span><span style="font-family:inherit;font-size:10pt;"><span>$375 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The outstanding swaps represent fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. Changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt. The amounts recorded during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> for changes in the fair value of these hedges were immaterial to the Company's consolidated financial results.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;">. If interest rate derivatives designated as cash flow hedges are terminated, the balance in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;"> attributable to those derivatives is reclassified into earnings over the remaining life of the hedged debt. The net realized loss related to terminated interest rate swaps expected to be reclassified and recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> within the next 12 months is </span><span style="font-family:inherit;font-size:10pt;"><span>$6 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of tax.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total notional amount of the Company's outstanding forward starting interest rate swaps was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company entered into these contracts in the fourth quarter of fiscal year 2019 to mitigate its exposure to interest rate risk. The Company recognized an after-tax gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$37 million</span></span><span style="font-family:inherit;font-size:10pt;"> in other comprehensive income relating to these interest rate hedges during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:83.4307992202729%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:49%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:12%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Risk Exposures</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company purchases resins, which are oil-based components used in the manufacture of certain products. Significant increases in world oil prices that lead to increases in resin purchase costs could impact future operating results. From time to time, the Company has managed price risks associated with these commodity purchases through commodity derivative forward contracts. The Company's outstanding commodity derivative forward contracts at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were immaterial to the Company's consolidated financial results.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Statement Effects</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of derivative instruments outstanding at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were not material to the Company's consolidated balance sheets.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:64.91228070175438%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The amounts reclassified from accumulated other comprehensive income relating to cash flow hedges during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were not material to the Company's consolidated financial results.</span> Hedges of the transactional foreign exchange exposures resulting primarily from intercompany payables and receivables are undesignated hedges. <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items have on financial position, financial performance, and cash flows are provided below.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s policy is to manage interest rate exposure using a mix of fixed and variable rate debt. The Company periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either fair value or cash flow hedges.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total notional amount of the Company’s outstanding interest rate swaps designated as fair value hedges was </span><span style="font-family:inherit;font-size:10pt;"><span>$375 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The outstanding swaps represent fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. Changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt. The amounts recorded during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> for changes in the fair value of these hedges were immaterial to the Company's consolidated financial results.</span></div><span style="font-family:inherit;font-size:10pt;">Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;">. If interest rate derivatives designated as cash flow hedges are terminated, the balance in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss)</span> attributable to those derivatives is reclassified into earnings over the remaining life of the hedged debt. 1200000000 2300000000 1400000000 3000000000.0 2300000000 <div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net (losses) gains recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;"> relating to the Company's net investment hedges for the </span><span style="font-family:inherit;font-size:10pt;">three-month</span><span style="font-family:inherit;font-size:10pt;"> periods were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.15009746588694%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency-denominated debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cross-currency swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -34000000 59000000 -52000000 0 375000000 -6000000 1500000000 37000000 Financial Instruments and Fair Value Measurements<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> to the total of these amounts shown on the Company's consolidated statements of cash flows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:435px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:224px;"/><td style="width:9px;"/><td style="width:88px;"/><td style="width:4px;"/><td style="width:6px;"/><td style="width:9px;"/><td style="width:88px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>536</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>609</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted cash consists of cash restricted from withdrawal and usage except for certain product liability matters.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s cash and equivalents include institutional money market accounts which permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy. The fair value of these accounts was immaterial at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the fair value of these accounts at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$39 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company’s remaining cash and equivalents, excluding restricted cash, were </span><span style="font-family:inherit;font-size:10pt;"><span>$560 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$497 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments consist of instruments with maturities greater than </span><span style="font-family:inherit;font-size:10pt;"><span>three months</span></span><span style="font-family:inherit;font-size:10pt;"> and less than </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments, which are considered Level 2 inputs in the fair value hierarchy. The fair value of long-term debt was </span><span style="font-family:inherit;font-size:10pt;"><span>$18.1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The fair value of the current portion of long-term debt was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other instruments measured by the Company at fair value, including derivatives and contingent consideration liabilities, are immaterial to the Company's consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transfers of trade receivables</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Over the normal course of its business activities, the Company transfers certain trade receivable assets to third parties under factoring agreements. Per the terms of these agreements, the Company surrenders control over its trade receivables upon transfer.  Accordingly, the Company accounts for the transfers as sales of trade receivables by recognizing an increase to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and equivalents</span><span style="font-family:inherit;font-size:10pt;"> and a decrease to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade receivables, net</span><span style="font-family:inherit;font-size:10pt;"> when proceeds from the transactions are received.  The Company’s balance of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade receivables, net</span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> excludes trade receivables of </span><span style="font-family:inherit;font-size:10pt;"><span>$328 million</span></span><span style="font-family:inherit;font-size:10pt;"> that have been transferred to third parties under factoring arrangements.  The costs incurred by the Company in connection with factoring activities were not material to its consolidated financial results.  The Company’s transfers of trade receivables during the three months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> were not material to its consolidated financial results.</span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> to the total of these amounts shown on the Company's consolidated statements of cash flows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:435px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:224px;"/><td style="width:9px;"/><td style="width:88px;"/><td style="width:4px;"/><td style="width:6px;"/><td style="width:9px;"/><td style="width:88px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>536</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>609</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 560000000 536000000 49000000 54000000 609000000 590000000 <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s cash and equivalents include institutional money market accounts which permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy. The fair value of these accounts was immaterial at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the fair value of these accounts at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$39 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company’s remaining cash and equivalents, excluding restricted cash, were </span><span style="font-family:inherit;font-size:10pt;"><span>$560 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$497 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments consist of instruments with maturities greater than </span><span style="font-family:inherit;font-size:10pt;"><span>three months</span></span><span style="font-family:inherit;font-size:10pt;"> and less than </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments, which are considered Level 2 inputs in the fair value hierarchy. The fair value of long-term debt was </span><span style="font-family:inherit;font-size:10pt;"><span>$18.1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The fair value of the current portion of long-term debt was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other instruments measured by the Company at fair value, including derivatives and contingent consideration liabilities, are immaterial to the Company's consolidated balance sheets.</span></div> 39000000 560000000 497000000 P3M P1Y 18100000000 19200000000 2500000000 1300000000 328000000 Leases<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company leases real estate, vehicles and other equipment which are used in the Company’s manufacturing, administrative and research and development activities. The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. The Company’s lease arrangements are generally classified as operating leases. These arrangements have remaining terms ranging from less than </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>25 years</span></span><span style="font-family:inherit;font-size:10pt;"> and the weighted-average remaining lease term of the Company’s leases is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>7.5 years</span></span><span style="font-family:inherit;font-size:10pt;">. An option to renew or terminate the current term of a lease arrangement is included in the lease term if the Company is reasonably certain to exercise that option.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet. For the longer-term lease arrangements that are recognized on the Company’s consolidated balance sheet, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. The costs associated with the Company’s short-term leases, as well as variable costs relating to the Company’s lease arrangements, are not material to its consolidated financial results.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The implicit interest rates of the Company’s lease arrangements are generally not readily determinable and as such, the Company applies an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. The weighted-average incremental borrowing rate that has been applied to measure the Company’s lease liabilities is </span><span style="font-family:inherit;font-size:10pt;"><span>2.3%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s lease costs recorded in its consolidated statement of income for the three months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$34 million</span></span><span style="font-family:inherit;font-size:10pt;">. Cash payments arising from the Company’s lease arrangements are reflected on its condensed consolidated statement of cash flows as outflows used for operating activities. The right-of-use assets and lease liabilities recognized on the Company’s condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.17543859649122%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-use-assets recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current lease liabilities recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Payables, accrued expenses and other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current lease liabilities recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Income Taxes and Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s payments due under its operating leases are as follows:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:48.343079922027286%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:33%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining for 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total payments due</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>445</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s future minimum rental commitments on non-cancelable leases at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, as disclosed in the Company’s </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K, were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:48.343079922027286%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:33%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>546</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. The Company’s lease arrangements are generally classified as operating leases. These arrangements have remaining terms ranging from less than <span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>25 years</span></span><span style="font-family:inherit;font-size:10pt;"> and the weighted-average remaining lease term of the Company’s leases is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>7.5 years</span></span><span style="font-family:inherit;font-size:10pt;">. An option to renew or terminate the current term of a lease arrangement is included in the lease term if the Company is reasonably certain to exercise that option.</span>The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet. For the longer-term lease arrangements that are recognized on the Company’s consolidated balance sheet, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. P1Y P25Y P7Y6M The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet. 0.023 34000000 The right-of-use assets and lease liabilities recognized on the Company’s condensed consolidated balance sheet as of <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.17543859649122%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-use-assets recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current lease liabilities recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Payables, accrued expenses and other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current lease liabilities recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Income Taxes and Other Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>340</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 426000000 105000000 340000000 <div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s payments due under its operating leases are as follows:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:48.343079922027286%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:33%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining for 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total payments due</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>445</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 86000000 95000000 74000000 49000000 33000000 158000000 494000000 49000000 445000000 <div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s future minimum rental commitments on non-cancelable leases at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, as disclosed in the Company’s </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K, were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:48.343079922027286%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:33%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Millions of dollars)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>546</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 122000000 103000000 83000000 57000000 56000000 123000000 546000000 Subsequent Event<div style="line-height:120%;padding-bottom:10px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 4, 2020, the Company initiated a voluntary recall of certain Alaris</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></span><span style="font-family:inherit;font-size:10pt;"> pump systems in order to address software errors and other alarm prioritization matters. The estimated cost of this recall of </span><span style="font-family:inherit;font-size:10pt;"><span>$59 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of products sold </span><span style="font-family:inherit;font-size:10pt;">during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company may record incremental charges in future periods associated with this recall.</span></div> 59000000 XML 22 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Restructuring Charges
 3 Months Ended
Dec. 31, 2019
Restructuring and Related Activities [Abstract]  
Business Restructuring Charges Business Restructuring Charges
The Company incurred restructuring costs during the three months ended December 31, 2019, in connection with the Company's acquisition of C.R. Bard, Inc. ("Bard") and portfolio rationalization initiatives, which were largely recorded within Acquisitions and other restructurings. Restructuring liability activity for the three months ended December 31, 2019 was as follows:
(Millions of dollars)
Employee
Termination
 
Other
 
Total
 
Bard
 
Other Initiatives
 
Bard (a)
 
Other Initiatives
 
Bard
 
Other Initiatives
Balance at September 30, 2019
$
22

 
$
31

 
$
1

 
$
3

 
$
23

 
$
34

Charged to expense
4

 
2

 
13

 
4

 
17

 
6

Cash payments
(7
)
 
(12
)
 
(6
)
 
(4
)
 
(13
)
 
(16
)
Non-cash settlements
—

 
—

 
(7
)
 
—

 
(7
)
 
—

Balance at December 31, 2019
$
19

 
$
21

 
1

 
$
3

 
$
20

 
$
24


(a)
Largely represents the cost associated with certain pre-acquisition equity awards of Bard which, to encourage post-acquisition employee retention, were converted to BD equity awards with substantially the same terms and conditions as were applicable under such Bard awards immediately prior to the acquisition date.
ZIP 23 0000010795-20-000010-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000010795-20-000010-xbrl.zip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�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�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`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ɒ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htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenues
 3 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Revenue Revenues
The Company’s policies for recognizing sales have not changed from those described in the Company’s 2019 Annual Report on Form 10-K. The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Measurement of Revenues
The Company’s estimate of probable credit losses relating to trade receivables is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. Such amounts are not material to the Company's consolidated financial results.
The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. The impact of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues.
Effects of Revenue Arrangements on Consolidated Balance Sheets
Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's condensed consolidated balance sheets. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's condensed consolidated balance sheets.
Contract liabilities for unearned revenue that is allocable to performance obligations, such as extended warranty and software maintenance contracts, which are performed over time are immaterial to the Company's consolidated financial results. The Company's liability for product warranties provided under its agreements with customers is not material to its condensed consolidated balance sheets.
Remaining Performance Obligations
The Company's obligations relative to service contracts and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided are estimated to be approximately $1.8 billion at December 31, 2019. The Company expects to recognize the majority of this revenue over the next three years.
Within the Company's Medication Management Solutions, Medication Delivery Solutions, Integrated Diagnostic Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately $2.7 billion at December 31, 2019.  This revenue will be recognized over the customer relationship period.
Disaggregation of Revenues
A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note 7.

XML 25 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details)
$ in Millions
Sep. 30, 2019
USD ($)
Leases [Abstract]  
Operating Leases, Future Minimum Payments Due, Next Twelve Months $ 122
Operating Leases, Future Minimum Payments, Due in Two Years 103
Operating Leases, Future Minimum Payments, Due in Three Years 83
Operating Leases, Future Minimum Payments, Due in Four Years 57
Operating Leases, Future Minimum Payments, Due in Five Years 56
Operating Leases, Future Minimum Payments, Due Thereafter 123
Operating Leases, Future Minimum Payments Due $ 546
XML 26 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings per Share (Detail) - shares
shares in Thousands
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Average common shares outstanding (shares) 271,102 269,035
Dilutive share equivalents from share-based plans (shares) 3,850 5,221
Average common and common equivalent shares outstanding - assuming dilution (shares) 274,952 274,256
Convertible Preferred Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded (in shares) 11,685 11,685
XML 27 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Data - Revenues by Geographic Areas (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Segment Reporting Information [Line Items]    
Revenues $ 4,225 $ 4,160
Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 2,090 2,135
Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 1,123 1,056
Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 1,012 970
United States    
Segment Reporting Information [Line Items]    
Revenues 2,430 2,387
United States | IVFluids    
Segment Reporting Information [Line Items]    
Revenues   2
United States | InterventionalSpecialties,BrachytherapyandFeedingProducts [Member]    
Segment Reporting Information [Line Items]    
Revenues   31
United States | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 1,204 1,239
United States | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 538 484
United States | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 688 664
International    
Segment Reporting Information [Line Items]    
Revenues 1,795 1,773
International | InterventionalSpecialties,BrachytherapyandFeedingProducts [Member]    
Segment Reporting Information [Line Items]    
Revenues   14
International | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 886 896
International | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 585 572
International | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 325 306
Medication Delivery Solutions | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 948 956
Medication Delivery Solutions | United States | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 520 519
Medication Delivery Solutions | International | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 428 438
Medication Management Solutions | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 575 625
Medication Management Solutions | United States | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 462 508
Medication Management Solutions | International | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 113 118
Diabetes Care | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 268 274
Diabetes Care | United States | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 139 145
Diabetes Care | International | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 129 129
Pharmaceutical Systems | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 299 280
Pharmaceutical Systems | United States | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 84 68
Pharmaceutical Systems | International | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 215 212
Preanalytical Systems | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 398 393
Preanalytical Systems | United States | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 202 201
Preanalytical Systems | International | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 196 192
Diagnostic Systems | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 402 382
Diagnostic Systems | United States | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 184 175
Diagnostic Systems | International | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 218 207
Integrated Diagnostic Solutions | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 800 774
Integrated Diagnostic Solutions | United States | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 386 376
Integrated Diagnostic Solutions | International | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 414 399
Biosciences | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 323 281
Biosciences | United States | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 152 108
Biosciences | International | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 171 173
Surgery | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 326 310
Surgery | United States | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 256 246
Surgery | International | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 70 64
Peripheral Intervention | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 395 382
Peripheral Intervention | United States | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 225 223
Peripheral Intervention | International | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 170 160
Urology and Critical Care | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 291 277
Urology and Critical Care | United States | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 206 195
Urology and Critical Care | International | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues $ 85 $ 83
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Divestiture
 3 Months Ended
Dec. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]  
Divestiture DivestitureThe Company completed the sale of its Life Sciences segment's Advanced Bioprocessing business in October 2018 pursuant to a definitive agreement that was signed in September 2018. The Company recognized a pre-tax gain on the sale of approximately $335 million which was recorded as a component of Other operating income, net in the first quarter of fiscal year 2019.
XML 30 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Contingencies
 3 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved.
In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows.
Product Liability Matters
The Company believes that certain settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers, or, in some circumstances, indemnification obligations to the Company from other parties, which if disputed, the Company intends to vigorously contest. Amounts recovered under the Company’s product liability insurance policies or indemnification arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available.
Hernia Product Claims
As of December 31, 2019, the Company is defending approximately 14,330 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The majority of those claims are currently pending in a coordinated proceeding in Rhode Island State Court, but claims are also pending in other state and/or federal court jurisdictions. In addition, those claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. From time to time, the Company engages in resolution discussions with plaintiffs’ law firms regarding certain of the Hernia Product Claims, but the Company also intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Trials are scheduled throughout 2020 in various state and/or federal courts. The Company expects additional trials of Hernia Product Claims to take place over the next 12 months. In August 2018, a new hernia multi-district litigation (“MDL”) was ordered to be established in the Southern District of Ohio. The Company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity.
Women’s Health Product Claims
As of December 31, 2019, the Company is defending approximately 750 product liability claims involving the Company’s line of pelvic mesh devices. The majority of those claims are currently pending in various federal court jurisdictions, and a coordinated proceeding in New Jersey State Court, but claims are also pending in other state court jurisdictions. In addition, those claims include putative class actions filed in the United States. Not included in the figures above are approximately 1,010 filed and unfiled claims that have been asserted or threatened against the Company but lack sufficient information to determine whether a pelvic mesh device of the Company is actually at issue.
The claims identified above also include products manufactured by both the Company and two subsidiaries of Medtronic plc (as successor in interest to Covidien plc) (“Medtronic”), each a supplier of the Company. Medtronic has an obligation to defend and indemnify the Company with respect to any product defect liability relating to products its subsidiaries had manufactured. In July 2015, the Company reached an agreement with Medtronic in which Medtronic agreed to take responsibility for pursuing settlement of certain of the Women’s Health Product Claims that relate to products distributed by the Company under supply agreements with Medtronic. In June 2017, the Company amended the agreement with Medtronic to transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on terms similar to the July 2015 agreement, including with respect to the obligation to make payments to Medtronic towards these potential settlements. As of December 31, 2019, the Company has paid Medtronic $141 million towards these potential settlements. The Company also may, in its sole discretion, transfer responsibility for settlement of additional Women’s Health Product Claims to Medtronic on similar terms. The agreements do not resolve the dispute between the Company and Medtronic with respect to Women’s Health Product Claims that do not settle, if any. The foregoing lawsuits, unfiled claims, putative class actions, and other claims, together with claims that have settled or are the subject of agreements or agreements in principle to settle, are referred to collectively as the “Women’s Health Product Claims.” The Women’s Health Product Claims generally seek damages for personal injury allegedly resulting from use of the products.
As of December 31, 2019, the Company has reached agreements or agreements in principle with various plaintiffs’ law firms to settle their respective inventories of cases totaling approximately 15,165 of the Women’s Health Product Claims. The Company believes that these Women’s Health Product Claims are not the subject of Medtronic’s indemnification obligation. These settlement agreements and agreements in principle include unfiled and previously unknown claims held by various plaintiffs’ law firms, which are not included in the approximate number of lawsuits set forth in the first paragraph of this section. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain
minimum number of plaintiffs. The Company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Women’s Health Product Claims, which may include additional inventory settlements.
Starting in 2014 in the MDL, the court entered certain pre-trial orders requiring trial work up and remand of a significant number of Women’s Health Product Claims, including an order entered in the MDL on January 30, 2018, that requires the work up and remand of all remaining unsettled cases (the “WHP Pre-Trial Orders”). The WHP Pre-Trial Orders may result in material additional costs or trial verdicts in future periods in defending Women’s Health Product Claims. Trials are anticipated throughout 2020 in state and federal courts. A trial in the New Jersey coordinated proceeding began in March 2018, and in April 2018 a jury entered a verdict against the Company in the total amount of $68 million ($33 million compensatory; $35 million punitive). The Company is in the process of appealing that verdict. The Company expects additional trials of Women’s Health Product Claims to take place over the next 12 months, which may potentially include consolidated trials.
During the course of engaging in settlement discussions with plaintiffs’ law firms, the Company has learned, and may in future periods learn, additional information regarding these and other unfiled claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company.
Filter Product Claims
As of December 31, 2019, the Company is defending approximately 2,650 product liability claims involving the Company’s line of inferior vena cava filters (collectively, the “Filter Product Claims”). The majority of those claims are currently pending in an MDL in the United States District Court for the District of Arizona, but those MDL claims either have been, or are in the process of being, remanded to various federal jurisdictions. Filter Product Claims are also pending in various state court jurisdictions, including a coordinated proceeding in Arizona State Court. In addition, those claims include putative class actions filed in the United States and Canada. The Filter Product Claims generally seek damages for personal injury allegedly resulting from use of the products. The Company has limited information regarding the nature and quantity of certain of the Filter Product Claims. The Company continues to receive claims and lawsuits and may in future periods learn additional information regarding other unfiled or unknown claims, or other lawsuits, which could materially impact the Company’s estimate of the number of claims or lawsuits against the Company. On May 31, 2019, the MDL Court ceased accepting direct filings or transfers into the Filter Product Claims MDL and, as noted above, remands for non-settled cases have begun and are expected to continue over the next three months. Federal and state court trials are scheduled throughout 2020. As of December 31, 2019, the Company entered into settlement agreements and/or settlement agreements in principle for approximately 6,400 cases. On March 30, 2018, a jury in the first MDL trial found the Company liable for negligent failure to warn and entered a verdict in favor of plaintiffs. The jury found the Company was not liable for (a) strict liability design defect; (b) strict liability failure to warn; and (c) negligent design. The Company has appealed that verdict. On June 1, 2018, a jury in the second MDL trial unanimously found in favor of the Company on all claims. On August 17, 2018, the Court entered summary judgment in favor of the Company on all claims in the third MDL trial. On October 5, 2018, a jury in the fourth MDL trial unanimously found in favor of the Company on all claims. The Company expects additional trials of Filter Product Claims may take place over the next 12 months.
In most product liability litigations (like those described above), plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.
In connection with the settlement of a prior litigation with certain of the Company's insurance carriers, an agreement with the Company's insurance carriers was reached to reimburse the Company for certain future costs incurred in connection with Filter Product Claims up to an agreed amount. For certain product liability claims or lawsuits, the Company does not maintain or has limited remaining insurance coverage.
Other Legal Matters
Since early 2013, the Company has received subpoenas or Civil Investigative Demands from a number of State Attorneys General seeking information related to the sales and marketing of certain of the Company’s products that are the subject of the Hernia Product Claims and the Women’s Health Product Claims. The Company is cooperating with these requests. Although the Company has had, and continues to have, discussions with the State Attorneys General with respect to overall potential resolution of this matter, there can be no assurance that a resolution will be reached or what the terms of any such resolution may be.
In July 2017, a civil investigative demand was served by the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec® and
QuantaFloTM devices. The Company is cooperating with these requests. Since it is not feasible to predict the outcome of these matters, the Company cannot give any assurances that the resolution of these matters will not have a material adverse effect on the Company’s business, results of operations, financial condition and/or liquidity.
The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the Company’s business and/or results of operations.
The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses to these suits pending against the Company and is engaged in a vigorous defense of each of these matters.
Litigation Reserves
The Company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.
In the second and fourth quarters of fiscal year 2019, the Company recorded pre-tax charges to Other operating expense, net, of approximately $331 million and $582 million, respectively, related to certain of the product liability matters discussed above under the heading “Product Liability Matters,” including the related legal defense costs. The Company recorded these charges based on additional information obtained during the second and fourth quarters of fiscal year 2019, including but not limited to: the nature and quantity of unfiled and filed claims and the continued rate of claims being filed in certain product liability matters; the status of certain settlement discussions with plaintiffs’ counsel; the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the Company; and the stage of litigation.
Accruals for the Company's product liability claims which are discussed above, as well as the related legal defense costs, amounted to approximately $2.4 billion at December 31, 2019 and $2.5 billion at September 30, 2019. These accruals, which are generally long-term in nature, are largely recorded within Deferred Income Taxes and Other Liabilities on the Company's condensed consolidated balance sheets. As of December 31, 2019 and September 30, 2019, the Company had $48 million and $53 million, respectively, in qualified settlement funds (“QSFs”), subject to certain settlement conditions, for certain product liability matters. Payments to QSFs are recorded as a component of Restricted cash. The Company's expected recoveries related to product liability claims and related legal defense costs were approximately $152 million and $150 million at December 31, 2019 and September 30, 2019, respectively. A substantial amount of these expected recoveries at December 31, 2019 and September 30, 2019 related to the Company’s agreements with Medtronic related to certain Women’s Health Product Claims. The expected recoveries at December 31, 2019 related to the indemnification obligation are not in dispute with respect to claims that Medtronic settles pursuant to the agreements.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments and Fair Value Measurements
 3 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Financial Instruments and Fair Value Measurements Financial Instruments and Fair Value Measurements
The following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at December 31, 2019 and September 30, 2019 to the total of these amounts shown on the Company's consolidated statements of cash flows:
(Millions of dollars)
December 31, 2019
 
September 30, 2019
Cash and equivalents
$
560

 
$
536

Restricted cash
49

 
54

Cash and equivalents and restricted cash
$
609

 
$
590


Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted cash consists of cash restricted from withdrawal and usage except for certain product liability matters.
The Company’s cash and equivalents include institutional money market accounts which permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy. The fair value of these accounts was immaterial at December 31, 2019 and the fair value of these accounts at September 30, 2019 was $39 million. The Company’s remaining cash and equivalents, excluding restricted cash, were $560 million and $497 million at December 31, 2019 and September 30, 2019, respectively.
Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments consist of instruments with maturities greater than three months and less than one year.
Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments, which are considered Level 2 inputs in the fair value hierarchy. The fair value of long-term debt was $18.1 billion and $19.2 billion at December 31, 2019 and September 30, 2019, respectively. The fair value of the current portion of long-term debt was $2.5 billion and $1.3 billion at December 31, 2019 and September 30, 2019, respectively.
All other instruments measured by the Company at fair value, including derivatives and contingent consideration liabilities, are immaterial to the Company's consolidated balance sheets.
Transfers of trade receivables
Over the normal course of its business activities, the Company transfers certain trade receivable assets to third parties under factoring agreements. Per the terms of these agreements, the Company surrenders control over its trade receivables upon transfer.  Accordingly, the Company accounts for the transfers as sales of trade receivables by recognizing an increase to Cash and equivalents and a decrease to Trade receivables, net when proceeds from the transactions are received.  The Company’s balance of Trade receivables, net at December 31, 2019 excludes trade receivables of $328 million that have been transferred to third parties under factoring arrangements.  The costs incurred by the Company in connection with factoring activities were not material to its consolidated financial results.  The Company’s transfers of trade receivables during the three months ended December 31, 2018 were not material to its consolidated financial results.
XML 32 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accounting Changes
 3 Months Ended
Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]  
Accounting Changes Accounting Changes
New Accounting Principle Adopted
In February 2016, the Financial Accounting Standards Board ("FASB") issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet, as well as requires expanded disclosures regarding leasing arrangements. The Company adopted this standard on October 1, 2019 and elected certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company also elected not to perform any reassessments relative to its expired and existing leases upon its adoption of the new requirements. The Company's adoption of this standard did not materially impact its condensed consolidated financial statements. Additional disclosures regarding the Company’s lease arrangements are provided in Note 14.
New Accounting Principles Not Yet Adopted
In June 2016, the FASB issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption on October 1, 2020.
In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The standard is effective for the Company on October 1, 2020, but early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption.
XML 33 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 34 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Statements of Income - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]    
Revenues $ 4,225 $ 4,160
Cost of products sold 2,247 2,187
Selling and administrative expense 1,121 1,073
Research and development expense 270 258
Acquisitions and other restructurings 86 91
Other operating income, net 0 (335)
Total Operating Costs and Expenses 3,724 3,273
Operating Income 501 888
Interest expense (136) (171)
Interest income, net 1 (12)
Other income, net 27 10
Income Before Income Taxes 394 714
Income tax provision 117 115
Net Income 278 599
Preferred stock dividends (38) (38)
Net income applicable to common shareholders $ 240 $ 562
Basic Earnings per Share (USD per share) $ 0.88 $ 2.09
Diluted Earnings per Share (USD per share) 0.87 2.05
Dividends per Common Share (USD per share) $ 0.79 $ 0.77
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Restructuring Charges (Tables)
 3 Months Ended
Dec. 31, 2019
Restructuring and Related Activities [Abstract]  
Summary of Restructuring Accrual Activity Restructuring liability activity for the three months ended December 31, 2019 was as follows:
(Millions of dollars)
Employee
Termination
 
Other
 
Total
 
Bard
 
Other Initiatives
 
Bard (a)
 
Other Initiatives
 
Bard
 
Other Initiatives
Balance at September 30, 2019
$
22

 
$
31

 
$
1

 
$
3

 
$
23

 
$
34

Charged to expense
4

 
2

 
13

 
4

 
17

 
6

Cash payments
(7
)
 
(12
)
 
(6
)
 
(4
)
 
(13
)
 
(16
)
Non-cash settlements
—

 
—

 
(7
)
 
—

 
(7
)
 
—

Balance at December 31, 2019
$
19

 
$
21

 
1

 
$
3

 
$
20

 
$
24


(a)
Largely represents the cost associated with certain pre-acquisition equity awards of Bard which, to encourage post-acquisition employee retention, were converted to BD equity awards with substantially the same terms and conditions as were applicable under such Bard awards immediately prior to the acquisition date.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Shareholders' Equity (Tables)
 3 Months Ended
Dec. 31, 2019
Stockholders' Equity Note [Abstract]  
Schedule of Shareholders Equity
Changes in certain components of shareholders' equity for the first quarters of fiscal years 2020 and 2019 were as follows:
 
Common
Stock  Issued
at Par Value
 
Capital in
Excess of
Par Value
 
Retained
Earnings
 
Deferred
Compensation
 
Treasury Stock
(Millions of dollars)
Shares (in
thousands)
 
Amount
Balance at September 30, 2019
$
347

 
$
16,270

 
$
12,913

 
$
23

 
(76,260
)
 
$
(6,190
)
Net income
—

 
—

 
278

 
—

 
—

 
—

Common dividends ($0.79 per share)
—

 
—

 
(215
)
 
—

 
—

 
—

Preferred dividends
—

 
—

 
(38
)
 
—

 
—

 
—

Common stock issued for share-based compensation and other plans, net
—

 
(32
)
 
—

 
1

 
758

 
(38
)
Share-based compensation
—

 
82

 
—

 
—

 
—

 
—

Common stock held in trusts, net (a)
—

 
—

 
—

 
—

 
(12
)
 
—

Balance at December 31, 2019
$
347

 
$
16,320

 
$
12,938

 
$
24

 
(75,514
)
 
$
(6,228
)
 
Common
Stock  Issued
at Par Value
 
Capital in
Excess of
Par Value
 
Retained
Earnings
 
Deferred
Compensation
 
Treasury Stock
(Millions of dollars)
Shares (in
thousands)
 
Amount
Balance at September 30, 2018
$
347

 
$
16,179

 
$
12,596

 
$
22

 
(78,463
)
 
$
(6,243
)
Net income
—

 
—

 
599

 
—

 
—

 
—

Common dividends ($0.77 per share)
—

 
—

 
(207
)
 
—

 
—

 
—

Preferred dividends
—

 
—

 
(38
)
 
—

 
—

 
—

Common stock issued for share-based compensation and other plans, net
—

 
(97
)
 
—

 
2

 
851

 
9

Share-based compensation
—

 
92

 
—

 
—

 
—

 
—

Common stock held in trusts, net (a)
—

 
—

 
—

 
—

 
(12
)
 
—

Effect of change in accounting principles
—

 
—

 
68

 
—

 
—

 
—

Balance at December 31, 2018
$
347

 
$
16,174

 
$
13,018

 
$
24

 
(77,624
)
 
$
(6,235
)
(a)
Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.
Schedule of Accumulated Other Comprehensive Income (Loss)
The components and changes of Accumulated other comprehensive income (loss) for the first quarters of fiscal years 2020 and 2019 were as follows:
(Millions of dollars)
Total
 
Foreign Currency
Translation
 
Benefit Plans
 

Cash Flow Hedges
Balance at September 30, 2019
$
(2,283
)
 
$
(1,256
)
 
$
(1,005
)
 
$
(23
)
Other comprehensive income before reclassifications, net of taxes
63

 
26

 
—

 
37

Amounts reclassified into income, net of taxes
19

 
—

 
17

 
2

Balance at December 31, 2019
$
(2,202
)
 
$
(1,230
)
 
$
(988
)
 
$
16

(Millions of dollars)
Total
 
Foreign Currency
Translation
 
Benefit Plans
 

Cash Flow Hedges
Balance at September 30, 2018
$
(1,909
)
 
$
(1,162
)
 
$
(729
)
 
$
(17
)
Other comprehensive (loss) income before reclassifications, net of taxes
(32
)
 
(35
)
 
3

 
(1
)
Amounts reclassified into income, net of taxes
14

 
—

 
13

 
1

Balance at December 31, 2018
$
(1,927
)
 
$
(1,197
)
 
$
(714
)
 
$
(16
)
XML 38 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]    
Intangible amortization expense $ 345 $ 378
XML 39 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Fair Value Disclosures [Abstract]        
Cash and equivalents $ 560 $ 536    
Restricted cash 49 54    
Cash and equivalents and restricted cash $ 609 $ 590 $ 1,042 $ 1,236
XML 40 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Supplemental Balance Sheet Information Related to Leases (Details)
$ in Millions
Dec. 31, 2019
USD ($)
Leases [Abstract]  
Right-use-assets recorded in Other Assets $ 426
Current lease liabilities recorded in Payables, accrued expenses and other current liabilities 105
Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities $ 340
XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 235 288 1 false 73 0 false 5 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.bd.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.bd.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Income Sheet http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 3 false false R4.htm 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 4 false false R5.htm 1004000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 2101100 - Disclosure - Basis of Presentation Sheet http://www.bd.com/role/BasisOfPresentation Basis of Presentation Notes 6 false false R7.htm 2102100 - Disclosure - Accounting Changes Sheet http://www.bd.com/role/AccountingChanges Accounting Changes Notes 7 false false R8.htm 2103100 - Disclosure - Shareholders' Equity Sheet http://www.bd.com/role/ShareholdersEquity Shareholders' Equity Notes 8 false false R9.htm 2104100 - Disclosure - Earnings Per Share Sheet http://www.bd.com/role/EarningsPerShare Earnings Per Share Notes 9 false false R10.htm 2105100 - Disclosure - Contingencies Sheet http://www.bd.com/role/Contingencies Contingencies Notes 10 false false R11.htm 2106100 - Disclosure - Revenues Sheet http://www.bd.com/role/Revenues Revenues Notes 11 false false R12.htm 2108100 - Disclosure - Segment Data Sheet http://www.bd.com/role/SegmentData Segment Data Notes 12 false false R13.htm 2111100 - Disclosure - Benefit Plans Sheet http://www.bd.com/role/BenefitPlans Benefit Plans Notes 13 false false R14.htm 2115100 - Disclosure - Divestiture Sheet http://www.bd.com/role/Divestiture Divestiture Notes 14 false false R15.htm 2116100 - Disclosure - Business Restructuring Charges Sheet http://www.bd.com/role/BusinessRestructuringCharges Business Restructuring Charges Notes 15 false false R16.htm 2117100 - Disclosure - Intangible Assets Sheet http://www.bd.com/role/IntangibleAssets Intangible Assets Notes 16 false false R17.htm 2118100 - Disclosure - Derivative Instruments and Hedging Activities Sheet http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivities Derivative Instruments and Hedging Activities Notes 17 false false R18.htm 2119100 - Disclosure - Financial Instruments and Fair Value Measurements Sheet http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurements Financial Instruments and Fair Value Measurements Notes 18 false false R19.htm 2122100 - Disclosure - Leases Sheet http://www.bd.com/role/Leases Leases Notes 19 false false R20.htm 2123100 - Disclosure - Subsequent Event (Notes) Notes http://www.bd.com/role/SubsequentEventNotes Subsequent Event (Notes) Notes 20 false false R21.htm 2202201 - Disclosure - Accounting Changes (Policies) Sheet http://www.bd.com/role/AccountingChangesPolicies Accounting Changes (Policies) Policies http://www.bd.com/role/AccountingChanges 21 false false R22.htm 2303301 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.bd.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.bd.com/role/ShareholdersEquity 22 false false R23.htm 2304301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.bd.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.bd.com/role/EarningsPerShare 23 false false R24.htm 2308301 - Disclosure - Segment Data (Tables) Sheet http://www.bd.com/role/SegmentDataTables Segment Data (Tables) Tables http://www.bd.com/role/SegmentData 24 false false R25.htm 2311301 - Disclosure - Benefit Plans (Tables) Sheet http://www.bd.com/role/BenefitPlansTables Benefit Plans (Tables) Tables http://www.bd.com/role/BenefitPlans 25 false false R26.htm 2316301 - Disclosure - Business Restructuring Charges (Tables) Sheet http://www.bd.com/role/BusinessRestructuringChargesTables Business Restructuring Charges (Tables) Tables http://www.bd.com/role/BusinessRestructuringCharges 26 false false R27.htm 2317301 - Disclosure - Intangible Assets (Tables) Sheet http://www.bd.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.bd.com/role/IntangibleAssets 27 false false R28.htm 2318301 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivities 28 false false R29.htm 2319301 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) Sheet http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsTables Financial Instruments and Fair Value Measurements (Tables) Tables http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurements 29 false false R30.htm 2322301 - Disclosure - Leases (Tables) Sheet http://www.bd.com/role/LeasesTables Leases (Tables) Tables http://www.bd.com/role/Leases 30 false false R31.htm 2403402 - Disclosure - Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details) Sheet http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details) Details 31 false false R32.htm 2403403 - Disclosure - Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail) Sheet http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail) Details 32 false false R33.htm 2404402 - Disclosure - Earnings Per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings per Share (Detail) Sheet http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail Earnings Per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings per Share (Detail) Details 33 false false R34.htm 2405401 - Disclosure - Contingencies - Additional Information (Detail) Sheet http://www.bd.com/role/ContingenciesAdditionalInformationDetail Contingencies - Additional Information (Detail) Details 34 false false R35.htm 2406401 - Disclosure - Revenues - Additional Information (Details) Sheet http://www.bd.com/role/RevenuesAdditionalInformationDetails Revenues - Additional Information (Details) Details 35 false false R36.htm 2408402 - Disclosure - Segment Data - Additional Information (Detail) Sheet http://www.bd.com/role/SegmentDataAdditionalInformationDetail Segment Data - Additional Information (Detail) Details 36 false false R37.htm 2408403 - Disclosure - Segment Data - Revenues by Geographic Areas (Detail) Sheet http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail Segment Data - Revenues by Geographic Areas (Detail) Details 37 false false R38.htm 2408405 - Disclosure - Segment Data - Financial Information for Company's Segments (Detail) Sheet http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail Segment Data - Financial Information for Company's Segments (Detail) Details 38 false false R39.htm 2411402 - Disclosure - Benefit Plans - Net Pension and Postretirement Cost (Detail) Sheet http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail Benefit Plans - Net Pension and Postretirement Cost (Detail) Details 39 false false R40.htm 2415401 - Disclosure - Divestiture - Additional Information (Details) Sheet http://www.bd.com/role/DivestitureAdditionalInformationDetails Divestiture - Additional Information (Details) Details 40 false false R41.htm 2416402 - Disclosure - Business Restructuring Charges - Summary of Restructuring Accrual Activity (Detail) Sheet http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail Business Restructuring Charges - Summary of Restructuring Accrual Activity (Detail) Details 41 false false R42.htm 2417402 - Disclosure - Intangible Assets - Components of Intangible Assets (Detail) Sheet http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail Intangible Assets - Components of Intangible Assets (Detail) Details 42 false false R43.htm 2417403 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.bd.com/role/IntangibleAssetsAdditionalInformationDetail Intangible Assets - Additional Information (Detail) Details 43 false false R44.htm 2417404 - Disclosure - Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail) Sheet http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail) Details 44 false false R45.htm 2418402 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail) Sheet http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail Derivative Instruments and Hedging Activities - Additional Information (Detail) Details 45 false false R46.htm 2418403 - Disclosure - Derivative Instruments and Hedging Activities Disclosure - Gains (Losses) on Net Investment Hedges (Details) Sheet http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesDisclosureGainsLossesOnNetInvestmentHedgesDetails Derivative Instruments and Hedging Activities Disclosure - Gains (Losses) on Net Investment Hedges (Details) Details 46 false false R47.htm 2419402 - Disclosure - Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details) Sheet http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsCashAndEquivalentsAndRestrictedCashDetails Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details) Details 47 false false R48.htm 2419403 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Detail) Sheet http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail Financial Instruments and Fair Value Measurements - Additional Information (Detail) Details 48 false false R49.htm 2422402 - Disclosure - Leases - Additional Information (Details) Sheet http://www.bd.com/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 49 false false R50.htm 2422403 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Leases (Details) Sheet http://www.bd.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails Leases - Supplemental Balance Sheet Information Related to Leases (Details) Details 50 false false R51.htm 2422404 - Disclosure - Leases - Lessee, Operating Lease, Liability, Maturity (Details) Sheet http://www.bd.com/role/LeasesLesseeOperatingLeaseLiabilityMaturityDetails Leases - Lessee, Operating Lease, Liability, Maturity (Details) Details 51 false false R52.htm 2422405 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) Sheet http://www.bd.com/role/LeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) Details 52 false false R53.htm 2423401 - Disclosure - Subsequent Event (Details) Sheet http://www.bd.com/role/SubsequentEventDetails Subsequent Event (Details) Details http://www.bd.com/role/SubsequentEventNotes 53 false false All Reports Book All Reports bdx1231201910-q.htm bdx-20191231.xsd bdx-20191231_cal.xml bdx-20191231_def.xml bdx-20191231_lab.xml bdx-20191231_pre.xml ex10c12312019.htm ex3112312019.htm ex3212312019.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/exch/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 42 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets
 3 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible Assets
Intangible assets consisted of:
 
December 31, 2019
 
September 30, 2019
(Millions of dollars)
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Gross
Carrying
Amount
 
Accumulated
Amortization
Amortized intangible assets
 
 
 
 
 
 
 
Developed technology
$
14,010

 
$
3,161

 
$
13,960

 
$
2,906

Customer relationships
4,610

 
1,265

 
4,608

 
1,183

Product rights
115

 
65

 
110

 
60

Trademarks
407

 
106

 
407

 
102

Patents and other
488

 
311

 
445

 
305

Amortized intangible assets
$
19,630

 
$
4,908

 
$
19,530

 
$
4,555

Unamortized intangible assets
 
 
 
 
 
 
 
Acquired in-process research and development
$
1

 
 
 
$
1

 
 
Trademarks
2

 
 
 
2

 
 
Unamortized intangible assets
$
3

 
 
 
$
3

 
 

Intangible amortization expense for the three months ended December 31, 2019 and 2018 was $345 million and $378 million, respectively.
The following is a reconciliation of goodwill by business segment:
(Millions of dollars)
Medical
 
Life Sciences
 
Interventional
 
Total
Goodwill as of September 30, 2019
$
9,989

  
$
772

 
$
12,615

  
$
23,376

Acquisitions (a)
10

 
—

 
—

 
10

Currency translation
17

 
2

 
30

 
49

Goodwill as of December 31, 2019
$
10,016

  
$
774

 
$
12,645

  
$
23,435

(a)
Represents goodwill recognized relative to certain acquisitions which were not material individually or in the aggregate.
XML 43 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Data
 3 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Segment Data Segment Data
The Company's organizational structure is based upon three principal business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.
Effective October 1, 2019, Life Sciences joined its former Preanalytical Systems and Diagnostic Systems organizational units to create a new Integrated Diagnostic Solutions organizational unit which focuses on driving growth and innovation around integrated specimen management to diagnostic solutions. The Integrated Diagnostic Solutions organizational unit consists of the following principal product lines:
Organizational Unit
 
Principal Product Lines
Integrated Diagnostic Solutions
 
Integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays for testing of respiratory infections; microbiology laboratory automation and plated media for clinical and industrial applications.
Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues.
 
Three Months Ended December 31,
(Millions of dollars)
2019
 
2018
 
United States
 
International
 
Total
 
United States
 
International
 
Total
Medical
 
 
 
 
 
 
 
 
 
 
 
Medication Delivery Solutions (a)
$
520

 
$
428

 
$
948

 
$
519

 
$
438

 
$
956

Medication Management Solutions (a)
462

 
113

 
575

 
508

 
118

 
625

Diabetes Care
139

 
129

 
268

 
145

 
129

 
274

Pharmaceutical Systems
84

 
215

 
299

 
68

 
212

 
280

Total segment revenues
$
1,204

 
$
886

 
$
2,090

 
$
1,239

 
$
896

 
$
2,135

 
 
 
 
 
 
 
 
 
 
 
 
Life Sciences
 
 
 
 
 
 
 
 
 
 
 
Integrated Diagnostic Solutions
 
 
 
 
 
 
 
 
 
 
 
Preanalytical Systems
$
202

 
$
196

 
$
398

 
$
201

 
$
192

 
$
393

Diagnostic Systems
184

 
218

 
402

 
175

 
207

 
382

Total Integrated Diagnostic Solutions
386

 
414

 
800

 
376

 
399

 
774

Biosciences
152

 
171

 
323

 
108

 
173

 
281

Total segment revenues
$
538

 
$
585

 
$
1,123

 
$
484

 
$
572

 
$
1,056

 
 
 
 
 
 
 
 
 
 
 
 
Interventional
 
 
 
 
 
 
 
 
 
 
 
Surgery (b)
$
256

 
$
70

 
$
326

 
$
246

 
$
64

 
$
310

Peripheral Intervention (b)
225

 
170

 
395

 
223

 
160

 
382

Urology and Critical Care (b)
206

 
85

 
291

 
195

 
83

 
277

Total segment revenues
$
688

 
$
325

 
$
1,012

 
$
664

 
$
306

 
$
970

 
 
 
 
 
 
 
 
 
 
 
 
Total Company revenues
$
2,430

 
$
1,795

 
$
4,225

 
$
2,387

 
$
1,773

 
$
4,160

(a)
Prior-period amounts reflect the reclassification of U.S. revenues of $2 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.
(b)Prior-period amounts reflect the total reclassifications of $31 million of U.S. revenues and $14 million of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.
 
 
 
 
 
 
 
 
 
 
 
 
Segment income for the three-month periods was as follows:
 
Three Months Ended
December 31,
(Millions of dollars)
2019
 
2018
Income Before Income Taxes
 
 
 
Medical (a)
$
564

 
$
665

Life Sciences
361

 
305

Interventional
243

 
209

Total Segment Operating Income
1,167

 
1,180

Acquisitions and other restructurings
(86
)
 
(91
)
Net interest expense
(134
)
 
(183
)
Other unallocated items (b)
(553
)
 
(192
)
Total Income Before Income Taxes
$
394

 
$
714

(a)
The amount for the three months ended December 31, 2019 included the estimated cost of a product recall of $59 million which was recorded to Cost of products sold and is further discussed in Note 15.
(b)
Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount for the three months ended December 31, 2018 included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $335 million, which is further discussed in Note 9.
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dividends per Common Share (USD per share) $ 0.79 $ 0.77
Beginning balance $ 21,081  
Net income 278 $ 599
Ending balance 21,202  
Common Stock Issued at Par Value    
Beginning balance 347 347
Ending balance 347 347
Capital in Excess of Par Value    
Beginning balance 16,270 16,179
Common stock issued for share-based compensation and other plans, net (32) (97)
Share-based compensation 82 92
Ending balance 16,320 16,174
Retained Earnings    
Beginning balance 12,913 12,596
Net income 278 599
Common dividends (215) (207)
Preferred dividends (38) (38)
Effect of changes in accounting principle   68
Ending balance 12,938 13,018
Deferred Compensation    
Beginning balance 23 22
Common stock issued for share-based compensation and other plans, net 1 2
Ending balance 24 24
Treasury Stock    
Beginning balance $ (6,190) $ (6,243)
Beginning balance (shares) (76,260) (78,463)
Common stock issued for share-based compensation and other plans, net $ (38) $ 9
Common stock issued for share-based compensation and other plans, net (in shares) 758 851
Common stock held in trusts, net (12) (12)
Ending balance $ (6,228) $ (6,235)
Ending balance (shares) (75,514) (77,624)
JSON 45 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bdx1231201910-q.htm": { "axisCustom": 2, "axisStandard": 21, "contextCount": 235, "dts": { "calculationLink": { "local": [ "bdx-20191231_cal.xml" ] }, "definitionLink": { "local": [ "bdx-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "bdx1231201910-q.htm" ] }, "labelLink": { "local": [ "bdx-20191231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bdx-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bdx-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 405, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 3, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 8 }, "keyCustom": 13, "keyStandard": 275, "memberCustom": 37, "memberStandard": 34, "nsprefix": "bdx", "nsuri": "http://www.bd.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.bd.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Contingencies", "role": "http://www.bd.com/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Revenues", "role": "http://www.bd.com/role/Revenues", "shortName": "Revenues", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Segment Data", "role": "http://www.bd.com/role/SegmentData", "shortName": "Segment Data", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Benefit Plans", "role": "http://www.bd.com/role/BenefitPlans", "shortName": "Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2019Q1QTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Divestiture", "role": "http://www.bd.com/role/Divestiture", "shortName": "Divestiture", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2019Q1QTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Business Restructuring Charges", "role": "http://www.bd.com/role/BusinessRestructuringCharges", "shortName": "Business Restructuring Charges", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - Intangible Assets", "role": "http://www.bd.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Derivative Instruments and Hedging Activities", "role": "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivities", "shortName": "Derivative Instruments and Hedging Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - Financial Instruments and Fair Value Measurements", "role": "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurements", "shortName": "Financial Instruments and Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122100 - Disclosure - Leases", "role": "http://www.bd.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.bd.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "lang": null, "name": "us-gaap:OtherShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123100 - Disclosure - Subsequent Event (Notes)", "role": "http://www.bd.com/role/SubsequentEventNotes", "shortName": "Subsequent Event (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Accounting Changes (Policies)", "role": "http://www.bd.com/role/AccountingChangesPolicies", "shortName": "Accounting Changes (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.bd.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.bd.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Segment Data (Tables)", "role": "http://www.bd.com/role/SegmentDataTables", "shortName": "Segment Data (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Benefit Plans (Tables)", "role": "http://www.bd.com/role/BenefitPlansTables", "shortName": "Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - Business Restructuring Charges (Tables)", "role": "http://www.bd.com/role/BusinessRestructuringChargesTables", "shortName": "Business Restructuring Charges (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317301 - Disclosure - Intangible Assets (Tables)", "role": "http://www.bd.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318301 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "role": "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesTables", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319301 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)", "role": "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsTables", "shortName": "Financial Instruments and Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Income", "role": "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome", "shortName": "Condensed Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bdx:SupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322301 - Disclosure - Leases (Tables)", "role": "http://www.bd.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bdx:SupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details)", "role": "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails", "shortName": "Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-6", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail)", "role": "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail", "shortName": "Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2018Q4", "decimals": "-6", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Earnings Per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings per Share (Detail)", "role": "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail", "shortName": "Earnings Per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405401 - Disclosure - Contingencies - Additional Information (Detail)", "role": "http://www.bd.com/role/ContingenciesAdditionalInformationDetail", "shortName": "Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-01-01", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406401 - Disclosure - Revenues - Additional Information (Details)", "role": "http://www.bd.com/role/RevenuesAdditionalInformationDetails", "shortName": "Revenues - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-01-01", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Segment Data - Additional Information (Detail)", "role": "http://www.bd.com/role/SegmentDataAdditionalInformationDetail", "shortName": "Segment Data - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Segment Data - Revenues by Geographic Areas (Detail)", "role": "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail", "shortName": "Segment Data - Revenues by Geographic Areas (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_bdx_MedicalMember", "decimals": "-6", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Segment Data - Financial Information for Company's Segments (Detail)", "role": "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail", "shortName": "Segment Data - Financial Information for Company's Segments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-6", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Benefit Plans - Net Pension and Postretirement Cost (Detail)", "role": "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail", "shortName": "Benefit Plans - Net Pension and Postretirement Cost (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:GainLossOnSaleOfBusiness", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415401 - Disclosure - Divestiture - Additional Information (Details)", "role": "http://www.bd.com/role/DivestitureAdditionalInformationDetails", "shortName": "Divestiture - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2019Q4_us-gaap_RestructuringPlanAxis_bdx_CRBardIncMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - Business Restructuring Charges - Summary of Restructuring Accrual Activity (Detail)", "role": "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail", "shortName": "Business Restructuring Charges - Summary of Restructuring Accrual Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2019Q4_us-gaap_RestructuringPlanAxis_bdx_CRBardIncMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417402 - Disclosure - Intangible Assets - Components of Intangible Assets (Detail)", "role": "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail", "shortName": "Intangible Assets - Components of Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417403 - Disclosure - Intangible Assets - Additional Information (Detail)", "role": "http://www.bd.com/role/IntangibleAssetsAdditionalInformationDetail", "shortName": "Intangible Assets - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417404 - Disclosure - Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail)", "role": "http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail", "shortName": "Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418402 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail)", "role": "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "shortName": "Derivative Instruments and Hedging Activities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_bdx_ForeignCurrencyDenominatedDebtMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418403 - Disclosure - Derivative Instruments and Hedging Activities Disclosure - Gains (Losses) on Net Investment Hedges (Details)", "role": "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesDisclosureGainsLossesOnNetInvestmentHedgesDetails", "shortName": "Derivative Instruments and Hedging Activities Disclosure - Gains (Losses) on Net Investment Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_bdx_ForeignCurrencyDenominatedDebtMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details)", "role": "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsCashAndEquivalentsAndRestrictedCashDetails", "shortName": "Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419403 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Detail)", "role": "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail", "shortName": "Financial Instruments and Fair Value Measurements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422402 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.bd.com/role/LeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422403 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Leases (Details)", "role": "http://www.bd.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails", "shortName": "Leases - Supplemental Balance Sheet Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422404 - Disclosure - Leases - Lessee, Operating Lease, Liability, Maturity (Details)", "role": "http://www.bd.com/role/LeasesLesseeOperatingLeaseLiabilityMaturityDetails", "shortName": "Leases - Lessee, Operating Lease, Liability, Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422405 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details)", "role": "http://www.bd.com/role/LeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails", "shortName": "Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InventoryRecallExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423401 - Disclosure - Subsequent Event (Details)", "role": "http://www.bd.com/role/SubsequentEventDetails", "shortName": "Subsequent Event (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Basis of Presentation", "role": "http://www.bd.com/role/BasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Accounting Changes", "role": "http://www.bd.com/role/AccountingChanges", "shortName": "Accounting Changes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountingChangesAndErrorCorrectionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Shareholders' Equity", "role": "http://www.bd.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Earnings Per Share", "role": "http://www.bd.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "bdx1231201910-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 73, "tag": { "bdx_AcquisitionRelatedCostsAndRestructuringCharges": { "auth_ref": [], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; business integration costs, systems integration and conversion costs, and severance and other employee-related costs; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Additionally includes the amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Acquisition Related Costs And Restructuring Charges", "negatedLabel": "Acquisitions and other restructurings", "verboseLabel": "Acquisitions and other restructurings" } } }, "localname": "AcquisitionRelatedCostsAndRestructuringCharges", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail" ], "xbrltype": "monetaryItemType" }, "bdx_AdvancedBioprocessingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Advanced Bioprocessing [Member]", "label": "Advanced Bioprocessing [Member]", "terseLabel": "Advanced Bioprocessing" } } }, "localname": "AdvancedBioprocessingMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/DivestitureAdditionalInformationDetails", "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail" ], "xbrltype": "domainItemType" }, "bdx_BiosciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Biosciences [Member]", "label": "Biosciences [Member]", "terseLabel": "Biosciences" } } }, "localname": "BiosciencesMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_CRBardIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "C.R. Bard Inc. [Member]", "label": "CR Bard Inc [Member]", "terseLabel": "CR Bard Inc" } } }, "localname": "CRBardIncMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "domainItemType" }, "bdx_ClaimsLackingSufficientInformation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of complaints for which the company cannot, based on the allegations in such complaints, determine whether the company's products are involved.", "label": "ClaimsLackingSufficientInformation", "terseLabel": "Claims lacking sufficient information" } } }, "localname": "ClaimsLackingSufficientInformation", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "bdx_CommonStockHeldInTrustsNetShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of common stock shares held in trust.", "label": "Common Stock Held In Trusts Net Shares", "terseLabel": "Common stock held in trusts, net" } } }, "localname": "CommonStockHeldInTrustsNetShares", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "bdx_CommonStockSharesHeldInEmployeeTrust1": { "auth_ref": [], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.", "label": "Common Stock, Shares Held in Employee Trust1", "terseLabel": "Deferred compensation" } } }, "localname": "CommonStockSharesHeldInEmployeeTrust1", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "bdx_CompensatoryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Compensatory [Member]", "label": "Compensatory [Member]", "terseLabel": "Compensatory" } } }, "localname": "CompensatoryMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bdx_ConsumablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consumables [Member]", "label": "Consumables [Member]", "terseLabel": "Consumables [Member]" } } }, "localname": "ConsumablesMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/RevenuesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bdx_CoreAndDevelopedTechnologyNet": { "auth_ref": [], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intangible assets arising from acquisitions. These assets represent acquired intellectual property that is already technologically feasible upon the acquisition date.", "label": "Core And Developed Technology Net", "terseLabel": "Developed Technology, Net" } } }, "localname": "CoreAndDevelopedTechnologyNet", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "bdx_DepositarysharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Depositary shares [Member]", "label": "Depositary shares [Member]", "terseLabel": "Depositary shares" } } }, "localname": "DepositarysharesMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_DiabetesCareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Diabetes Care [Member]", "label": "Diabetes Care [Member]", "terseLabel": "Diabetes Care" } } }, "localname": "DiabetesCareMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_DiagnosticSystemsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Diagnostic Systems [Member]", "label": "Diagnostic Systems [Member]", "terseLabel": "Diagnostic Systems" } } }, "localname": "DiagnosticSystemsMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_FairValueOfDebtClassifiedFromLongTermToShortTerm": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair Value Of Debt Classified From Long Term To Short Term", "label": "Fair Value Of Debt Classified From Long Term To Short Term", "terseLabel": "Fair value of debt reclassified from long term to short term" } } }, "localname": "FairValueOfDebtClassifiedFromLongTermToShortTerm", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bdx_FilterProductClaimsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "FilterProductClaims [Member]", "label": "FilterProductClaims [Member]", "terseLabel": "Filter Product Claims" } } }, "localname": "FilterProductClaimsMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bdx_FiniteAndIndefiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finite And Indefinite Lived Intangible Assets [Line Items]", "label": "Finite And Indefinite Lived Intangible Assets [Line Items]", "terseLabel": "Finite And Indefinite Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteAndIndefiniteLivedIntangibleAssetsLineItems", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "bdx_FiniteAndIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finite And Indefinite Lived Intangible Assets [Table]", "label": "Finite And Indefinite Lived Intangible Assets [Table]", "terseLabel": "Finite And Indefinite Lived Intangible Assets [Table]" } } }, "localname": "FiniteAndIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "bdx_FiniteLivedCustomerRelationshipsNet": { "auth_ref": [], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Net carrying amount as of the balance sheet date of an asset acquired in a business combination representing a favorable existing relationship with customers having a finite beneficial life.", "label": "Finite Lived Customer Relationships Net", "terseLabel": "Customer Relationships, Net" } } }, "localname": "FiniteLivedCustomerRelationshipsNet", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "bdx_FixedToFloatingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed To Floating [Member]", "label": "Fixed To Floating [Member]", "terseLabel": "Fixed to Floating" } } }, "localname": "FixedToFloatingMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bdx_ForeignCurrencyDenominatedDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign-Currency Denominated Debt [Member]", "label": "Foreign Currency-Denominated Debt [Member]", "terseLabel": "Foreign Currency-Denominated Debt" } } }, "localname": "ForeignCurrencyDenominatedDebtMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesDisclosureGainsLossesOnNetInvestmentHedgesDetails" ], "xbrltype": "domainItemType" }, "bdx_HerniaProductClaimsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "HerniaProductClaims [Member]", "label": "HerniaProductClaims [Member]", "terseLabel": "Hernia Product Claims" } } }, "localname": "HerniaProductClaimsMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bdx_IVFluidsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "IVFluids [Member]", "label": "IVFluids [Member]", "terseLabel": "IVFluids" } } }, "localname": "IVFluidsMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_IntegratedDiagnosticSolutionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Integrated Diagnostic Solutions [Member]", "label": "Integrated Diagnostic Solutions [Member]", "terseLabel": "Integrated Diagnostic Solutions" } } }, "localname": "IntegratedDiagnosticSolutionsMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_InterventionalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interventional [Member]", "label": "Interventional [Member]", "terseLabel": "Interventional" } } }, "localname": "InterventionalMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail", "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_InterventionalSpecialtiesBrachytherapyandFeedingProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "InterventionalSpecialties,BrachytherapyandFeedingProducts [Member]", "label": "InterventionalSpecialties,BrachytherapyandFeedingProducts [Member]", "terseLabel": "InterventionalSpecialties,BrachytherapyandFeedingProducts [Member]" } } }, "localname": "InterventionalSpecialtiesBrachytherapyandFeedingProductsMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_LifeSciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Life Sciences [Member]", "label": "Life Sciences [Member]", "terseLabel": "Life Sciences" } } }, "localname": "LifeSciencesMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail", "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_MaturityPeriodOfShortTermInvestment": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maturity period of time deposits classified as short-term investments in the consolidated balance sheet.", "label": "Maturity Period Of Short Term Investment", "terseLabel": "Maturity period of short-term investments at the time of purchase" } } }, "localname": "MaturityPeriodOfShortTermInvestment", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "bdx_MedicalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical.", "label": "Medical [Member]", "terseLabel": "Medical" } } }, "localname": "MedicalMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail", "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_MedicationDeliverySolutionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medication Delivery Solutions [Member]", "label": "Medication Delivery Solutions [Member]", "terseLabel": "Medication Delivery Solutions" } } }, "localname": "MedicationDeliverySolutionsMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_MedicationManagementSolutionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medication Management Solutions [Member]", "label": "Medication Management Solutions [Member]", "terseLabel": "Medication Management Solutions" } } }, "localname": "MedicationManagementSolutionsMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_Notes0.174dueJune42021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 0.174% due June 4, 2021 [Member]", "label": "Notes 0.174% due June 4, 2021 [Member]", "terseLabel": "Notes 0.174% due June 4, 2021 [Member]" } } }, "localname": "Notes0.174dueJune42021Member", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes0.632dueJune42023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 0.632% due June 4, 2023 [Member]", "label": "Notes 0.632% due June 4, 2023 [Member]", "terseLabel": "Notes 0.632% due June 4, 2023" } } }, "localname": "Notes0.632dueJune42023Member", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes1.000dueDecember152022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 1.000% due December 15, 2022 [Member]", "label": "Notes 1.000% due December 15, 2022 [Member]", "terseLabel": "Notes 1.000% due December 15, 2022" } } }, "localname": "Notes1.000dueDecember152022Member", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes1.208dueJune42026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 1.208% due June 4, 2026 [Member]", "label": "Notes 1.208% due June 4, 2026 [Member]", "terseLabel": "Notes 1.208% due June 4, 2026" } } }, "localname": "Notes1.208dueJune42026Member", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes1.401dueMay242023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 1.401% due May 24, 2023 [Member]", "label": "Notes 1.401% due May 24, 2023 [Member]", "terseLabel": "Notes 1.401% due May 24, 2023" } } }, "localname": "Notes1.401dueMay242023Member", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes1.900dueDecember152026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 1.900% due December 15, 2026 [Member]", "label": "Notes 1.900% due December 15, 2026 [Member]", "terseLabel": "Notes 1.900% due December 15, 2026" } } }, "localname": "Notes1.900dueDecember152026Member", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_Notes3.020dueMay242025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Notes 3.020% due May 24, 2025 [Member]", "label": "Notes 3.020% due May 24, 2025 [Member]", "terseLabel": "Notes 3.020% due May 24, 2025 [Member]" } } }, "localname": "Notes3.020dueMay242025Member", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "bdx_NumberOfClaimsInSettlementAgreement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of settlements or settlements in principle reached.", "label": "NumberOfClaimsInSettlementAgreement", "terseLabel": "Number of claims in settlement agreement" } } }, "localname": "NumberOfClaimsInSettlementAgreement", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "bdx_OrganizationalUnitAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Organizational Unit [Axis]", "label": "Organizational Unit [Axis]", "terseLabel": "Organizational Unit [Axis]" } } }, "localname": "OrganizationalUnitAxis", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "stringItemType" }, "bdx_OrganizationalUnitDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Organizational Unit [Axis]", "label": "Organizational Unit [Domain]", "terseLabel": "Organizational Unit [Domain]" } } }, "localname": "OrganizationalUnitDomain", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_OtherInitiativesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Initiatives [Member]", "label": "Other Initiatives [Member]", "terseLabel": "Other Initiatives" } } }, "localname": "OtherInitiativesMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "domainItemType" }, "bdx_PaymentstoSupplier": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Payments to a supplier with an obligation to defend and indemnify the company with respect to any product defect liability for products its subsidiaries had manufactured.", "label": "PaymentstoSupplier", "terseLabel": "PaymentstoSupplier" } } }, "localname": "PaymentstoSupplier", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bdx_PeripheralInterventionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Peripheral Intervention [Member]", "label": "Peripheral Intervention [Member]", "terseLabel": "Peripheral Intervention" } } }, "localname": "PeripheralInterventionMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_PharmaceuticalSystemsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharmaceutical Systems [Member]", "label": "Pharmaceutical Systems [Member]", "terseLabel": "Pharmaceutical Systems" } } }, "localname": "PharmaceuticalSystemsMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_PreanalyticalSystemsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preanalytical Systems [Member]", "label": "Preanalytical Systems [Member]", "terseLabel": "Preanalytical Systems" } } }, "localname": "PreanalyticalSystemsMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_ProductRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquired technological intellectual property and know how, as well as product marketing rights.", "label": "Product Rights [Member]", "terseLabel": "Product rights" } } }, "localname": "ProductRightsMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "bdx_ProductsandorServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Products and/or Services [Member]", "label": "Products and/or Services [Member]", "terseLabel": "Products and/or Services" } } }, "localname": "ProductsandorServicesMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/RevenuesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "bdx_PunitiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Punitive [Member]", "label": "Punitive [Member]", "terseLabel": "Punitive" } } }, "localname": "PunitiveMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bdx_QualifiedSettlementFunds": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "An amount of cash the entity has designated as qualified settlement funds relative to pending legal matters.", "label": "QualifiedSettlementFunds", "terseLabel": "Qualified settlement funds" } } }, "localname": "QualifiedSettlementFunds", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bdx_RemainingCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amounts of cash equivalents that are carried at cost and are not measured at fair value under the fair value measurement requirements for financial assets and liabilities.", "label": "Remaining Cash Equivalents", "terseLabel": "Remaining cash equivalents" } } }, "localname": "RemainingCashEquivalents", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bdx_RevenueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue Disclosure [Abstract]", "label": "Revenue Disclosure [Abstract]" } } }, "localname": "RevenueDisclosureAbstract", "nsuri": "http://www.bd.com/20191231", "xbrltype": "stringItemType" }, "bdx_SupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplemental Balance Sheet Information Related to Leases [Table Text Block]", "label": "Supplemental Balance Sheet Information Related to Leases [Table Text Block]", "terseLabel": "Supplemental Balance Sheet Information Related to Leases [Table Text Block]" } } }, "localname": "SupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bdx_SurgeryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Surgery [Member]", "label": "Surgery [Member]", "terseLabel": "Surgery" } } }, "localname": "SurgeryMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_TypeofDamagesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of Damages [Axis]", "label": "Type of Damages [Axis]", "terseLabel": "Type of Damages [Axis]" } } }, "localname": "TypeofDamagesAxis", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bdx_TypeofDamagesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Type of Damages [Axis]", "label": "Type of Damages [Domain]", "terseLabel": "Type of Damages [Domain]" } } }, "localname": "TypeofDamagesDomain", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bdx_UrologyandCriticalCareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Urology and Critical Care [Member]", "label": "Urology and Critical Care [Member]", "terseLabel": "Urology and Critical Care" } } }, "localname": "UrologyandCriticalCareMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "bdx_WomensHealthProductClaimsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "WomensHealthProductClaims [Member]", "label": "WomensHealthProductClaims [Member]", "terseLabel": "Womens Health Product Claims" } } }, "localname": "WomensHealthProductClaimsMember", "nsuri": "http://www.bd.com/20191231", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "verboseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r331" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]", "terseLabel": "NEW YORK STOCK EXCHANGE, INC." } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r115", "r125" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail", "http://www.bd.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail", "http://www.bd.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r127", "r195", "r197", "r318", "r319" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bd.com/role/RevenuesAdditionalInformationDetails", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bd.com/role/RevenuesAdditionalInformationDetails", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail", "http://www.bd.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail", "http://www.bd.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r129", "r195", "r198", "r320", "r321", "r324" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.", "label": "Accounting Changes and Error Corrections [Text Block]", "terseLabel": "Accounting Changes" } } }, "localname": "AccountingChangesAndErrorCorrectionsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/AccountingChanges" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Payables, accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r16", "r28", "r131", "r132", "r196" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade receivables, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r53", "r57", "r58", "r214", "r242" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Benefit Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r39", "r154" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less allowances for depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r57", "r65", "r241" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Cash Flow Hedges" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r55", "r56", "r57" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax, ending balance", "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax, beginning balance", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets", "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r52", "r57", "r58", "r242" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r29" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Capital in excess of par value" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Capital in Excess of Par Value" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r228", "r229", "r232", "r233" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to net income to derive net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r88", "r143", "r149" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Intangible amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r120", "r298", "r310" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r17", "r18", "r50" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r14", "r37", "r90" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsCashAndEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets", "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsCashAndEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents, fair value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r85", "r90", "r91" ], "calculation": { "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsCashAndEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Closing Cash and Equivalents and Restricted Cash", "periodStartLabel": "Opening Cash and Equivalents and Restricted Cash", "totalLabel": "Cash and equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsCashAndEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r85", "r276" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r175", "r302", "r314" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r174", "r184" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r92", "r187", "r322", "r323" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends per Common Share (USD per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock Issued at Par Value", "verboseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage", "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r27" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r61", "r63", "r64" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r71" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r70" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total Operating Costs and Expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Currency Swap" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesDisclosureGainsLossesOnNetInvestmentHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "terseLabel": "Short-term debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r21", "r22", "r23", "r299", "r300", "r309" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtMember": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates.", "label": "Debt [Member]", "terseLabel": "Debt" } } }, "localname": "DebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationShareBasedPaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary.", "label": "Deferred Compensation, Share-based Payments [Member]", "terseLabel": "Deferred Compensation" } } }, "localname": "DeferredCompensationShareBasedPaymentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r212", "r223", "r225" ], "calculation": { "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Amortization of loss" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r213", "r224", "r225" ], "calculation": { "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of prior service credit" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r211", "r222", "r225" ], "calculation": { "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r205", "r210", "r221", "r225" ], "calculation": { "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r208", "r219", "r225" ], "calculation": { "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net pension and postretirement cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r204", "r209", "r220", "r225" ], "calculation": { "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r88", "r118" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesDisclosureGainsLossesOnNetInvestmentHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r254", "r255", "r257", "r262" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesDisclosureGainsLossesOnNetInvestmentHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments and Hedging Activities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r252", "r254", "r257" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r252", "r254", "r257", "r262", "r263", "r265", "r266" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesDisclosureGainsLossesOnNetInvestmentHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesDisclosureGainsLossesOnNetInvestmentHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r246", "r248" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r92", "r96", "r245", "r247", "r252", "r253", "r264" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/RevenuesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/RevenuesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r12", "r160" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Divestiture" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/Divestiture" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DivestitureAdditionalInformationDetails", "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Common dividends" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r189", "r308" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock", "negatedTerseLabel": "Preferred dividends" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r69", "r99", "r105", "r106", "r107", "r108", "r111", "r305", "r317" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic Earnings per Share (USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r69", "r99", "r105", "r106", "r107", "r108", "r111", "r305", "r317" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted Earnings per Share (USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r276" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Termination" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail", "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r269", "r270", "r271", "r273" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r272" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Financial Instruments and Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedging" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r92", "r274", "r275" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r148" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r144", "r146", "r148", "r151", "r297" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r148", "r297" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r144", "r147" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r207", "r261" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r88", "r243" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "terseLabel": "Gain (loss) on disposition of business", "verboseLabel": "Gain on sale of business" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.bd.com/role/DivestitureAdditionalInformationDetails", "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r137", "r138" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill as of December 31, 2019", "periodStartLabel": "Goodwill as of September 30, 2019", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets", "http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r139" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r140" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r95" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income Before Income Taxes", "verboseLabel": "Income (Loss) Before Income Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DivestitureAdditionalInformationDetails", "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DivestitureAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r9", "r10", "r11", "r158", "r159" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DivestitureAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r119", "r236" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r87" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "auth_ref": [ "r87" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.", "label": "Increase (Decrease) in Operating Capital", "negatedLabel": "Change in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r87" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPensionPlanObligations": { "auth_ref": [ "r87" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation for pension benefits. Includes, but is not limited to, defined benefit or defined contribution plans. Excludes other postretirement benefits.", "label": "Increase (Decrease) in Obligation, Pension Benefits", "terseLabel": "Pension obligation" } } }, "localname": "IncreaseDecreaseInPensionPlanObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r145", "r150" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r150" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Unamortized intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r145", "r150" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]", "terseLabel": "Patents and other" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r66", "r117", "r278", "r279", "r307" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r306" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Net interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r267" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Reclassification of terminated interest rate swaps to interest expense within the next 12 months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap [Member]" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r34", "r136" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished products" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r15", "r48", "r135" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r36", "r136" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRecallExpense": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.", "label": "Inventory Recall Expense", "terseLabel": "Inventory Recall Expense" } } }, "localname": "InventoryRecallExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail", "http://www.bd.com/role/SubsequentEventDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r35", "r136" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r74", "r116" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income, net" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r292", "r294" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases of Lessee Disclosure [Text Block]" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Lessee, Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesLesseeOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesLesseeOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesLesseeOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesLesseeOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesLesseeOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesLesseeOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesLesseeOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesLesseeOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, Operating Lease, Term of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r301", "r312" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of contractual obligation to pay money on demand or on fixed or determinable dates.", "label": "Loans Payable, Fair Value Disclosure", "terseLabel": "Fair value of long-term debt" } } }, "localname": "LoansPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "verboseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r175", "r176", "r177", "r179", "r180", "r181", "r183", "r185", "r186" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r175", "r176", "r177", "r179", "r180", "r181", "r183", "r185", "r186" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r175" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss contingency accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyClaimsSettledNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of claims settled.", "label": "Loss Contingency, Claims Settled, Number", "terseLabel": "Loss Contingency, Claims Settled, Number" } } }, "localname": "LossContingencyClaimsSettledNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r175", "r178", "r182" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Damages awarded" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r175", "r176", "r177", "r179", "r180", "r181", "r183", "r185", "r186" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Pending claims" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyReceivable": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable.", "label": "Loss Contingency, Receivable", "terseLabel": "Loss contingency, receivable" } } }, "localname": "LossContingencyReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r122", "r123" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Used for Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash (Used for) Provided by Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r85", "r86", "r89" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r59", "r62", "r68", "r89", "r110", "r304", "r316" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income", "totalLabel": "Net Income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r99", "r103" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income applicable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1": { "auth_ref": [ "r98", "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative effect of the change in accounting principle or new accounting pronouncement on retained earnings or other components of equity or net assets in the statement of financial position as of the beginning of the earliest period presented.", "label": "New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets", "terseLabel": "Effect of changes in accounting principle" } } }, "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Principles Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-Cash Investing Activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of principal business segments (segment)" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating Income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating Lease, Liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesLesseeOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current lease liabilities recorded in Payables, accrued expenses and other current liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r285" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-use-assets recorded in Other Assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r291", "r294" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r290", "r294" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r280", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "terseLabel": "Operating Leases, Future Minimum Payments Due" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r280", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "Operating Leases, Future Minimum Payments Due, Next Twelve Months" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r280", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Five Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r280", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Four Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r280", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Three Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r280", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Two Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r280", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Operating Leases, Future Minimum Payments, Due Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r115", "r125" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r13", "r244" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other Assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r57", "r65" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive income before reclassifications, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r55" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r51", "r277" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r258" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesDisclosureGainsLossesOnNetInvestmentHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r60", "r63", "r65", "r188" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other Comprehensive Income (Loss), Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r54", "r55" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Defined benefit pension and postretirement plans" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Other Intangible Assets, Net", "terseLabel": "Other Intangibles, Net" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Deferred Income Taxes and Other Liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other operating income (expense).", "label": "Other Operating Income (Expense) [Member]", "terseLabel": "Other Operating Income (Expense)" } } }, "localname": "OtherOperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedTerseLabel": "Other operating income, net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other Restructuring" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherShortTermInvestments": { "auth_ref": [ "r49", "r303", "r315" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term investments classified as other.", "label": "Other Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "OtherShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r77", "r79", "r97" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r84", "r162" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Cash payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r81" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r78" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r24", "r202", "r203", "r206" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "terseLabel": "Long-Term Employee Benefit Obligations" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r200", "r215", "r216", "r226" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "auth_ref": [], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.", "label": "Preferred Stock Dividends, Income Statement Impact", "negatedTerseLabel": "Preferred stock dividends" } } }, "localname": "PreferredStockDividendsIncomeStatementImpact", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r26" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r76" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from divestitures, net" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r80", "r83", "r97" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [ "r97" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Change in credit facility borrowings" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductLiabilityAccrualPeriodExpense": { "auth_ref": [ "r175" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of loss reported during the period pertaining to product liability.", "label": "Product Liability Accrual, Period Expense", "terseLabel": "Product liability accrual, period expense" } } }, "localname": "ProductLiabilityAccrualPeriodExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r38", "r153" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r19", "r20", "r155", "r313" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, Plant and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r57", "r58", "r65" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified into income, net of taxes" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r82" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments of debt and term loans" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r234", "r325" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndInvestmentsCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsCashAndEquivalentsAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.", "label": "Restricted Cash and Investments, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndInvestmentsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets", "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsCashAndEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Business Restructuring Charges" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringCharges" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r88", "r161", "r166", "r171" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Charged to expense" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r162", "r168" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance at December 31, 2019", "periodStartLabel": "Balance at September 30, 2019" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "auth_ref": [ "r161", "r167" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.", "label": "Restructuring Reserve, Settled without Cash", "negatedLabel": "Non-cash settlements" } } }, "localname": "RestructuringReserveSettledWithoutCash2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r30", "r189", "r311" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r200", "r201", "r215", "r216", "r226" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r200", "r201", "r215", "r216", "r226" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r93", "r199" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/Revenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue from External Customers by Geographic Area" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r193" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue, remaining performance obligation, amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/RevenuesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/RevenuesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/RevenuesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r67", "r114", "r115", "r124" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r215", "r216", "r217", "r218", "r225" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlansNetPensionAndPostretirementCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r141", "r142" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r141", "r142" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Reconciliation of Goodwill by Business Segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Components of Intangible Assets" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Net Pension and Postretirement Cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r259" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r164", "r165", "r169" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r162", "r170" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Summary of Restructuring Accrual Activity" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r113", "r120", "r121", "r122", "r141" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r113", "r120", "r121", "r122", "r141" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Financial Information for Company's Segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Shareholders Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail", "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Data" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentData" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r73", "r134" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r87" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermLeasesPolicyTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy election for short-term lease to recognize lease payments on straight-line basis over lease term and variable lease payments as incurred.", "label": "Short-term Leases [Policy Text Block]", "terseLabel": "Short-term Leases" } } }, "localname": "ShortTermLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r120", "r141", "r157", "r163", "r172", "r318" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationOfGoodwillByBusinessSegmentDetail", "http://www.bd.com/role/SegmentDataFinancialInformationForCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesByGeographicAreasDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r25", "r26", "r27", "r188" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r47", "r188" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsAndChangesOfAccumulatedOtherComprehensiveIncomeLossDetail", "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r26", "r27", "r188", "r189" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Common stock issued for share-based compensation and other plans, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r26", "r27", "r189", "r230", "r231" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Common stock issued for share-based compensation and other plans, net" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r27", "r31", "r32", "r133" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total Shareholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets", "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r192" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/SubsequentEventNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": { "auth_ref": [ "r296" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.", "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "terseLabel": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r46", "r190" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r46", "r190" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "negatedPeriodEndLabel": "Ending balance (shares)", "negatedPeriodStartLabel": "Beginning balance (shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesInCertainComponentsOfShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r46", "r190", "r191" ], "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Common stock in treasury - at cost" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesSummaryOfRestructuringAccrualActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Costs of contractual or legal rights meeting the criteria for capitalization as intangible assets apart from goodwill, which have indefinite life and that are not otherwise specified in the taxonomy.", "label": "Unclassified Indefinite-lived Intangible Assets [Member]", "terseLabel": "Acquired in-process research and development" } } }, "localname": "UnclassifiedIndefinitelivedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments": { "auth_ref": [ "r256" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) related to derivatives designated as cash flow hedging instruments, recorded in results of operations to the extent that the cash flow hedge is determined to be ineffective.", "label": "Unrealized Gain (Loss) on Cash Flow Hedging Instruments", "terseLabel": "Unrealized Gain (Loss) on Cash Flow Hedging Instruments" } } }, "localname": "UnrealizedGainLossOnCashFlowHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r108" ], "calculation": { "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Dilutive share equivalents from share-based plans (shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r104", "r108" ], "calculation": { "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Average common and common equivalent shares outstanding - assuming dilution (shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r102", "r108" ], "calculation": { "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Average common shares outstanding (shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bd.com/role/EarningsPerShareWeightedAverageCommonSharesUsedInComputationsOfBasicAndDilutedEarningsPerShareDetail" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r12": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r13": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r174": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28446-109314" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5558-128473" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r283": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888369&loc=SL77918418-209957" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.5)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r326": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r327": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r328": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r329": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r331": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" } }, "version": "2.1" } XML 46 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenues - Additional Information (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
$ in Billions
Dec. 31, 2019
USD ($)
Disaggregation of Revenue [Line Items]  
Revenue, remaining performance obligation, expected timing of satisfaction 3 years
Products and/or Services  
Disaggregation of Revenue [Line Items]  
Revenue, remaining performance obligation, amount $ 1.8
Consumables [Member]  
Disaggregation of Revenue [Line Items]  
Revenue, remaining performance obligation, amount $ 2.7
XML 47 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Benefit Plans - Net Pension and Postretirement Cost (Detail) - Pension Plans - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]    
Service cost $ 40 $ 35
Interest cost 22 28
Expected return on plan assets (49) (47)
Amortization of prior service credit (3) (3)
Amortization of loss 25 20
Net pension and postretirement cost $ 35 $ 32
EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 49 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Operating Activities    
Net income $ 278 $ 599
Adjustments to net income to derive net cash provided by operating activities:    
Depreciation and amortization 530 563
Share-based compensation 82 93
Deferred income taxes (71) (28)
Change in operating assets and liabilities 102 (473)
Pension obligation 24 (225)
Gain on sale of business 0 335
Other, net (231) 52
Net Cash Provided by Operating Activities 713 245
Investing Activities    
Capital expenditures (173) (167)
Proceeds from divestitures, net 0 476
Other, net (114) (9)
Net Cash (Used for) Provided by Investing Activities (287) 299
Financing Activities    
Change in credit facility borrowings 210 50
Payments of debt and term loans (303) (453)
Dividends paid (252) (245)
Other, net (68) (86)
Net Cash Used for Financing Activities (413) (734)
Effect of exchange rate changes on cash and equivalents and restricted cash 6 (5)
Net increase (decrease) in cash and equivalents and restricted cash 18 (195)
Opening Cash and Equivalents and Restricted Cash 590 1,236
Closing Cash and Equivalents and Restricted Cash $ 609 $ 1,042
XML 50 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Derivative Instruments and Hedging Activities (Tables)
 3 Months Ended
Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)
Net (losses) gains recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges for the three-month periods were as follows:
 
Three Months Ended
December 31,
(Millions of dollars)
2019
 
2018
Foreign currency-denominated debt
$
(34
)
 
$
59

Cross-currency swaps
$
(52
)
 
$
—
XML 51 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Page
 3 Months Ended
Dec. 31, 2019
shares
Entity Information [Line Items]  
Document Type 10-Q
Document Quarterly Report true
Document Period End Date Dec. 31, 2019
Document Transition Report false
Entity File Number 001-4802
Entity Registrant Name Becton, Dickinson and Company
Entity Central Index Key 0000010795
Current Fiscal Year End Date --09-30
Document Fiscal Year Focus 2020
Document Fiscal Period Focus Q1
Amendment Flag false
Entity Incorporation, State or Country Code NJ
Entity Tax Identification Number 22-0760120
Entity Address, Address Line One 1 Becton Drive,
Entity Address, City or Town Franklin Lakes,
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07417-1880
City Area Code (201)
Local Phone Number 847-6800
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Large Accelerated Filer
Entity Small Business false
Entity Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 271,173,148
Common Stock | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security Common stock, par value $1.00
Trading Symbol BDX
Security Exchange Name NYSE
Depositary shares | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security Depositary Shares, each representing 1/20th of a share of 6.125% Cumulative Preferred Stock Series A
Trading Symbol BDXA
Security Exchange Name NYSE
Notes 1.000% due December 15, 2022 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.000% Notes due December 15, 2022
Trading Symbol BDX22A
Security Exchange Name NYSE
Notes 1.900% due December 15, 2026 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.900% Notes due December 15, 2026
Trading Symbol BDX26
Security Exchange Name NYSE
Notes 1.401% due May 24, 2023 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.401% Notes due May 24, 2023
Trading Symbol BDX23A
Security Exchange Name NYSE
Notes 3.020% due May 24, 2025 [Member] | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 3.020% Notes due May 24, 2025
Trading Symbol BDX25
Security Exchange Name NYSE
Notes 0.174% due June 4, 2021 [Member] | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 0.174% Notes due June 4, 2021
Trading Symbol BDX/21
Security Exchange Name NYSE
Notes 0.632% due June 4, 2023 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 0.632% Notes due June 4, 2023
Trading Symbol BDX/23A
Security Exchange Name NYSE
Notes 1.208% due June 4, 2026 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.208% Notes due June 4, 2026
Trading Symbol BDX/26A
Security Exchange Name NYSE
XML 52 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Data (Tables)
 3 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Revenue from External Customers by Geographic Area
Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues.
 
Three Months Ended December 31,
(Millions of dollars)
2019
 
2018
 
United States
 
International
 
Total
 
United States
 
International
 
Total
Medical
 
 
 
 
 
 
 
 
 
 
 
Medication Delivery Solutions (a)
$
520

 
$
428

 
$
948

 
$
519

 
$
438

 
$
956

Medication Management Solutions (a)
462

 
113

 
575

 
508

 
118

 
625

Diabetes Care
139

 
129

 
268

 
145

 
129

 
274

Pharmaceutical Systems
84

 
215

 
299

 
68

 
212

 
280

Total segment revenues
$
1,204

 
$
886

 
$
2,090

 
$
1,239

 
$
896

 
$
2,135

 
 
 
 
 
 
 
 
 
 
 
 
Life Sciences
 
 
 
 
 
 
 
 
 
 
 
Integrated Diagnostic Solutions
 
 
 
 
 
 
 
 
 
 
 
Preanalytical Systems
$
202

 
$
196

 
$
398

 
$
201

 
$
192

 
$
393

Diagnostic Systems
184

 
218

 
402

 
175

 
207

 
382

Total Integrated Diagnostic Solutions
386

 
414

 
800

 
376

 
399

 
774

Biosciences
152

 
171

 
323

 
108

 
173

 
281

Total segment revenues
$
538

 
$
585

 
$
1,123

 
$
484

 
$
572

 
$
1,056

 
 
 
 
 
 
 
 
 
 
 
 
Interventional
 
 
 
 
 
 
 
 
 
 
 
Surgery (b)
$
256

 
$
70

 
$
326

 
$
246

 
$
64

 
$
310

Peripheral Intervention (b)
225

 
170

 
395

 
223

 
160

 
382

Urology and Critical Care (b)
206

 
85

 
291

 
195

 
83

 
277

Total segment revenues
$
688

 
$
325

 
$
1,012

 
$
664

 
$
306

 
$
970

 
 
 
 
 
 
 
 
 
 
 
 
Total Company revenues
$
2,430

 
$
1,795

 
$
4,225

 
$
2,387

 
$
1,773

 
$
4,160

(a)
Prior-period amounts reflect the reclassification of U.S. revenues of $2 million associated with the movement, effective on October 1, 2019, of certain products from the Medication Delivery Solutions unit to the Medication Management Solutions unit.
(b)Prior-period amounts reflect the total reclassifications of $31 million of U.S. revenues and $14 million of international revenues associated with the movement, effective on October 1, 2019, of certain products from the Surgery unit and the Urology and Critical Care unit to the Peripheral Intervention unit.
 
 
 
 
 
 
 
 
 
 
 
 
Financial Information for Company's Segments
Segment income for the three-month periods was as follows:
 
Three Months Ended
December 31,
(Millions of dollars)
2019
 
2018
Income Before Income Taxes
 
 
 
Medical (a)
$
564

 
$
665

Life Sciences
361

 
305

Interventional
243

 
209

Total Segment Operating Income
1,167

 
1,180

Acquisitions and other restructurings
(86
)
 
(91
)
Net interest expense
(134
)
 
(183
)
Other unallocated items (b)
(553
)
 
(192
)
Total Income Before Income Taxes
$
394

 
$
714

(a)
The amount for the three months ended December 31, 2019 included the estimated cost of a product recall of $59 million which was recorded to Cost of products sold and is further discussed in Note 15.
(b)
Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount for the three months ended December 31, 2018 included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $335 million, which is further discussed in Note 9.
XML 53 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Earnings Per Share
 3 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Earnings per Share Earnings per Share
The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:
 
Three Months Ended
December 31,
 
2019
 
2018
Average common shares outstanding
271,102

 
269,035

Dilutive share equivalents from share-based plans
3,850

 
5,221

Average common and common equivalent shares outstanding – assuming dilution
274,952

 
274,256

 
 
 
 
Share equivalents excluded from the diluted shares outstanding calculation because the result would have been antidilutive:
 
 
 
Mandatory convertible preferred stock
11,685

 
11,685
XML 54 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Subsequent Event (Notes)
 3 Months Ended
Dec. 31, 2019
Subsequent Events [Abstract]  
Subsequent Events Subsequent Event
On February 4, 2020, the Company initiated a voluntary recall of certain AlarisTM pump systems in order to address software errors and other alarm prioritization matters. The estimated cost of this recall of $59 million was recorded to Cost of products sold during the three months ended December 31, 2019. The Company may record incremental charges in future periods associated with this recall.
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Business Restructuring Charges - Summary of Restructuring Accrual Activity (Detail)
$ in Millions
 3 Months Ended
Dec. 31, 2019
USD ($)
CR Bard Inc  
Restructuring Reserve [Roll Forward]  
Balance at September 30, 2019 $ 23
Charged to expense 17
Cash payments (13)
Non-cash settlements (7)
Balance at December 31, 2019 20
CR Bard Inc | Employee Termination  
Restructuring Reserve [Roll Forward]  
Balance at September 30, 2019 22
Charged to expense 4
Cash payments (7)
Non-cash settlements 0
Balance at December 31, 2019 19
CR Bard Inc | Other Restructuring  
Restructuring Reserve [Roll Forward]  
Balance at September 30, 2019 1
Charged to expense 13
Cash payments (6)
Non-cash settlements (7)
Balance at December 31, 2019 1
Other Initiatives  
Restructuring Reserve [Roll Forward]  
Balance at September 30, 2019 34
Charged to expense 6
Cash payments (16)
Non-cash settlements 0
Balance at December 31, 2019 24
Other Initiatives | Employee Termination  
Restructuring Reserve [Roll Forward]  
Balance at September 30, 2019 31
Charged to expense 2
Cash payments (12)
Non-cash settlements 0
Balance at December 31, 2019 21
Other Initiatives | Other Restructuring  
Restructuring Reserve [Roll Forward]  
Balance at September 30, 2019 3
Charged to expense 4
Cash payments (4)
Non-cash settlements 0
Balance at December 31, 2019 $ 3
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Reclassification of terminated interest rate swaps to interest expense within the next 12 months $ (6)  
Debt | Net Investment Hedging    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, Notional Amount 1,400 $ 1,400
Foreign Exchange Contract    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, Notional Amount 1,200 2,300
Currency Swap    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, Notional Amount 3,000 2,300
Fixed to Floating | Fair Value Hedging    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, Notional Amount 375 375
Interest Rate Swap [Member] | Cash Flow Hedging [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative, Notional Amount 1,500 $ 1,500
Unrealized Gain (Loss) on Cash Flow Hedging Instruments $ 37  
XML 57 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Additional Information (Details)
$ in Millions
 3 Months Ended
Dec. 31, 2019
USD ($)
Lessee, Lease, Description [Line Items]  
Operating Lease, Weighted Average Remaining Lease Term 7 years 6 months
Operating Lease, Weighted Average Discount Rate, Percent 2.30%
Lease, Cost $ 34
Minimum  
Lessee, Lease, Description [Line Items]  
Lessee, Operating Lease, Term of Contract 1 year
Maximum  
Lessee, Lease, Description [Line Items]  
Lessee, Operating Lease, Term of Contract 25 years
XML 58 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Benefit Plans (Tables)
 3 Months Ended
Dec. 31, 2019
Retirement Benefits [Abstract]  
Net Pension and Postretirement Cost
Net pension cost included the following components for the three months ended December 31:
 
Three Months Ended
December 31,
(Millions of dollars)
2019
 
2018
Service cost
$
40

 
$
35

Interest cost
22

 
28

Expected return on plan assets
(49
)
 
(47
)
Amortization of prior service credit
(3
)
 
(3
)
Amortization of loss
25

 
20

Net pension cost
$
35

 
$
32
XML 59 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Shareholders' Equity
 3 Months Ended
Dec. 31, 2019
Stockholders' Equity Note [Abstract]  
Shareholders' Equity Shareholders' Equity
Changes in certain components of shareholders' equity for the first quarters of fiscal years 2020 and 2019 were as follows:
 
Common
Stock  Issued
at Par Value
 
Capital in
Excess of
Par Value
 
Retained
Earnings
 
Deferred
Compensation
 
Treasury Stock
(Millions of dollars)
Shares (in
thousands)
 
Amount
Balance at September 30, 2019
$
347

 
$
16,270

 
$
12,913

 
$
23

 
(76,260
)
 
$
(6,190
)
Net income
—

 
—

 
278

 
—

 
—

 
—

Common dividends ($0.79 per share)
—

 
—

 
(215
)
 
—

 
—

 
—

Preferred dividends
—

 
—

 
(38
)
 
—

 
—

 
—

Common stock issued for share-based compensation and other plans, net
—

 
(32
)
 
—

 
1

 
758

 
(38
)
Share-based compensation
—

 
82

 
—

 
—

 
—

 
—

Common stock held in trusts, net (a)
—

 
—

 
—

 
—

 
(12
)
 
—

Balance at December 31, 2019
$
347

 
$
16,320

 
$
12,938

 
$
24

 
(75,514
)
 
$
(6,228
)
 
Common
Stock  Issued
at Par Value
 
Capital in
Excess of
Par Value
 
Retained
Earnings
 
Deferred
Compensation
 
Treasury Stock
(Millions of dollars)
Shares (in
thousands)
 
Amount
Balance at September 30, 2018
$
347

 
$
16,179

 
$
12,596

 
$
22

 
(78,463
)
 
$
(6,243
)
Net income
—

 
—

 
599

 
—

 
—

 
—

Common dividends ($0.77 per share)
—

 
—

 
(207
)
 
—

 
—

 
—

Preferred dividends
—

 
—

 
(38
)
 
—

 
—

 
—

Common stock issued for share-based compensation and other plans, net
—

 
(97
)
 
—

 
2

 
851

 
9

Share-based compensation
—

 
92

 
—

 
—

 
—

 
—

Common stock held in trusts, net (a)
—

 
—

 
—

 
—

 
(12
)
 
—

Effect of change in accounting principles
—

 
—

 
68

 
—

 
—

 
—

Balance at December 31, 2018
$
347

 
$
16,174

 
$
13,018

 
$
24

 
(77,624
)
 
$
(6,235
)
(a)
Common stock held in trusts represents rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.
The components and changes of Accumulated other comprehensive income (loss) for the first quarters of fiscal years 2020 and 2019 were as follows:
(Millions of dollars)
Total
 
Foreign Currency
Translation
 
Benefit Plans
 

Cash Flow Hedges
Balance at September 30, 2019
$
(2,283
)
 
$
(1,256
)
 
$
(1,005
)
 
$
(23
)
Other comprehensive income before reclassifications, net of taxes
63

 
26

 
—

 
37

Amounts reclassified into income, net of taxes
19

 
—

 
17

 
2

Balance at December 31, 2019
$
(2,202
)
 
$
(1,230
)
 
$
(988
)
 
$
16

(Millions of dollars)
Total
 
Foreign Currency
Translation
 
Benefit Plans
 

Cash Flow Hedges
Balance at September 30, 2018
$
(1,909
)
 
$
(1,162
)
 
$
(729
)
 
$
(17
)
Other comprehensive (loss) income before reclassifications, net of taxes
(32
)
 
(35
)
 
3

 
(1
)
Amounts reclassified into income, net of taxes
14

 
—

 
13

 
1

Balance at December 31, 2018
$
(1,927
)
 
$
(1,197
)
 
$
(714
)
 
$
(16
)
The amounts of foreign currency translation recognized in other comprehensive income during the three months ended December 31, 2019 and 2018 included net (losses) gains relating to net investment hedges. The amount recognized in other comprehensive income relating to cash flow hedges during the three months ended December 31, 2019 related to forward starting interest rate swaps. Additional disclosures regarding the Company's derivatives are provided in Note 12.
XML 60 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accounting Changes (Policies)
 3 Months Ended
Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]  
New Accounting Principles Adopted
New Accounting Principle Adopted
In February 2016, the Financial Accounting Standards Board ("FASB") issued a new lease accounting standard which requires lessees to recognize lease assets and lease liabilities on the balance sheet, as well as requires expanded disclosures regarding leasing arrangements. The Company adopted this standard on October 1, 2019 and elected certain practical expedients permitted under the transition guidance, including a transition method which allows application of the new standard at its adoption date, rather than at the earliest comparative period presented in the financial statements. The Company also elected not to perform any reassessments relative to its expired and existing leases upon its adoption of the new requirements. The Company's adoption of this standard did not materially impact its condensed consolidated financial statements. Additional disclosures regarding the Company’s lease arrangements are provided in Note 14.
New Accounting Principles Not Yet Adopted
In June 2016, the FASB issued a new accounting standard which requires earlier recognition of credit losses on loans and other financial instruments held by entities, including trade receivables. The new standard requires entities to measure all expected credit losses for financial assets held at each reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption on October 1, 2020.
In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The standard is effective for the Company on October 1, 2020, but early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the impact that this new accounting standard will have on its consolidated financial statements upon its adoption.
Commitments and Contingencies
Given the uncertain nature of litigation generally, the Company is not able, in all cases, to estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which the Company is a party. In accordance with U.S. GAAP, the Company establishes accruals to the extent probable future losses are estimable (in the case of environmental matters, without considering possible third-party recoveries). With respect to putative class action lawsuits in the United States and certain of the Canadian lawsuits described below relating to product liability matters, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class. With respect to the civil investigative demand served by the Department of Justice, as discussed below, the Company is unable to estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved.
In view of the uncertainties discussed below, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations and consolidated cash flows.
Revenue
Measurement of Revenues
The Company’s estimate of probable credit losses relating to trade receivables is determined based on historical experience and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. Such amounts are not material to the Company's consolidated financial results.
The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. The impact of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues.
Derivatives Hedges of the transactional foreign exchange exposures resulting primarily from intercompany payables and receivables are undesignated hedges.
The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items have on financial position, financial performance, and cash flows are provided below.
The Company’s policy is to manage interest rate exposure using a mix of fixed and variable rate debt. The Company periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either fair value or cash flow hedges.
For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates.
The total notional amount of the Company’s outstanding interest rate swaps designated as fair value hedges was $375 million at December 31, 2019 and September 30, 2019. The outstanding swaps represent fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. Changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt. The amounts recorded during the three months ended December 31, 2019 and 2018 for changes in the fair value of these hedges were immaterial to the Company's consolidated financial results.
Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss). If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings over the remaining life of the hedged debt.
Fair Value of Financial Instruments
The Company’s cash and equivalents include institutional money market accounts which permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions, which are considered Level 1 inputs in the fair value hierarchy. The fair value of these accounts was immaterial at December 31, 2019 and the fair value of these accounts at September 30, 2019 was $39 million. The Company’s remaining cash and equivalents, excluding restricted cash, were $560 million and $497 million at December 31, 2019 and September 30, 2019, respectively.
Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments consist of instruments with maturities greater than three months and less than one year.
Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments, which are considered Level 2 inputs in the fair value hierarchy. The fair value of long-term debt was $18.1 billion and $19.2 billion at December 31, 2019 and September 30, 2019, respectively. The fair value of the current portion of long-term debt was $2.5 billion and $1.3 billion at December 31, 2019 and September 30, 2019, respectively.
All other instruments measured by the Company at fair value, including derivatives and contingent consideration liabilities, are immaterial to the Company's consolidated balance sheets.
Lessee, Leases The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. The Company’s lease arrangements are generally classified as operating leases. These arrangements have remaining terms ranging from less than one year to approximately 25 years and the weighted-average remaining lease term of the Company’s leases is approximately 7.5 years. An option to renew or terminate the current term of a lease arrangement is included in the lease term if the Company is reasonably certain to exercise that option.The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet. For the longer-term lease arrangements that are recognized on the Company’s consolidated balance sheet, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement.
Short-term Leases The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet.
XML 61 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Statement of Comprehensive Income [Abstract]    
Net Income $ 278 $ 599
Other Comprehensive Income (Loss), Net of Tax    
Foreign currency translation adjustments 26 (35)
Defined benefit pension and postretirement plans 17 15
Cash flow hedges 39 1
Other Comprehensive Income (Loss), Net of Tax 82 (18)
Comprehensive Income $ 359 $ 581
XML 62 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments and Fair Value Measurements (Tables)
 3 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Schedule of Cash and Cash Equivalents
The following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at December 31, 2019 and September 30, 2019 to the total of these amounts shown on the Company's consolidated statements of cash flows:
(Millions of dollars)
December 31, 2019
 
September 30, 2019
Cash and equivalents
$
560

 
$
536

Restricted cash
49

 
54

Cash and equivalents and restricted cash
$
609

 
$
590
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments and Fair Value Measurements - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents, fair value   $ 39
Remaining cash equivalents $ 560 497
Fair value of long-term debt 18,100 19,200
Fair value of debt reclassified from long term to short term 2,500 $ 1,300
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized $ 328  
Minimum    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Maturity period of short-term investments at the time of purchase 3 months  
Maximum    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Maturity period of short-term investments at the time of purchase 1 year  
XML 64 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Divestiture - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Gain (loss) on disposition of business $ 0 $ 335
Advanced Bioprocessing    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Gain (loss) on disposition of business   $ 335
XML 65 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail)
$ in Millions
 3 Months Ended
Dec. 31, 2019
USD ($)
Goodwill [Roll Forward]  
Goodwill as of September 30, 2019 $ 23,376
Goodwill, Acquired During Period 10
Currency translation 49
Goodwill as of December 31, 2019 23,435
Medical  
Goodwill [Roll Forward]  
Goodwill as of September 30, 2019 9,989
Goodwill, Acquired During Period 10
Currency translation 17
Goodwill as of December 31, 2019 10,016
Life Sciences  
Goodwill [Roll Forward]  
Goodwill as of September 30, 2019 772
Goodwill, Acquired During Period 0
Currency translation 2
Goodwill as of December 31, 2019 774
Interventional  
Goodwill [Roll Forward]  
Goodwill as of September 30, 2019 12,615
Goodwill, Acquired During Period 0
Currency translation 30
Goodwill as of December 31, 2019 $ 12,645
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Lessee, Operating Lease, Liability, Maturity (Details)
$ in Millions
Dec. 31, 2019
USD ($)
Leases [Abstract]  
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year $ 86
Lessee, Operating Lease, Liability, Payments, Due Year Two 95
Lessee, Operating Lease, Liability, Payments, Due Year Three 74
Lessee, Operating Lease, Liability, Payments, Due Year Four 49
Lessee, Operating Lease, Liability, Payments, Due Year Five 33
Lessee, Operating Lease, Liability, Payments, Due after Year Five 158
Lessee, Operating Lease, Liability, Payments, Due 494
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 49
Operating Lease, Liability $ 445
XML 67 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Derivative Instruments and Hedging Activities
 3 Months Ended
Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities
The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items have on financial position, financial performance, and cash flows are provided below.
Foreign Currency Risks and Related Strategies
The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts. In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has hedged the currency risk associated with those investments with instruments, such as foreign currency-denominated debt, cross-currency swaps and currency exchange contracts, which are designated as net investment hedges.
Hedges of the transactional foreign exchange exposures resulting primarily from intercompany payables and receivables are undesignated hedges. As such, the gains or losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. The net amounts recognized in Other income, net, during the three months ended December 31, 2019 and 2018 were immaterial to the Company's consolidated financial results. The total notional amounts of the Company’s outstanding foreign exchange contracts as of December 31, 2019 and September 30, 2019 were $1.2 billion and $2.3 billion, respectively.
Certain of the Company's foreign currency-denominated long-term notes outstanding, which had a total carrying value of $1.4 billion as of December 31, 2019 and September 30, 2019, were designated as, and were effective as, economic hedges of net investments in certain of the Company's foreign subsidiaries. The Company has entered into cross-currency swaps, all of which are designated and effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. The notional amounts of the cross-currency swaps were $3.0 billion and $2.3 billion as of December 31, 2019 and September 30, 2019, respectively.
Net gains or losses relating to the net investment hedges, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as accumulated foreign currency translation in Other comprehensive income (loss). Upon the termination of a net investment hedge, any net gain or loss included in Accumulated other comprehensive income (loss) relative to the investment hedge remains until the foreign subsidiary investment is disposed of or is substantially liquidated.
Net (losses) gains recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges for the three-month periods were as follows:
 
Three Months Ended
December 31,
(Millions of dollars)
2019
 
2018
Foreign currency-denominated debt
$
(34
)
 
$
59

Cross-currency swaps
$
(52
)
 
$
—


Interest Rate Risks and Related Strategies
The Company’s policy is to manage interest rate exposure using a mix of fixed and variable rate debt. The Company periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either fair value or cash flow hedges.
For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates.
The total notional amount of the Company’s outstanding interest rate swaps designated as fair value hedges was $375 million at December 31, 2019 and September 30, 2019. The outstanding swaps represent fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on LIBOR. Changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt. The amounts recorded during the three months ended December 31, 2019 and 2018 for changes in the fair value of these hedges were immaterial to the Company's consolidated financial results.
Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss). If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings over the remaining life of the hedged debt. The net realized loss related to terminated interest rate swaps expected to be reclassified and recorded in Interest expense within the next 12 months is $6 million, net of tax.
The total notional amount of the Company's outstanding forward starting interest rate swaps was $1.5 billion at December 31, 2019 and September 30, 2019. The Company entered into these contracts in the fourth quarter of fiscal year 2019 to mitigate its exposure to interest rate risk. The Company recognized an after-tax gain of $37 million in other comprehensive income relating to these interest rate hedges during the three months ended December 31, 2019.
 
 
 
 
 
 
 
 

Other Risk Exposures
The Company purchases resins, which are oil-based components used in the manufacture of certain products. Significant increases in world oil prices that lead to increases in resin purchase costs could impact future operating results. From time to time, the Company has managed price risks associated with these commodity purchases through commodity derivative forward contracts. The Company's outstanding commodity derivative forward contracts at December 31, 2019 and September 30, 2019 were immaterial to the Company's consolidated financial results.
Financial Statement Effects
The fair values of derivative instruments outstanding at December 31, 2019 and September 30, 2019 were not material to the Company's consolidated balance sheets.
 

The amounts reclassified from accumulated other comprehensive income relating to cash flow hedges during the three months ended December 31, 2019 and 2018 were not material to the Company's consolidated financial results.
XML 68 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Benefit Plans
 3 Months Ended
Dec. 31, 2019
Retirement Benefits [Abstract]  
Benefit Plans Benefit Plans
The Company has defined benefit pension plans covering certain employees in the United States and certain international locations. The measurement date used for these plans is September 30.
Net pension cost included the following components for the three months ended December 31:
 
Three Months Ended
December 31,
(Millions of dollars)
2019
 
2018
Service cost
$
40

 
$
35

Interest cost
22

 
28

Expected return on plan assets
(49
)
 
(47
)
Amortization of prior service credit
(3
)
 
(3
)
Amortization of loss
25

 
20

Net pension cost
$
35

 
$
32

The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in Accumulated other comprehensive income (loss) in prior periods. All components of the Company’s net periodic pension cost, aside from service cost, are recorded to Other income (expense), net on its condensed consolidated statements of income.
XML 69 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Data - Financial Information for Company's Segments (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Segment Reporting Information [Line Items]    
Income (Loss) Before Income Taxes $ 394 $ 714
Acquisitions and other restructurings (86) (91)
Inventory Recall Expense 59  
Gain on sale of business 0 335
Advanced Bioprocessing    
Segment Reporting Information [Line Items]    
Gain on sale of business   335
Operating Segments    
Segment Reporting Information [Line Items]    
Income (Loss) Before Income Taxes 1,167 1,180
Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Income (Loss) Before Income Taxes 564 665
Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Income (Loss) Before Income Taxes 361 305
Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Income (Loss) Before Income Taxes 243 209
Segment Reconciling Items    
Segment Reporting Information [Line Items]    
Acquisitions and other restructurings (86) (91)
Net interest expense (134) (183)
Corporate, Non-Segment    
Segment Reporting Information [Line Items]    
Income (Loss) Before Income Taxes $ (553) $ (192)
XML 70 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases (Tables)
 3 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Supplemental Balance Sheet Information Related to Leases [Table Text Block] The right-of-use assets and lease liabilities recognized on the Company’s condensed consolidated balance sheet as of December 31, 2019 were as follows:
(Millions of dollars)
December 31, 2019
Right-use-assets recorded in Other Assets
$
426

Current lease liabilities recorded in Payables, accrued expenses and other current liabilities
$
105

Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities
$
340
Lessee, Operating Lease, Liability, Maturity [Table Text Block]
The Company’s payments due under its operating leases are as follows:
(Millions of dollars)
 
Remaining for 2020
$
86

2021
95

2022
74

2023
49

2024
33

Thereafter
158

Total payments due
494

Less: imputed interest
49

Total
$
445
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
The Company’s future minimum rental commitments on non-cancelable leases at September 30, 2019, as disclosed in the Company’s 2019 Annual Report on Form 10-K, were as follows:
(Millions of dollars)
 
2020
$
122

2021
103

2022
83

2023
57

2024
56

Thereafter
123

Total
$
546
XML 71 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Contingencies - Additional Information (Detail)
$ in Millions
 1 Months Ended 3 Months Ended
Apr. 30, 2018
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Loss Contingencies [Line Items]        
Loss contingency accrual   $ 2,400 $ 2,500  
Qualified settlement funds   48 53  
Loss contingency, receivable   $ 152 150  
Other Operating Income (Expense)        
Loss Contingencies [Line Items]        
Product liability accrual, period expense     $ 582 $ 331
Hernia Product Claims        
Loss Contingencies [Line Items]        
Pending claims   14,330    
Womens Health Product Claims        
Loss Contingencies [Line Items]        
Pending claims   750    
Claims lacking sufficient information   1,010    
PaymentstoSupplier   $ 141    
Number of claims in settlement agreement   15,165    
Damages awarded $ 68      
Womens Health Product Claims | Compensatory        
Loss Contingencies [Line Items]        
Damages awarded 33      
Womens Health Product Claims | Punitive        
Loss Contingencies [Line Items]        
Damages awarded $ 35      
Filter Product Claims        
Loss Contingencies [Line Items]        
Pending claims   2,650    
Loss Contingency, Claims Settled, Number   6,400